 
Official Title:   
A Phase I b Study Evaluating Cobimetinib Plus Atezolizumab in 
Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have 
Progressed During o r After Treatment With Anti −PD-1 Therapy  and 
Atezolizumab Monotherapy i n Patients With Previously Untreated 
Advanced BRAF V600  Wild-Type Melanoma  
 
Study ID: [REMOVED] 
Document  Date : Protocol  Version 5: 26- Octo ber-2018 
 
 
 
PROTOCOL AMENDMENT APPROVAL  
CONFI
DENTIAL  
This clinical study is being sponsored globally by F. Hoffmann- La [COMPANY_002] Ltd of Basel, 
Switzerland.   However, it may be implemented in individual countries by [CONTACT_26702]’s local affiliates, 
including Genentech, Inc. in the [LOCATION_002].  The information contained in this document, especially 
any unpublished data, is the property of F.  Hoffmann- La [COMPANY_002] Ltd (or under its control) and therefore 
is provided to you in confidence as an investigator, potential investigator, or consultant, for review by 
[CONTACT_10825], your staff, and an applicable Ethics Committee or Institutional Review Board.  It is understood that 
this information will not be disclosed to others without written authorization from [COMPANY_002] except to the 
extent necessary to obtain informed consent from persons  to whom the drug may be administered.  
Cobimetinib  and Atezolizumab  —F.  Hoffmann -La [COMPANY_002] Ltd  
Protocol CO39721, Version 5 PROTOCOL  
TITLE:  A PHASE  IB STUDY  EVALUATING  COBIMETINIB
PLUS  ATEZOLIZUMAB  IN PATIENTS  WITH
ADVANCED  BRAFV600 WILD -TYPE  MELANOMA
WHO  HAVE  PROGRESSED  DURING  OR AFTER
TREATMENT  WITH  ANTI−PD-1 THERAPY  AND
ATEZOLIZUMAB  MONOTHERAPY  IN PATIENTS
WITH  PREVIOUSLY  UNTREATED  ADVANCED
BRAFV600 WILD -TYPE  MELANOMA  
PROTOCOL NUMBER:  CO39721  
VERSION NUMBER:  [ADDRESS_437329] NUMBER:  2016- 004402- 34 
IND NUMBER:  135,[ADDRESS_437330] S: Cobimetinib (RO5514041)  
Atezolizumab (RO5541267)  
MEDICAL MONITOR:   M.D. 
SPONSOR:  F. Hoffmann -La [COMPANY_002] Ltd
DATE FINAL:  14 December 2016  
DATES AMENDED:  Version 2:  23 June 2017  
Version 3:  19 September 2017  
Version 4:  3 February 2018  
Version 5:  See electronic  date stamp below . 
 
26-Oct-2018 10:19:14
Title
Approver's Name
[CONTACT_26862] (UTC)

Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
2/Protocol CO39721,  Version 5  PROTOCOL AMENDMENT, VERSION 5 
RATIONALE  
Protocol CO39721 has been amended primarily to update the  primary anal ysis timelines  
and to align with current atezolizumab risk language .  
•The primary analysis will be conducted in Cohorts A and B approximately [ADDRESS_437331]
a minimum follow  up o f approximately 24 weeks.  The primary analysis for Cohort C
may be analysed independently , with a minimum of 24 weeks follow up for patients
in Cohort C  (Section 6) .
•The list of risks associated with atezolizumab has been revised to align with currentatezolizumab risk language  (Section 5.1.2 ).
•Guidelines for managing patients who experience atezolizumab- associated adverse
events have been revised to include nephritis (Appendix 8).
A
dditional changes to the protocol are summarized below:  
•Independent review committee (IRC) -assessed objective response rate (ORR),
duration of response (DOR), disease control rate (DCR) , and progression- free
survival (PFS) have been added as secondary efficacy endpoints for Cohort C(Table 1 in Section 2 and Section s 3.1 and  6.4.2).
•Text has been added to clarify that the patient numbers for each cohort areapproximate (Sections 3.1, [IP_ADDRESS], and 6.1).
•T
he inclusion criterion that addresses female contraception has been modified to
specify when women must refrain from donating eggs  ( Section [IP_ADDRESS]) .
•The exclusion criterion related to treatment with immunosuppressive medication forpatients who have received acute, low -dose systemic immunosuppressant
medication ( ≤
 10 mg/day oral prednisone or equivalent)  or a on e-time pulse dose of
systemic immunosuppressant medication (e.g., [ADDRESS_437332] allergy) has been revised, specifying that such patients are  eligible for the
study  a
fter Medical Monitor approval has been obtained (Section [IP_ADDRESS]) .
•Denosumab has been removed from the list of prohibited therapi[INVESTIGATOR_014] (Section 4.3.2) .
•Text stating that ophthalmologic examinations should be performed prior to dosinghas been added, and the frequency of the examinations has been clarified (Table 3
in Se c
tion 4.4.7).
•Text stating recurrent Grade 1 pneumonitis should be treated as a Grade 3 or 4event has been removed (Table 6 in Section [IP_ADDRESS]).
•T
he Medical Monitor has been changed and updated contact [CONTACT_351833] (Section 5.4.1).
•Lang
uage has been added for consistency with [COMPANY_002]'s current data retention
policy and to accommodate more stringent local requirements (if applicable)(
Section 7.5).
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
3/Protocol CO39721,  Version [ADDRESS_437333] been made to improve clarity and consistency.  
Substantive new information appears in italics.  This amendment represents cumulative 
changes to the original protocol. 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
4/Protocol CO39721,  Version 5   TABLE OF CONTENTS  
PROTOCOL AMENDMENT A CCEPTANCE FORM  .......................................... 12 
PROTOCOL SYNOPSIS  .................................................................................... 13 
1. BACKGROUND ........................................................................................... 26 
1.1  Background on Melanoma  ..................................................... 26 
1.1.1   Incidence and Pathogenesis  .................................................. 26 
1.1.2   Treatment Options for Melanoma  .......................................... 26 
1.2  Background on the Study Treatments  ................................... 28 
1.2.1   Cobimetinib  ............................................................................ 28 
1.2.2   Atezolizumab  ......................................................................... 28 
1.3  Study Rationale and Benefit -Risk Assessment  ...................... 29 
1.3.1   Rationale for Combining Cobimetinib and 
Atezolizumab for Advanced BRAFV600 Wild-Type 
Melanoma after Progression on Anti -PD-1 
Therapy  ................................................................................. 29 
[IP_ADDRESS]  Rationale for Atezolizumab Monotherapy for 
Previously Untreated Patients with Advanced 
BRAFV600-Wild-Type Melanoma  ............................................ 29 
1.3.2   Activity of Atezolizumab in Advanced Melanoma  .................. 30 
[IP_ADDRESS]  Study PCD4989g:  Atezolizumab Monotherapy  ..................... [ADDRESS_437334] of MAPK Inh ibition on Tumor -Immune 
Contexture  ............................................................................. 31 
1.3.5   Clinical Data for Combination Treatment with Cobimetinib and Atezolizumab in Advanced 
Melanoma  .............................................................................. 32 
[IP_ADDRESS]  Study GP28363  ..................................................................... 32 
1.3.6   Risk-Benefit Statement  .......................................................... 36 
2. OBJECTIVES AND ENDPO INTS  ................................................................ 36 
3. STUDY DESIGN  .......................................................................................... 39 
3.1  Description of the Study ......................................................... 39 
3.1.1   Biopsies and Archival Tissue  ................................................. 42 
[IP_ADDRESS]  Optional Biopsies (Cohort A)  ................................................. 43 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
5/Protocol CO39721,  Version 5  [IP_ADDRESS]  Mandatory Biopsies (Cohort B)  .............................................. 43 
[IP_ADDRESS]  Optional Biopsies (Cohort C)  ................................................. 44 
3.1.2   Dosing of Study Treatment beyond Disease 
Progression ........................................................................... 44 
3.2  End of Study and Length of Study  ......................................... 45 
3.3  Rationale for Study Design .................................................... 45 
3.3.1   Rational e for Cobimetinib plus Atezolizumab 
Dose and Schedule  ............................................................... 45 
[IP_ADDRESS]  Cohort A (Cobimetinib plus Atezolizumab with 
Concurrent Start)  ................................................................... 45 
[IP_ADDRESS]  Cohort B (Biopsy Cohort)  ....................................................... 46 
[IP_ADDRESS]  Cohort C (Atezolizumab Monotherapy Cohort)  ...................... 46 
3.3.2   Rationale for Patient Population and Cohorts  ........................ 46 
[IP_ADDRESS]  Cohort A (Cobimetinib plus Atezolizumab with 
Concurrent Start)  ................................................................... 46 
[IP_ADDRESS]  Cohort B (Biopsy Cohort)  ....................................................... 46 
[IP_ADDRESS]  Cohort C (Atezolizumab Monotherapy) .................................. [ADDRESS_437335]  v1.1 ...................................................... 48 
3.3.5   Rationale for Biomarker Assessments  ................................... 49 
3.3.6   Rationale for Blood Sampling for Biomarker Assessments ......................................................................... 49 
3.3.7   Rationale for Ophthalmologic Assessments 
(Cohorts A and B)  .................................................................. 49 
[IP_ADDRESS]  Rationale for Optional Whole Genome 
Sequencing  ............................................................................ 50 
3.3.8   Rationale for Pharmacokinetic Assessments  ......................... 51 
4. MATERIALS AND METHOD S ..................................................................... 51 
4.1  Patients  .................................................................................. 51 
4.1.1   Inclusion Criteria  .................................................................... 52 
[IP_ADDRESS]  Disease -Specific Inclusion Criteria: Cohorts A 
and B  ..................................................................................... 52 
[IP_ADDRESS]  Additional Disease -Specific Inclusion Criteria in 
Cohort B (Biopsy Cohort)  ....................................................... 52 
[IP_ADDRESS]  Disease -Specific Inclusion Criteria:  Cohort C  .......................
 52 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
6/Protocol CO39721,  Version 5  [IP_ADDRESS]  General Inclusion Criteria ...................................................... 53 
4.1.2   Exclusion Criteria  ................................................................... 55 
[IP_ADDRESS]  Cancer -Related Exclusion Criteria  ......................................... 55 
[IP_ADDRESS]  Ocular Exclusion Criteria (Cohorts A and B)  .......................... 56 
[IP_ADDRESS]  Cardiac Exclusion Criteria (Cohorts  A and B)  ........................ 56 
[IP_ADDRESS]  Central Nervous System Exclusion Criteria  ........................... 56 
[IP_ADDRESS] Exclusions Related to Infections  ............................................ 57 
[IP_ADDRESS]  Exclusion Criteria Related to Autoimmune 
Conditions and Immunomodulatory Drugs ............................. 57 
[IP_ADDRESS]  Additional Exclusion Criteria .................................................. 58 
4.2  Study Treatment  .................................................................... 59 
4.2.1   Formulation, Packaging, and Handling  .................................. 59 
[IP_ADDRESS]  Cobimetinib  ............................................................................ 59 
[IP_ADDRESS]  Atezolizumab  ......................................................................... 59 
4.2.2   Dosage, Administration, and Compliance  .............................. 60 
[IP_ADDRESS]  Cobimetinib  ............................................................................ 60 
[IP_ADDRESS]  Atezolizumab  ......................................................................... [ADDRESS_437336]- Trial Access to Cobimetinib and 
Atezolizumab  ......................................................................... 62 
4.3  Concomitant Therapy  ............................................................ 63 
4.3.1   Permitted Therapy  ................................................................. 63 
4.3.2   Prohibited Therapy  ................................................................ 64 
4.3.3   Cautionary Therapy for Atezolizumab- Treated 
Patients  .................................................................................. 65 
[IP_ADDRESS]  Corticosteroids and Tumor Necrosis Fact or-α 
Inhibitors  ................................................................................ 65 
4.4  Study Assessments  ............................................................... 65 
4.4.1   Informed Consent Forms and Screening Log  ........................ 66 
4.4.2   Medical History and Demographic Data  ................................ 66 
4.4.3   Physical Examinations  ........................................................... 66 
4.4.4   Vital Signs  .............................................................................. 67 
4.4.5   Tumor and Response Eval
uations  ......................................... 67 
4.4.6   Left Ventricular Ejection Fraction  ........................................... 68 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
7/Protocol CO39721,  Version 5  4.4.7   Ophthalmologic Examination (Cohorts A and B)  ................... 69 
4.5  Patient, Treatment, Study, and Site 
Discontinuation  ...................................................................... 70 
4.5.1   Patient Discontinuation  .......................................................... 70 
4.5.2   Laboratory, Biomarker, and Other Biologic 
Samples  ................................................................................. 71 
[IP_ADDRESS]  Local Laboratory Assessments  .............................................. 71 
[IP_ADDRESS]  Central Laboratory Assessments ........................................... 72 
4.5.3   Study Treatment Discontinuation  ........................................... 75 
4.5.4   Study and Site Discontinuation  .............................................. 76 
5. ASSESSMENT OF SAFETY  ........................................................................ 76 
5.1  Safety Plan ............................................................................ 76 
5.1.1   Risks Associated with Cobimetinib  ........................................ 77 
[IP_ADDRESS]  Important Identified Risks Associated with Cobimetinib  ............................................................................ 77 
[IP_ADDRESS]  Potential Risks Associated with Cobimetinib  ......................... 79 
[IP_ADDRESS]  Other Risks with Cobimetinib  ................................................. 80 
5.1.2   Risks Associated with Atezolizumab  ..................................... 82 
5.1.3   Management of Patients Who Experience 
Specific Adverse Events  ........................................................ 82 
[IP_ADDRESS]  Cobimetinib Dose Modifications  ............................................ 82 
[IP_ADDRESS]  Atezolizumab Dose Modifications  .......................................... 83 
[IP_ADDRESS]  Management of Cobimetinib- and 
Atezolizumab- Specific Adverse Events  ................................. 83 
5.2  Safety Parameters and Definitions  ........................................ 97 
5.2.1   Adverse Events  ..................................................................... 97 
5.2.2   Serious Adverse Events (Immediately Reportable to the Sponsor)  ...................................................................... [ADDRESS_437337] (Immediately 
Reportable to the Sponsor)  .................................................... 99 
5.3  Methods and Timing for Capturing and Assessing Safety  Parameters  .............................................. 100 
5.3.1   Adverse Event Reporting Period  ......................................... 100 
5.3.2   Eliciting Adverse Event Information  .....................................
 100 
5.3.3  Assessment of Severity of Adverse Events  ......................... 101 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
8/Protocol CO39721,  Version 5  5.3.4   Assessment of Causality of Adverse Events  ....................... 101 
5.3.5   Procedures for Recording Adverse Events  .......................... 102 
[IP_ADDRESS]  Infusion -Related Reactions  .................................................. 102 
[IP_ADDRESS]  Diagnosis versus Signs and Symptoms ............................... 102 
[IP_ADDRESS]  Adverse Events That are Secondary to Other 
Events .................................................................................. 102 
[IP_ADDRESS]  Persistent or Recurrent Adverse Events  .............................. 103 
[IP_ADDRESS]  Abnormal Laboratory Values  ............................................... 103 
[IP_ADDRESS]  Abnormal Vital Sign Values  ................................................. 104 
[IP_ADDRESS]  Abnormal Liver Function Tests  ............................................ 105 
[IP_ADDRESS]  Deaths  ................................................................................. 105 
[IP_ADDRESS]  Preexisting Medical Conditions  ............................................ 105 
[IP_ADDRESS]  Lack of Efficacy or Worsening of Melanoma  ........................ 106 
[IP_ADDRESS]  Hospi[INVESTIGATOR_351804] ........................ 106 
[IP_ADDRESS]  Adverse Events Associated with an Overdose or Error in Drug Administration  ................................................ [ADDRESS_437338]  ................... 108 
[IP_ADDRESS]  Events That Occur before Study Drug Initiation ................... 108 
[IP_ADDRESS]  Events That Occur after Study Drug Initiation  ...................... 108 
5.4.3   Reporting Requirements for Pregnancies  ............................ 109 
[IP_ADDRESS]  Pregnancies in Female Patients  .......................................... 109 
[IP_ADDRESS]  Pregnancies in Female Partners of Male Pa tients  ............... 109 
[IP_ADDRESS]  Abortions  ............................................................................. 109 
[IP_ADDRESS]  Congenital Anomalies/Birth Defects .................................... 110 
5.5  Follow -Up of Patients after Adverse Events  ........................ 110 
5.5.1   Investigator Follow -Up ......................................................... 110 
5.5.2   Sponsor Follow -Up .............................................................. 110 
5.6  Adverse Events That Occur after the Adverse Event Reporting Period........................................................ 110 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
9/Protocol CO39721,  Version [ADDRESS_437339] or Ethics  Committee  .................. 118 
8.4  Confidentiality  ...................................................................... 118 
8.5  Financial Disclosu re ............................................................ 119 
9. STUDY DOCUMENTATION,  MONITORING, AND 
ADMINISTRATION ................................................................................... 119 
9.1  Study Documentation  .......................................................... 119 
9.2  Protocol Deviations  .............................................................. 119 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
10/Protocol CO39721,  Version [ADDRESS_437340] and Subsequent Infusions  of 
Atezolizumab  .............................................................................. 61 
Table  3  Ophthalmologic Examination Schedule  ...................................... 69 
Table  4  Proposed Biomarkers for Exploratory Research ......................... 74 
Table  5  Recommended Cobimetinib Dose Modifications  ......................... 83 
Table  6  Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  .......... [ADDRESS_437341] v1.1 in All Melanoma Patients:  Study GP28363  ..................................................................................... [ADDRESS_437342] v1.1 in Patients with BRAF
V600-Wild-
Type Melanoma: Study GP28363  ............................................... 34 
Figure  4  Study Schema  ............................................................................. 40 
Figure 5  Treatment and Biopsy Schedule (Cohort A) ................................ 40 
Figure 6  Treatment and Biopsy Schedule (Cohort B) ................................ 41 
Figure  7  Treatment and Biopsy Schedule (Cohort C)  ............................... 41 
 
 
 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
11/Protocol CO39721,  Version [ADDRESS_437343] OF APPENDICES 
Appendix  1  Schedule of Activities  ................................................................ 127 
Appendix  2  Schedule of Pharmacokinetic, Immunogenicity, and 
Biomarker  Samples  ................................................................... 142 
Appendix  3  Response Evaluation Criteria in Solid Tumors:  Modified Excerpt from Original Publication  .............................................. 145 
Appendix  4  Response Evaluation Criteria in Solid Tumors:  Modified- Immune Criteria (Excerpt from Original Publication)  .. 157 
Appendix  5  Eastern Cooperative Oncology Group Performance Status Scale  ......................................................................................... 167 
Appendix  6  Preexisti ng Autoimmune Diseases and Immune Deficiencies  .. 168 
Appendix  7  Anaphylaxis Precautions  ........................................................... 169 
Appendix  8  Risks Associated with Atezolizumab and Guidelines for Management of Adverse Events Associated with Atezolizumab  ............................................................................ 170 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
12/Protocol CO39721, Version 5  PROTOCOL AMENDMENT ACCEPTANCE FORM  
TITLE:  A PHASE  IB STUDY  EVALUATING  COBIMETINIB  PLUS  
ATEZOLIZUMAB  IN PATIENTS  WITH  ADVANCED  
BRAFV600 WILD -TYPE  MELANOMA  WHO  HAVE  
PROGRESSED  DURING  OR AFTER  TREATMENT  WITH  
ANTI−PD-1 THERAPY  AND  ATEZOLIZUMAB  
MONOTHERAPY  IN PATIENTS  WITH  PREVIOUSLY  
UNTREATED  ADVANCED  BRAFV600 WILD -TYPE  
MELANOMA  
PROTOCOL NUMBER:  CO39721  
VERSION NUMBER:  [ADDRESS_437344] NUMBER:  2016- 004402- 34 
IND NUMBER:  135,[ADDRESS_437345] PRODUCTS:  Cobimetinib (RO5514041)  
Atezolizumab (RO5541267)  
MEDICAL MONITOR:   M.D. 
SPONSOR:  F. Hoffmann -La [COMPANY_002]  Ltd 
 
I agree to conduct the study in accordance with the current protocol.  
   
Principal Investigator ’s Name  (print)    
   
Principal Investigator ’s Signature   [CONTACT_77065].  Please return a copy as 
instructed by [CONTACT_112623].  

 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
16/Protocol CO39721, Version 5  • Cohort B (biopsy cohort):  Approximately [ADDRESS_437346] meet the following criteria for study entry:  
Disease- Specific Inclusion Criteria:  Cohorts A and B  
• Histologically confirmed Stage IV (metastatic) or unresectable Stage IIIc B RAFV600 WT 
(locally advanced) melanoma  
• Documentation of BRAFV600 mutation− negative status in melanoma tumor tissue (archival 
[< 5 years old] or newly obtained) through use of a clinical mutation test approved by [CONTACT_351834] (e.g., U.S. Food and Drug Administration [FDA] -approved test, CE-
marked [European conformity] in vitro diagnostic in E.U. countries, CLIA -certified NGS test, 
or equivalent)  
• Measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 
(RECIST v1 .1)  
• Disease progression during or after treatment with a PD -1 inhibitor either as monotherapy 
or in combination with other agent(s)  
 
Additional Disease- Specific Inclusion Criteria in Cohort B (Biopsy Cohort)  
• Patients in this cohort must have progressed during or after anti −PD-1 therapy within 
12 weeks before study start.  
• Patients in this cohort must have received a minimum of two cycles of anti −PD-1 therapy.  
• Patients in this cohort must meet criteria for primary (n = 6) or secondary (n = 6) resistance 
to an anti−PD-1 agent as outlined below:  
Primary resistance is defined as progressive disease, according to RECIST v1.1, as best response.  
Secondary resistance is defined as progressive disease after initial confirmed response according to RECIST v1.1,  
• Patients in this cohort must consent to undergo tumor biopsies of accessible lesions before 
and during treatment  and at radiographic progression for biomarker analyses.  
• Patients in this cohort must have at least two accessible lesions that are amenable to excisi onal or core- needle (minimum three cores and minimum diameter 18 gauge; however, 
16 gauge is desirable) biopsy with acceptable risk of a major procedural complication.  
Exceptions may be made if patient has only one lesion that allows multiple biopsies 
following discussion with Medical Monitor.  
 
Disease- Specific Inclusion Criteria:  Cohort C  
• Histologically confirmed Stage IV (metastatic) or unresectable Stage IIIc BRAFV600 WT 
(locally advanced) melanoma  
• Naive to prior systemic anti -cancer therapy for melanoma (e.g., chemotherapy, hormonal 
therapy, targeted therapy, immunotherapy, or other biologic therapi[INVESTIGATOR_014]), with the following 
exceptions:  
Adjuvant treatment with interferon- α (IFN-α), interleukin- 2 (IL- 2), or vaccine therapi[INVESTIGATOR_014], 
if discontinued at least  [ADDRESS_437347] 7 days prior to initiation of stu dy treatment  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
17/Protocol CO39721, Version 5  • Documentation of BRAFV600 mutation− negative status in melanoma tumor tissue (archival 
[< 5 years old] or newly obtained) through use of a clinical mutation test approved by [CONTACT_351834] (e.g., U.S. Food and Drug Administration [F DA]-approved test, 
CE-marked [European conformity] in vitro diagnostic in E.U. countries, CLIA -certified next -
generation sequencing [NGS] test or equivalent)  
• A representative, formalin- fixed, paraffin- embedded (FFPE) tumor specimen in a paraffin 
block (preferred) or [ADDRESS_437348] 
be obtained from a biopsy performed at screening.  
• Measureable disease according to R ECIST v1.1  
 
General Inclusion Criteria  
• Signed Informed Consent Form  
• Age ≥ 18 years  
• Ability to comply with the study protocol, in the investigator’s judgment  
• Eastern Cooperative Oncology Group Performance Status of  0 or 1  
• Available and adequate baseline tumor tissue sample (archival  [< 5 years old] or newly 
obtained biopsy ) 
• Life expectancy ≥  18 weeks  
• Adequate hematologic and end- organ function, defined using the following laboratory test 
results, obtained within 14 days before initiation of study treatment:  
Neutrophils (ANC ≥  1500 cells/ µL without granulocyte- colony stimulating factor support 
within 2 weeks before Cycle 1, Day  1) 
WBC counts >  2500 cells / µL and <  15,000 cells / µL 
Lymphocyte count ≥  500 cells/ µL 
Platelet count ≥  100,000 cells / µL (without transfusion within 2 weeks before Cycle 1, 
Day 1) 
Hemoglobin ≥ 9.0 g/dL (without transfusion)  
Serum creatinine ≤  1.5 × ULN or creatinine clearance (CrCl) ≥  40 mL/min on the basis of 
measured CrCl from a 24- hour urine collection or Cockcroft -Gault glomerular filtration 
rate estimation:  
CrCl = (140 −  age) × (weight in kg)  
( × 0.85 if female)  
72 × (serum creatinine in mg/dL)  
 
AST, ALT, and alkaline phosphatase ≤  2.5 ×  upper limit of normal (ULN), with the 
following exceptions.   
Patients with documented liver metastases:  AST and/or ALT ≤  5 × ULN.  Patients 
with documented liver or bone metastases:  alkaline phosphatase ≤  5 × ULN 
Serum albumin ≥  25 g/L  
Total bilirubin  ≤ 1.5 × ULN; patients with known Gilbert’s disease may have a 
bilirubin  ≤ 3.0 ×  ULN 
For patients not receiving therapeutic anticoagulation:  INR or aPTT  ≤ 1.5 ×  ULN within 
28 days before initiation of study treatment  
For patients receiving therapeutic anticoagulation:  stable anticoagulant regimen and 
stable INR during the 28 days immediately preceding initiation of study treatment  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
18/Protocol CO39721, Version 5  • For women of childbearing potential:  agreement to remain abstinent (refrain from 
heterosexual intercourse) or use contraceptive methods with a failure rate of <  1% per year 
during the treatment period and for [ADDRESS_437349] refrain from donating eggs 
during this same period.  
A woman is considered to be of childbearing potential if she is postmenarcheal, has not 
reached a postmenopausal state ( ≥ 12 continuous months of amenorrhea with no 
identified cause other than menopause), and has not undergone surgical sterilization 
(removal of ovaries and/or uterus).  
Examples of contraceptive methods with a failure rate of <  1% per year include bilateral 
tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone- releasing intrauterine devices, and copper intrauterine devices.  
The reliability of sexual abstinence should be evaluated in relation to the duration of the 
clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., 
calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not 
acceptable methods of contracept ion. 
• For men:  agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:  
With female partners of childbearing potential or pregnant female partners, men must 
remai n abstinent or use a condom during the treatment period and for at least [ADDRESS_437350] refrain from 
donating sperm during this same period.  
The reliability of sexual abstinence should be evaluated in relation to the duration of the 
clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence 
(e.g.,  calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are 
not acceptable methods of contraception.  
 
Exclusion Criteria  
Patients who meet any of the following criteria will be excluded from study entry:  
Cancer -Related Exclusion Criteria  
• Prior treatment with a MAPK inhibitor  
• Ocular melanoma 
• Major surgical procedure other than for diagnosis within 4 weeks before initiation of study 
treatment, or anticipation of need for a major surgical procedure during the course of the 
study  
• Traumatic injury within 2 weeks before initiation of study treatment  
• Palliative radiotherapy within 14 days before initiation of study treatment  
• Active malignancy (other than BRAFV600 mutation− negative melanoma) or malignancy 
within [ADDRESS_437351] 3  years  
Patients wit h a history of isolated elevation in prostate -specific antigen in the absence of 
radiographic evidence of metastatic prostate cancer are eligible for the study.  
• Treatment with any anti -cancer agent 14 days prior to Cycle, Day 1 other than aPD -1 based 
therapy  
• Adverse events from prior anti -cancer therapy that have not resolved to Grade ≤ 1  
Clinically stable patients with manageable immune- related adverse events resulting from 
prior cancer immunotherapy may be eligible for the study after discussion with and 
approval by [CONTACT_1689].  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
19/Protocol CO39721, Version 5  •For Cohort C, specific exclusion criteria include any prior anti -cancer therapy for advanced
melanoma
Ocular Exclusion Criteria (Cohorts A and B)  
•History of serous retinopathy
•History of retinal vein occlusion (RVO)
•Evide nce of ongoing serous retinopathy or RVO at baseline
Cardiac Exclusion Criteria (Cohorts A and B)  
•History of clinically significant cardiac dysfunction, including the following:
Unstable angina, or new -onset angina within 3 months before initiation of study 
treatment  
Symptomatic congestive heart failure, defined as [LOCATION_001] Heart Association Class II or 
higher  
Myocardial infarction within 6 months before initiation of study treatment  
Unstable arrhythmia  
History or presence of an abnormal ECG that is clinic ally significant in the investigator’s 
opi[INVESTIGATOR_1649], including complete left bundle branch block, second- or third- degree heart block, 
or evidence of prior myocardial infarction  
Left ventricular ejection fraction below the institutional lower limit of normal or  below 50%, 
whichever is lower  
Central Nervous System Exclusion Criteria  
•Untreated or actively progressing central nervous system (CNS) lesions (carcinomatous
meningitis)
Patients with stable and asymptomatic CNS metastases are eligible, if they meet all of the
following:
Measurable disease, per RECIST v1.1, must be present outside the CNS.  
All known CNS lesions  are clinically stable.  
CNS lesions have not been treated with whole- brain radiotherapy, except in patients 
who underwent definitive resection of or stereotactic therapy for all radiologically 
detectable parenchymal brain lesions.  
Absence of interim progression must be confirmed by [CONTACT_351835] [ADDRESS_437352] be completed ≥  [ADDRESS_437353] be discontinued ≥  2 weeks before initiation of study treatment.  
Treatment with an anticonvulsant at a stable dose is allowed.  
•History of metastases to brain stem, midbrain, pons, or medulla, or within 10 mm of the
optic apparatus (optic nerves and chiasm)
•History of leptomeningeal metastatic disease
Exclusions Related to Infections  
•HIV infection
•Active tuberculosis infection
•Severe infections within 4 weeks prior to Day 1 of Cycle 1 , including, but not limited to,
hospi[INVESTIGATOR_33377], bacteremia, or severe pneumonia
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
20/Protocol CO39721, Version 5  • Signs or symptoms of clinically relevant infection within  2 weeks prior to Day 1 of Cycle  1 
• Treatment with oral or IV antibiotics within 2 weeks prior to Day 1 of Cycle 1  
Patients receiving prophylactic antibiotics (e.g., for prevention of urinary tract infection or 
chronic obstructive pulmonary disease) are eli gible.  
• Active or chronic viral hepatitis B or C infection  
Patients with a past or resolved HBV infection, defined as having a negative HBsAg test 
and a positive total hepatitis B core antibody (HBcAb) test at screening, are eligible for 
the stud y if quanti tative HBV DNA <  500 IU/mL at screening. 
Patients with hepatitis C virus (HCV) infection are eligible if polymerase chain reaction test for HCV RNA is negative.  
 
Exclusion Criteria Related to Autoimmune Conditions and Immunomodulatory Drugs  
• Active or history of autoimmune disease or immune deficiency, including, but not limited to, 
myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, anti −phospholipid antibody syndrome, 
Wegener granulomatosis, Sjögren syndrome, Guillain -Barré syndrome, or multiple sclerosis, 
with the following exceptions:  
Patients with a history of autoimmune- related hypothyroidism who are on a stable dose 
of thyroid- replacement hormone are eligible for the study.  
Patients with controlled Type 1 diabetes mellitus who are on a stable insulin regimen are eligible for the study.  
Patients with a history of manageable immune- related adverse events resulting from 
prior immunotherapy may be eligible for the study after discussion with and approval by 
[CONTACT_1689].  
Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic 
manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the 
study provided all  of following conditions are met:  
Rash must cover less than 10% of body surface area.  
Disease is well controlled at baseline and requires only low −potency topi[INVESTIGATOR_351805] A radiation, methotrexate, retinoids, biologic agents, oral 
calcineurin inhibitors, or high- potency or oral corticosteroids within the previous 
12 months.  
• Prior allogeneic stem cell or solid organ transplantation 
• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), 
drug- induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on 
screening chest computed tomography scan  
History of radiation pneumonitis in the radiation field (fibrosis) is permitted.  
• Treatment with systemic immunosuppressive medication (including, but not limited to, 
prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti −tumor 
necrosis factor −alpha [ TNF-α] agents) within 2 weeks before initiation of study treatment, or 
anticipation of need for systemic immunosuppressive medication during the course of the 
study  with the following exceptions:  
Patients who have received acute, low -dose systemic immunosuppressant medication 
(≤ 10 mg/day oral prednisone or equivalent) or a one- time pulse dose of systemic 
immunosuppressant medication (e.g., [ADDRESS_437354] allergy) are eligible for the study  after Medical Monitor approval has been obtained . 
Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids
 for 
chronic obstructive pulmonary disease (COPD) or asthma, or low- dose corticosteroids 
for orthostatic hypotension or adrenal insufficiency are eligible for the study  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
21/Protocol CO39721, Version 5  Additional Exclusion Criteria 
• Current severe, uncontrolled systemic disease (including, but not limited to, clinically 
significant cardiovascular, pulmonary, or renal disease) other than cancer  
• Any Grade  ≥ 3 hemorrhage or bleeding event within 28 days of Day 1 of Cycle 1  
• History of stroke, reversible ischemic neurological defect, or transient ischemic attack within 
6 months prior to Day 1  
• Any psychological, familial, sociological, or geographic condition that may hamper 
compliance with the protocol and follow -up after treatment discontinuation  
• Inability or unwillingness to swallow pi[INVESTIGATOR_3353]  
• History of malabsorption or other clinically significant metabolic dysfunction that may 
interfere with absorption of oral study treatment  
• Pregnant or breastfeeding, or intending to become pregnant during the study  
Women of childbearing potential must have a negative serum pregnancy test result within 14 days before initiation of study treatment.  
• Known clinically significant liver disease, including alcoholism, cirrhosis, fatty liver, and 
other i nherited liver disease as well as active viral disease, including positive HIV test at 
screening  
• Any other disease, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding that contraindicates the use of an investigational drug,  may affect the 
interpretation of the results, or may render the patient at high risk from treatment 
complications  
• Treatment with a live, attenuated vaccine within 4 weeks before initiation of study treatment or anticipation of need for such a vaccine during the course of the study 
• Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary 
cells 
• Known hypersensitivity to any component of the atezolizumab or cobimetinib formulations  
• History of severe allergic, anaphylactic, or other  hypersensitivity reactions to chimeric or 
humanized antibodies or fusion proteins  
• Treatment with any other investigational agent or participation in another clinical study with 
therapeutic intent  
• Requirement for concomitant therapy or food that is prohibited during the study  
 
End of Study  
The study will end when all patients enrolled have been followed until death, have withdrawn 
consent, have been lost to follow -up, or when the Sponsor decides to end the trial, whichever 
occurs first.   
Length of S tudy  
The total length of the study, from first patient in until the end of follow -up, is expected to be 
approximately [ADDRESS_437355] Products (Investigational Drugs)  
Cobimetinib tablets  will be supplied by [CONTACT_1034].  The 20- mg cobimetinib drug product is a 
film-coated, white, round, immediate- release tablet.  Patients in Cohorts A and B will receive 
60 mg (three tablets of 20 mg each) orally QD for Days  1−21 of each 28- day cycle.  Thi s 4-week 
period is considered a treatment cycle.  
Atezolizumab will be supplied by [CONTACT_40857] 20- mL glass vials.  The vial is 
designed to deliver 20  mL (1200  mg) of atezolizumab solution but may contain more than the 
stated volume to enable delivery of the entire 20- mL volume.  For Cohorts A and B, extraction of 
14 mL of atezolizumab solution from a 1200 mg vial contains an 840- mg dose.   
Cohort A:  Patients will initiate dosing with atezolizumab concurrently with cobimetinib and will receive atezolizumab 840 mg intravenously Q2W on Days 1 and 15 of all cycles.  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
22/Protocol CO39721, Version 5  Cohort B:  Patients will receive the first dose of atezolizumab at 840 mg intravenously on Day 
15 of Cycle 1.  Thereafter, they will receive atezolizumab 840 mg intravenously Q2W on Days 1 
and 15 of Cycle 2 and all subsequent cycles.  
Cohort C:  Patients will receive atezolizumab [ADDRESS_437356] response rates of less than 17%.  For example, with 
102 patients in Cohorts A and B , observing 26 patients with objective response corresponds to 
ORR (95% CI) of 25.5%  (17.4%, 35.1%)  and observing 60 patients with disease control 
corresponds to a DCR (95% CI) of 58.8%  (48.6%, 68.5%).  
Enrolling [ADDRESS_437357] not been previously treated to allow for an accurate understanding of the 
achievable magnitude of efficacy in this population.   
For example, observing 17  patients with objective response corresponds to ORR (95% CI) of 
34.0% (21.1%, 48.8%) and observing 32 patients with disease control corresponds to DCR 
(95%  CI) of 64% (49.2%, 77.1%).  Enrolling [ADDRESS_437358] an optional interim analysis and the ti ming 
of the analysis will be documented in the Sponsor's trial master file prior to the conduct of the 
interim analysis.  The interim analysis will be performed and interpreted by [CONTACT_33482].  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
23/Protocol CO39721, Version [ADDRESS_437359] OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
Abbreviation  Definition  
ADA anti-drug antibody  (anti-therapeutic antibody)  
anti−PD-1 anti−programmed death-1 
anti−PD-L1 anti−programmed death ligand-[ADDRESS_437360]  
IND Investigational New Drug ( Application ) 
 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
24/Protocol CO39721, Version [ADDRESS_437361] 
IRR infusion- related reaction  
IV intravenous  
IxRS  interactive voice - or web -based response system  
LVEF  left ventricular ejection function  
MAPK  mitogen activated− protein kinase  
MHC  major histocompatibility complex 
MHCI  major histocompatibility complex class I  
MRI magnetic resonance imaging 
MUGA  multiple -gated acquisition  
NCI CTCAE  National Cancer Institute Common Terminology Criteria 
for Adverse Events  
NGS  next-generation sequencing 
NRAS  neuroblastoma RAS 
NSCLC  non− small cell lung cancer  
OCT  optical coherence tomography  
OR objective response  
ORR objective response rate  
OS overall survival  
PD progressive disease  
PD-1 programmed death− 1 
PD-L1 programmed death− ligand [ADDRESS_437362]  Response Evaluation Criteria in Solid Tumors  
RVO  retinal vein occlusion  
QD once daily  
QW every week  
Q2W  every 2 weeks  
Q3W  every 3 weeks  
Q4W  every 4 weeks  
SD stable disease  
 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
25/Protocol CO39721, Version [ADDRESS_437363] upper limit of normal 
VF visual field  
WT wild type  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
26/Protocol CO39721, Version 5  1. BACKGROUND  
1.1 BACKGROUND ON MELANOMA  
1.1.1  Incidence and Pathogenesis  
Melanoma is a potentially deadly form of skin cancer that originates from melanocytes.  
The clinical outcome of patients with melanoma is highly dependent on the stage of 
disease at presentation.   Although the outcome for promptly diagnosed superficial 
tumors is good and despi[INVESTIGATOR_351806] , melanoma is associated with 
high rates of mortality and disease- related morbidity  in the metastatic setting (see 
Section 1.1.2 ).  
In 2012, there were about  232,000 new cases and 55,000 deaths from melanoma 
worldwide, with more than 100,000 new cases and 22,000 deaths in Europe (Ferlay  et al. 2013).  In the [LOCATION_002], an estimated 76,380 new cases of melanoma 
will be diagnosed and approximately 10,130 patients are expected to die of the disease in 2016 (American Cancer Society 2016).  Moreover, the number of melanoma cases worldwide is increasing faster than any other cancer, especially in fair -skinned, 
Caucasian populations (Diepgen and Mahler  2002); estimates suggest a doubling of 
melanoma incidence every 10− 20 years (Garbe and Leiter  2009).  The incidence is 
particularly high among Caucasian populations in Australia (42.4 per 100,000) and Western Europe (10.6 per 100,000) (American Cancer Society 2016 ). 
The mitogen−activated protein kinase (MAPK) signaling cascade is a key intracellular signaling network that transduces multiple proliferative and differentiating signals from the extracellular environment to the nucleus of cells to activate cellular growth and differentiation ( Johnson and Lapadat 2002; Roberts and Der 2007 ).  This pathway is 
highly implicated in pathogenesis of melanoma.  Approximately 40% −50% of all 
melanomas harbor an activating mutation in BRAF , a major driver of MAPK signaling 
(Davies et al . 2002; Curtin et al . 2005 ; Jakob et al 2012) , and an additional 15% −30% 
harbor an activating mutation of  neuroblastoma RAS (NRAS ) (Lee et al . 2011; CGAN  
2015) .  Approximately 14% harbor  mutations of NF1, an inhibitory protein of the MA PK 
pathway ( CGAN 2015) .  Thus, the MAPK pathway is an important driver of pathogenesis 
in BRAF
V600 wild-type (WT)  melanoma , as well as BRAFV600-mutated melanoma. 
1.1.[ADDRESS_437364]- line treatment with response rates of 5% –12%, median 
progression- free survival (PFS) of less than 2  months,  and a median overall survival (OS) 
of 6.4−9.1 months ( Middleton et  al. 2000; Bedikian et al. 2006 ; Chapman et  al. 2011; 
Robert et  al. 2011).  Combination chemotherapy and chemotherapy combined w ith 
interferon (IFN) -alpha or interleukin -2 (IL-2), although  showing improved response rates, 
have not resulted in improved OS ( Chapman et al. 1999; Ives et  al. 2007 ). 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
27/Protocol CO39721, Version [ADDRESS_437365] has emerged as an  effec tive treatment 
strategy in BRAFV600-mutated melanoma , and several targeted therapi[INVESTIGATOR_351807] (Richman et al. 2015).  
Treatment options for BRAFV600 WT melanoma have also improved dramatically  with 
approvals of several immunotherapeutic agents.  Melanoma cells are highly 
immunogenic and thus an appropriate target for these agents (Zhu et al 2016).  T-cell 
activation is an essential component of cell -mediated immunity, which has led to the 
development of immunomodulation as a strategy for anti -cancer therapy.  The two -signal 
model of T -cell activation involves interaction of the T -cell receptor (TCR) with its antigen 
(signal one), followed by [CONTACT_351836], which is a co- stimulatory interaction between CD28 
on the T -cell surface and its ligand B7 -1 on antigen- presenting cells  (Chen and Flies 
2013).  Co-inhibitory receptors, or “immune checkpoints”, including CTLA -4 and 
programmed death −1 (PD-1) receptor can prevent T -cell overactivation and 
downregulate the immune system, protecting against autoimmunity (Freeman et al. 
2000).  Targeting of these checkpoints can render cancer cells susceptible to immune 
attack and has been applied in the treatment of melanoma.   
Immunotherapeutic agents currently available for advanced melanoma include the 
following : 
• The anti−CTLA -4 antibody , ipi[INVESTIGATOR_125]  
• Two anti−PD-1 antibodies, nivolumab and pembrolizumab 
• N ivolumab and ipi[INVESTIGATOR_351808]− PD-1 agents can be prolonged, they are limited to 30% −40% 
of patients across several  clinical trials .  Median PFS for these agents is 5 −6 months  
(Robert et al . 2015a; Robert et al . 2015b ; Weber  et al. 2015) , and OS is approximately  
20−24 months (Hodi et al 2016; Robert et al.  2016) .  Reported response rates  for 
ipi[INVESTIGATOR_351809] 10%−15% and OS 10− 11 months ( Hodi et al . 2010; 
Robert  et al. 2011 ).  In Phase III studies  in previously untreated patients with advanced 
melanoma,  the combination of ipi[INVESTIGATOR_351810] ( ORR) and improved PFS relative to either agent as  monotherapy, but it 
resulted in challenging toxicity, with more than 50% of patients experiencing Grade ≥ 3 
adverse events.  The OS benefit for this combination is not yet known 
(Larkin et al. 2015 ). 
Thus, despi[INVESTIGATOR_351811], there still 
exists a high unmet need for all patients with advanced BRAFV600 WT melanoma.  
For BRAFV600 WT patients whose disease relapsed or is refractory to anti −PD-1 agents, 
treatment options are currently limited to ipi[INVESTIGATOR_125] ( if they have not previously received 
this agent ), chemotherapy, or rechallenge with anti −PD-1 therapy.  Consequently , there 
is an urgent need to develop new therapi[INVESTIGATOR_351812]. 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
28/Protocol CO39721, Version [ADDRESS_437366] in melanoma cells ( Solit et al. 2006; Haass et al. 2008).   In vitro, 
MEK inhibitors reduce cell proliferation, soft agar colony formation, and matrigel invasion of BRAF
V600 mutation− positive melanoma cells and are also effective against BRAFV600 
mutation− positive melanoma xenografts, suggesting a potentially important role for MEK 
inhibitors in melanoma and other tumors that harbor the BRAFV600 mutation 
(Solit et al. 2006).   
Cobimetinib (Cotellic®) is approved for use with vemurafenib for the treatment of 
advanced BRAFV600-mutated melanoma in the European Union, [LOCATION_002], and 
Switzerland as well as a number of other countries across the world.  
Cobimetinib shows anti -tumor activity in both nonclinical models and cancer patients and 
is being investigated as a potential therapy in a wide variety of malignancies, in combination with chemotherapy, other targeted therapi[INVESTIGATOR_014], and cancer immunotherapy.  
Refer to the Cobimetinib Investigator ’s Brochure for details on nonclinical and clinical 
studies.  
1.2.2  Atezolizumab  
Atezolizumab is  a humanized immunoglobulin G1 monoclonal antibody that targets 
programmed death −ligand 1 (PD -L1) and inhibits the interaction between PD -L1 and its 
receptors, PD -1 and B7 -1 (also known as CD80), both of which function as inhibitory 
receptors expressed on T cells.  Therapeutic blockade of PD -L1 binding by [CONTACT_351837] -specific T- cell 
responses, resulting in improved anti -tumor activity ( Fehrenbacher et al. 2016; 
Rosenberg et al. 2016).  Atezolizumab has minimal binding to fragment crystallizable 
(Fc) + receptors, thus eliminating detectable Fc -effector function and associated 
antibody -mediated clearance of activated effector T cells. 
Atezolizumab shows anti -tumor activity in both nonclinical models  and cancer patients 
and is being investigated as a potential therapy in a wide variety of malignancies.  Atezolizumab is being studied as a single agent in the advanced cancer and adjuvant therapy settings, as well as in combination with chemotherapy, tar geted therapy, and 
cancer immunotherapy.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
29/Protocol CO39721, Version 5  Atezolizumab (Tecentriq®) is approved in the [LOCATION_002] for the treatment of patients 
with locally advanced or metastatic urothelial bladder carcinoma and metastatic 
non− small cell lung cancer (NSCLC) who have disease progression during or following 
platinum -containing chemotherapy  and are  currently in clinical develop ment for other 
indications.  
Refer to the Atezolizumab Investigator's Brochure for details on nonclinical and clinical studies.  
1.3 STUDY RATIONALE AND BENEFIT -RISK ASSESSMENT  
1.3.1  Rationale for C ombining Cobimetinib and Atezolizumab for 
Advanced BRAFV600 Wild-Type Melanoma after Progression on 
Anti-PD-1 Therapy  
The rationale for combining cobimetinib, a MEK inhibitor,  with atezolizumab, an 
anti−PD-L1 antibody, in treatment of patients with advanced BRAFV600 WT melanoma is 
based on the complementary mechanisms of action of these agents , as well as on 
observations that the effects of MAPK pathway inhibition on tumor microenvironment 
may enhance anti-tumor T  cell−mediated immunity .  This rationale is supported by 
[CONTACT_351838].   
As detailed in Sections 1.1.2  and Section 1.3.2 , only 30%– 40% of patients with 
metastatic melanoma respond to anti −PD-1 monotherapi[INVESTIGATOR_014] , and many of those who 
respond initially eventually progress.   Patients who do not  respond or attain disease 
stabilization  are defined as having refractory disease or primary resistance, whereas 
those whose tumors progress after initial response or stabilization are defined as having relapsed disease or secondary resistance.   The molecular mechanisms of primary and 
secondary resistance to immunotherapy are poorly understood.  However, the known 
effects of MAPK inhibitors, including cobimetinib, on tumor mic roenvironment  (see 
Section 1.3.4 ) include effects that may enable conversion to an immuno- responsive 
phenotype, s ensitize refractory tumors to anti −PD-1/PD-L1 agents , and/or resensitize 
relapsed tumors  to these agents , leading researchers to the hypothesis that combining 
MEK inhibition with anti− PD-1/PD -L1 therapy may lead to improved efficacy .  This 
hypothesis is supported by [CONTACT_351839]28363 (see Section 1.3.5 ), which 
has shown that combination therapy with cobimetinib and atezolizumab in advanced 
melanoma results in improved ORR and PFS  relative to  either PD -1/PD -L1 or MEK 
inhibitor monotherapy .  
[IP_ADDRESS]  Rationale for Atezolizumab Monotherapy for P reviously 
Untreated Patients with Advanced BRAFV600-Wild -Type 
Melanoma  
While evidence of efficacy of atezolizumab monotherapy in melanoma has also been demonstrated  in Study PCD4989g, as described below , the patient population was 
heterogeneous with respect to line of therapy and BRAF
V600 status.   Enrolling a cohort of 
previously untreated patients with advanced BRAFV600 WT melanoma in a separat e 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
30/Protocol CO39721, Version 5  atezolizumab monotherapy cohort will allow a more accurate evaluat ion of the 
magnitude of efficacy achievable, pharmacokinetics , and safety profile  in this patient 
population.  In addition, it will  allow comparison of the potential molecular mechanisms of 
resistance to checkpoint inhibitor therapy between patients  in Cohort C and those  
previously treated patients enrolled in Cohorts A and B.   
1.3.2  Activity of Atezolizumab in Advanced Melanoma  
[IP_ADDRESS]  Study PCD4989g:  Atezolizumab Monotherapy  
In the Phase Ia setting (Study PCD4989g), atezolizumab monotherapy has shown 
anti-tumor efficacy  in melanoma efficacy parameters  comparable to those documented 
reported for  two PD -1 inhibitors that are currently approved for the treatment of 
melanoma (pembrolizumab and nivolumab; Hodi et al . 2014;  see Figure  1).  In patients 
with metastatic  non-ocular  melanoma enrolled i n Study PCD4989g who received doses 
of at least 10  mg/kg every 3 weeks ( Q3W ; N = 37), ORR by  [CONTACT_351840] 1.1 ( RECIST v1.1 ) was 33% and m edian PFS was 5.5 months  
as of the 15 December  2015 data cut .  In addition, atezolizumab monotherapy was well  
tolerated by [CONTACT_351841]. 
Figure  1 Phase I Study  of Atezolizumab Monotherapy in Cutaneous 
Melanoma  
 
mPFS  = median progression- free survival; ORR  = objective response rate; SLD  = sum longest 
diameter . 
Note:  n  = 37. 
 
Please see the current A tezolizumab I nvestigator ’s Brochure for the most current safety 
and efficacy data from atezolizumab studies.   

 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
31/Protocol CO39721, Version [ADDRESS_437367] proven 
efficacy in advanced BRAFV600-mutated melanoma (Chapman et al. 2011; Flaherty et al . 
2012; Larkin et al. 2014; Long et al . 2014 ; Robert et al . 2015a), and cobimetinib in 
combination with vemurafenib is approved in this indication.  
As described in S ection  1.1.[ADDRESS_437368] anti-tumor activity of MEK inhibition in a subset 
of patients with BRAFV600 WT melanoma has recently been provided by [CONTACT_351842] [STUDY_ID_REMOVED] (NEMO ), which showed improved PFS  for single -agent binimetinib, 
a small molecule MEK inhibitor, in patients with BRAFV600 WT, NRAS -mutated, 
advanced melanoma when compared with dacarbazine ( hazard ratio  = 0.62; 
Dummer et al. 2016). 
1.3.[ADDRESS_437369] was 
shown to increase antigen expression and enhance reactivity to antigen −specific 
T lymphocytes (Boni et al. 2010).  Further,  in tumor biopsies from melanoma patients, 
BRAF  and MEK inhibitors, alone or in combination, have been shown to increase 
melanoma antigen expression, major histocompatibility complex ( MHC ) expression, 
T-cell infiltration, and PD -L1 expression ( Wilmott et al. 2012; Frederick  et al. 2013; 
Kaka vand et al.  2015; Liu et al. 2015 ; Hu-Lieskovan et al. 2015 ).  MEK inhibition has 
also been shown to increase tumor MHC expression and PD -L1 expression in 
triple -negative breast cancer cells in  vivo and in vitro ( Loi et al. 2016).   
Additional MAPK inhibition effects may further modulate the tumor microenvironment in 
ways that could enable an improved immune reaction against the tumor.  These effects include increased recruitment and activation status of CD8
+ and CD4+ T cells  and 
reduced secretion of granulocyte colony -stimulating factor  (G-CSF)  with reduced 
mobilization and activity of CD11- positive GRL+ myeloid−derived suppressor cells 
(Phan et al. 2013; Ebert et al. 2016), as well as reduced expression of angiogenesis 
factors with altered tumor vascular support (Ciuffreda et al. 2009 ; Chang et al. 2013; 
Mohan et al. 2015 ). 
In addition, the MEK inhibitor G -[ZIP_CODE], which is mechanistically similar to cobimetinib, 
promotes the effector phenotype and longevity of tumor -infiltrating T cells in a CT26 
colon cancer mouse model and combines synergistically with anti −PD-L1 in inhibiting 
growth of CT26 tumors (Ebert et al. 2016 ).   
The nonclinical and clinical data described above show  that inhibition of the MAPK 
pathway leads to an increase in immune effector cells in the tu mor, thereby  [CONTACT_351843].   
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
32/Protocol CO39721, Version 5  1.3.5  Clinical Data for  Combination Treatment with Cobimetinib and 
Atezolizumab in Advanced Melanoma  
[IP_ADDRESS]  Study GP28363  
Study GP28363 is an ongoing Phase Ib, open -label, multicenter study designed to 
assess the safety, tolerability, and pharmacokinetics of cobimetinib plus atezolizumab in 
patients with advanced solid tumors who are naive to anti −PD-[ADDRESS_437370] therapy is available.  
The study has two stages:  Stage 1 (dose escalation) and Stage 2 (expansion).  
Stage  1 is designed to establish the combination maximum tolerated dose or maximum 
administered dose for cobimetinib plus atezolizumab.  In Stage 2, the recommended 
Phase II dose and schedule were investigated in tumor -specific expansion cohorts:  
metastatic melanoma, KRAS -mutant and WT metastatic colorectal cancer (CRC), and 
NSCLC.   
In a separate mandatory biopsy cohort, patients with diverse solid tumors (n  = 16), 
including CRC, received 60 mg of cobimetinib once daily (QD) as monotherapy before initiation of atezolizumab treatment and underwent mandatory fresh biopsy collection before initiation of cobimetinib dosing and at the end of the 14- day period of cobimetinib 
monotherapy.  
During the Sta ge 1 dose -escalation phase, there were no dose- limiting toxicities, and 
60 mg of cobimetinib on a 21 days on/7 days off schedule with 800 mg of atezolizumab 
every 2  weeks (Q2W) was determined to be the recommended Phase  II dose  
(Miller  et al. 2017). 
[IP_ADDRESS].1  Effica cy in Non- Ocular Melanoma  
As of the data cutoff ( 17 January 2017), 20 patients with non- ocular melanoma, including 
10 patients with BRAFV600-mutated disease and 10 patients with BRAFV600 WT disease 
who had received no prior anti −PD-1 or anti−PD-L1 therapy, were evaluable for efficacy.  
The data were comparable in both BRAFV600-mutant and BRAFV600 WT melanoma.  Of 
note, [ADDRESS_437371] v1.1 responses for all melanoma patients and BRAFV600 WT 
melanoma patients, respectively.  
Among these patients (n  = 20), the ORR was 45% (confirmed response per  
RECIST  v1.1), disease control rate (DCR; defined as a complete response  [CR], a 
partial response [PR], or stable disease [SD]) was 75%, and median PFS was  15.7 
months (95% CI: 2.8, not evaluable).  Patients with metastatic melanoma had durability of response, as shown over time in Figure  2 (Miller et a l. 2017). 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
33/Protocol CO39721, Version [ADDRESS_437372] v1.1 in All Melanoma Patients:  Study GP28363  
 
CR  = complete response; PD  = progressive disease; PR  = partial response; RECIST 
v1.1  = Response Evaluation Criteria in Solid Tumors, Version 1.1, SD  = stable disease.  
Note:  n  = 10. 
 
For patients with BRAFV600 WT melanoma, the ORR was 50% (confirmed response per 
RECIST  v1.1), the DCR was 80%, and median PFS was 15.7 months (95%  CI: 2.8, not 
evaluable).  Patients with BRAFV600 WT metastatic melanoma had durability of response 
(confirmed response per RECIST v1.1), as shown in Figure  3.  

 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
34/Protocol CO39721, Version [ADDRESS_437373] v1.1 in Patients with BRAFV600  Wild -Type Melanoma: 
Study GP28363  
 
CR  = complete response; PD  = progressive disease; PR  = partial response; RECIST 
v1.1  = Response Evaluation Criteria in Solid Tumors, Version 1.1, SD  = stable disease.  
Note:  n  = 10 
 
Biomarker Data  
Biomarker evaluation from the serial tumor biopsy cohort showed a 4- fold increase in 
CD8-positive  T-cell infiltration in 75% of tumors, as well as increases in PD -L1 and 
MHC -I (major histocompatibility complex class I) expression (Bendell et al. 2016 ).  The 
data support the hypothesis that cobimetinib has beneficial immunomodulatory effects at 
the tumor site that allow for immune anti- tumor activity.  
Safety in Patients with Non -Ocular Melanoma  
At the time of the data cutoff ( 17 January 2017), 22 patients with melanoma, including 
20 with non- ocular melanoma and 2 patients with ocular melanoma, were evaluated for 
safety.  The median safety follow -up in these patients (n  = 22) was 19.4  months (range, 
1.4−26.3 months).  All grade adverse events occurred in 100% of patients; study 
treatment −related Grade s 3 and 4 adverse events were reported for 59.1% of patients, 
with diarrhea and dermatitis acneiform being the most common (reported for 3 patients [13.6%] and 2  patients  [9.1%], respectively).  All adverse events were manageable.  
Although no cobimetinib- related Grade 5 adverse event s occurred, 14% of patients had 

 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
35/Protocol CO39721, Version 5  study treatment −related serious adverse events, 82% of patients had an adverse event 
leading to study treatment dose modification and/or interruption, and 27 % of patients 
had discontinued at least one treatment because of adverse events.  
Safety in All Patients  
As of 17 January 2017, a total of 150 patients were enrolled in the study and evaluable 
for safety.  Fourteen patients had been accrued in the dose- escalation phase (Stage 1, 
Cohorts  1−3), and 136 patients had been accrued in the expansion phase (Stage 2).  
To be considered evaluable for safety, patients must have received at least one dose of atezolizumab.  All patients who received atezolizumab also received cobimetinib.  The 
mean duration of safety follow -up was  3.3 months (0.0 −31.3 months) .  Safety follow -up 
is defined as the number of days from date of first dose to the minimum of date of last 
dose
 + 30 days, discontinuation date, initiation date of anti -cancer therapy, cutoff date, or 
death date.   
Overall, 98.7% of patients experienced at least one adverse event regardless of 
attribution; 64 .0% experienced a Grade ≥ 3 adverse event; and 44.  7 % experienced a 
serious adverse event.  There were 7 (4 .0%) Grade 5 (fatal) adverse events in the study, 
of which [ADDRESS_437374] common adverse events (occurring in ≥
 20% of patients) were diarrhea 
(70.7%), fatigue ( 56.0%), rash ( 48.0%), vomiting ( 42.0%), nausea ( 36.0%), pruritus 
(35.3%), decreased appetite ( 34.7%), constipation ( 29.3%), peripheral edema (26.0%), 
pyrexia (23.3%), acneiform dermatitis (23.3%), increased creatine phosphokinase (CPK) (22.7%), dyspnea (20.0%), and anemia (20.0%).  The most common Grade
 ≥ 3 events 
(occurring in ≥ 5% of patients) were fatigue ( 10.0%), ane mia 9.3%, and diarrhea (8.0%).  
In the 17 Jan 2017 data cut for melanoma, the safety data were  generally similar.  
The mean duration of safety follow -up was 19.4 months (range: 1.4−26.3 months).  For 
treatment -related adverse events, 100% of patients experienced at least one adverse 
event; 59.0% of patients experienced a Grade ≥ 3 adverse event; and 14.0% of patients 
experienced a serious adverse event and included pulmonary embolism, bacterial infection, and pain management.  There was one (treatment -unrelated) Grade 5 (fatal) 
adverse event in the melanoma cohort. 
The most common treatment -related adverse events (occurring in ≥ 20% of melanoma 
patients) , as of 17 Jan 2017 , were diarrhea (86.0%), rash (68.0%), fatigue (45.0%), 
nausea (45.0%), pruritus (45.0%), blood creatine phosphokinase increased (32.0%), 
vomiting (32.0%), abdominal pain (23.0%), decreased appetite (23.0%), and dermatitis acneiform (23.0%).  In this cohort, the most common Grade  ≥ 3 events (occurring in 
≥ 5% of patients) were diarrhea (14.0%), anemia (9.0%), dermatitis acneiform (9.0%), 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
36/Protocol CO39721, Version 5  amylase increased (5.0%), asthenia (5.0%), bacterial infection (5.0%), edema peripheral 
(5%), lipase increased (5.0%), maculopapular rash (5.0%), musculoskeletal pain (5.0%), myalgia (5.0%), rash (5.0%), pain management (5.0%), pulmonary embolism (5.0%), pruritus (5.0%), seizure (5.0%), and vomiting ( 5.0%).  
[IP_ADDRESS].[ADDRESS_437375] that cobimetinib may alter tumor immune 
contexture, thereby [CONTACT_351844].  The safety profile was consistent with other cobimetinib studies, and no new safety concerns were reported.  
1.3.6  Risk -Benefit Statement 
This Phase Ib protocol includes eligibility criteria, baseline measurements, and 
recommendations for management of adverse events, including guidelines for dose 
modifications, delays, and discontinuation of one or more of the study drugs in order  to 
enhance the saf ety of patients in this trial.  Oversight will be provided by [CONTACT_351845] .   
Treatment options are extremely limited for patients with advanced BRAFV600 WT 
melanoma whose disease has progressed on or after treatment with an anti −PD-1 
therapy.  Given  1) the observed efficacy and safety data for cobimetinib and 
atezolizumab as single agents and in combination in the Phase Ib study GP28363, 2) 
biomarker data from Study  GP28363, suggest ing that the effects of cobimetinib on tumor 
immune contexture may sensitize refractory tumors or re- sensitize relapsed tumors to 
anti−PD-1/PD -L1 agents, and 3) the extent of safety monitoring proposed, the potential 
benefits for patients receiving this combination treatment for advanced melanoma 
outweigh the potential risks.  
The observed efficacy data for atezolizumab as a single agent in Study PCD 4989g 
suggests comparable efficacy to the currently available anti -PD-[ADDRESS_437376] progressed on prior anti −PD-1 
therapy  and atezolizumab monotherapy in patients with previously untreated advanced 
BRAFV600 WT melanoma .  Specific objectives and corresponding endpoints are outlined 
in Table 1 . 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
39/Protocol CO39721, Version [ADDRESS_437377] progressed on a prior anti −PD-[ADDRESS_437378] 
progressed on a prior anti −PD-1 therapy will be enrolled in Cohorts A and  B of this study  
(see Figure  4). 
• Cohort A:   Approximately [ADDRESS_437379] progressed on or af ter treatment 
with an anti -PD-1 agent  will be enrolled.  
• Cohort B  (biopsy cohort ):  Approximately [ADDRESS_437380] not received any prior anti -cancer treatment in the 
metastatic setting will be enrolled  in Cohort C. 
Cohort A and B  
All cycles will be 28 days  in length for Cohort s A and  B.  Patients in C ohort A will begin 
dosing with cobimetinib and atezolizumab concurrently and will receive in all cycles 
840 mg atezolizumab intravenous  (IV) Q2W and 60 mg cobimetinib QD 21/7 
(see Figure  5).   
Patients in Cohort B  (biopsy cohort ) will also receive 60 mg  cobimetinib QD 21/[ADDRESS_437381] 14 days of 
Cycle  1.  Atezolizumab dosing (840 mg IV ) will begin  on Day 15, Cycle 1, and will 
continue thereafter at 840 mg IV Q 2W.  In Cycle 2 and all subsequent cycles, patients in 
this cohort will r eceive 60 mg cobimetinib QD 21/7 and 840 mg atezolizumab IV Q2W 
(see Figure 6).  
Cohort C  
All cycles  in Cohort C will be 21 days in length.  Patients in Cohort C  will receive 
atezolizumab (1200 mg) Q3W ( see Figure 6). 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
40/Protocol CO39721, Version 5  Figure  4 Study Schema  
 
 
aPD-1 = anti−programmed cell death 1; ECOG  = Eastern Cooperative Oncology Group;  
PD  = progressive disease; PS  = performance score;  RECIST  = Response Evaluation Criteria in 
Solid Tumors.  
 
Figure 5 Treatment and Biopsy Schedule (Cohort A)  
 
D = day; IV  = intravenous; PO  = by [CONTACT_1966].  
 

Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
42/Protocol CO39721, Version 5  All patients will be closely monitored for safety and tolerability throughout the study.  
The National Cancer Institute Common Terminology  Criteria for Adverse Events, 
Version 4.0 (NCI CTCAE v4.0) will be used to characterize the toxicity profile of the 
study treatments for all patients.  The protocol includes a detailed risk management plan for monitoring and managing molecule- specific and potential combination toxicities 
(see Section 5). 
For all cohorts, tumor response will be evaluated by [CONTACT_3142] v1.1 ( see Appendix  3); immune-m odified RECIST v1.1 (see Appendix  4) will 
also be assessed by [CONTACT_093] .  For Cohort C, tumor response will also be 
determined by [CONTACT_351846] ( IRC) according to RECIST  v1.1 .  All 
measurable and non -measurable lesions will be documented at screening.   Response 
will be as sessed at 8 -week intervals until in vestigator -determined disease progression 
(according to RECIST v1.1), death, or initiation of subsequent  anti-cancer therapy, 
whichever occurs first.  Patients who experience disease progression must have scans  
repeated 4 weeks after initial documentation of progression to confirm disease 
progression.  Tumor assessments are to continue according to schedule in patients who discontinue treatment for reasons other than confirmed disease progression, unless subsequent anti -cancer therapy is initiated.  
Study treatment will continue for all patients until investigator -determined disease 
progression (confirmed 4 weeks later, for clinically stable patients with a favorable benefit -risk assessment ), death, unacceptable toxicity, or pregnancy, whichever occurs 
first.  Patients in Cohort s A and B who discontinue one study drug may be abl e to 
continue the remaining study drug  per guidelines for management of specific adverse 
events provided in Table [ADDRESS_437382].  
3.1.1  Biopsies and Archival Tissue  
Biomarker assessments on tumor biopsy tissue are an important part of this study and will be used to elucidate mechanisms of resistance to anti −PD-1/anti−PDL-[ADDRESS_437383] 
provide archival (<  5 years  old) tissue or a fresh biopsy before treatment start . 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
43/Protocol CO39721, Version 5  [IP_ADDRESS]  Optional Biopsies (Cohort A)  
Patients in Cohort A will be requested, via separate optional consent, to provide biopsies 
(core needle [minimum three cores and minimum diameter 18  gauge; 16 gauge is 
preferable] or excisional  biopsy) for the study of pharmacodynamic changes related to 
the activity of cobimetinib and atezolizumab.  For patients who consent to biopsies, a predose specimen will be obtained after eligibility criteria have been fulfilled before  
Cycle  1, Day  1, only if archival tissue (<  5 years old) was provided for the BRAF  WT 
testing .  Predose specimens are not required for patients who provide a fresh biopsy 
before treatment start.  A subsequent biopsy will be performed 4 −[ADDRESS_437384] 
atezolizumab dose.  An additional biopsy may be collected per investigator discretion, preferably at the time of radiographic progression or response.  
[IP_ADDRESS]  Mandatory Biopsies (Cohort B)  
Patients enrolled in Cohort B, the biopsy cohort, must have at least two (preferably three) accessible lesions that  meet the requirements specified in the eligibility criteria.  
Exceptions may be made if patient has only one lesion that allows multiple biopsies following discussion with Medical Monitor .  One pretreatment , up to  two on-treatment 
biopsies , and one post -progression biopsy  will be performed.  If more than one biopsy 
will be obtained from one lesion, the lesion should be large enough to permit successive 
biopsies ≥
 1 cm apart.  Investigators are strongly encouraged to obtain two on- treatment 
biopsies as described below; at a minimum, the Day 10− [ADDRESS_437385] for possible immunologic effects of cobimetinib alone.  
Patients in the biopsy cohort will undergo biopsies according to the following schedule:  
• A predose biopsy will be taken before Day 1, Cycle 1 .  (The predose biopsy is not  
required if a fresh biopsy was provided during screening ). 
• On Day 1, Cycle 1, patients will start treatment with cobimetinib alone. 
• A mandatory on- treatment biopsy will be obtained between Days 10 and 14 of 
Cycle  1. 
• Patients will receive their first atezolizumab dose on Day 15 of Cycle 1.  
• A second, optional, on- treatment biopsy will be obtained during Cycle 2, 4 −[ADDRESS_437386] dose of atezolizumab to assess the combined effects of cobimetinib 
and atezolizumab.  
• A mandatory, post -treatment biopsy will be obtained at the time of radiographic 
progression . 
 
Patients in tumor biopsy cohorts whose tissue sample is not evaluable may receive 
study treatment, but these patients may be replaced for the purpose of serial biopsy assessment. 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
44/Protocol CO39721, Version [ADDRESS_437387] provided specific consent in order for discarded samples from routine care to be obtained. 
[IP_ADDRESS]  Optiona l Biopsies (Cohort C)  
Patients in Cohort C  are required to provide archival tissue or fresh biopsy during 
screening.  They  will be requested to provide optional fresh biopsies (core needle 
[minimum three cores and minimum diameter 18  gauge; 16 gauge is preferable] or 
excisional biopsy) for the study of tumor immun e contextures related to activity or 
resistance of atezolizumab.  For patients who consent to biopsies, a predose specimen 
will be obtained after eligibility criteria have been fulfilled  before Cycle 1, Day [ADDRESS_437388] v1.1 −defined disease progression is allowed 
for patients in all treatment arms.  
Atezolizumab will be administered by [CONTACT_22671] a fixed dose of 840 mg Q2W 
(Cohorts A  and B) and 1200 mg IV Q3W (Cohort C) until unacceptable toxicity or loss of 
clinical benefit, as determined by [CONTACT_093], after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status (e.g., symptomatic deterioration such as pain secondary to disease).  Due to the 
possibility of an initial increase in tumor burden caused by [CONTACT_351847] a T-cell response (termed pseudoprogression) with atezolizumab treatme nt, 
radiographic progression per RECIST v1.[ADDRESS_437389]  v1.1 while receiving atezolizumab will be permitted to 
continue atezolizumab if they meet all of the following criteria:  
• Evidence of clinical benefit , as determined by [CONTACT_169830] a review of 
all available data 
• Absence of symptoms and signs (including laboratory values, such as new or 
worsening hypercalcemia) indicating unequivocal progression of disease  
• No decline in Eastern Cooperative Oncology Group (ECOG) Performance Status that can be attributed to disease progression  
• Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal disease) that cannot be managed by [CONTACT_990] -allowed medical interventions  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
45/Protocol CO39721, Version 5  • Patient's written consent to acknowledge deferring other treatment options in favor 
of continuing study treatment at the time of initial disease progression  
• Approval by [CONTACT_1689]  
 
3.[ADDRESS_437390] patient in until end of follow -up, is expected to be approximately  4 years.  
3.3 RATIONALE FOR STUDY DESIGN  
3.3.1  Rationale for Cobimetinib plus Atezolizumab Dose and 
Schedule  
Concomitant administration of cobimetinib and atezolizumab was studied in Phase Ib 
Study GP28363 (Section  1.3.5 ).  Cobimetinib and atezolizumab in combination were 
found to be safe and tolerable with an atezolizumab dose of  800 mg IV Q2W (equivalent 
to the approved dose and schedule for treatment of bladder cancer of 1200 mg IV Q3W) and cobimetinib on the approved dose and schedule of 60  mg QD 21/7.  
Atezolizumab was administered as a single agent  in Study PCD4989g with encouraging 
efficacy and safety outcomes at  doses equivalent to the approved dose and schedule for 
treatment of bladder cancer of 1200  mg IV Q3W  (Section 1.3.2 ).  Simulations using a 
population PK model for atezolizumab demonstrate that at the dose of 840 mg IV Q2W 
(atezolizumab dose schedule in Arm A and Arm B)  provides an exposure within the 
range typi[INVESTIGATOR_351813] 1200 mg IV Q3W dose (Arm C atezolizumab dose  schedule ).  
Observed Phase 1 data after Q2W administration was consistent with p opPK simulated 
profiles providing confidence in the predictability of  the simulations.   Based on the data 
available, the two dose schedules are expected to be comparable  in safety and efficacy.   
[IP_ADDRESS]  Cohort  A (Cobimetinib plus Atezolizumab with Concurrent 
Start)   
Cobimetinib will be given  at the approved dose and schedule of 60 mg QD 21/7.  For 
administration with cobimetinib on this 28-day cycle, a dose of 840  mg atezolizumab will 
be given  Q2W .  The 840 -mg dose is expected to be similar to the 800 -mg dose of 
atezolizumab and was selected in this study to simplify dose administration.  
Atezolizumab is formulated at a concentration of 60 mg/mL; thus, 800  mg corresponds 
to a volume of 13.33 mL.  To ensure consistent, precise, and clinically feasible 
administration in this study, the volume was rounded up to 14 mL, corresponding to a 
dose of 840 mg.  The 840-mg dose is not expected to result in meaningfully different 
exposures compared with an 800 -mg dose.   
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
46/Protocol CO39721, Version 5  In addition, the atezolizumab dose of 840 mg Q2W  is equivalent to an average body 
weight−based dose of 15  mg/kg Q3W , the Phase II dose for atezolizumab derived from  
nonclinical and clinical studies .  It has been used in multiple atezolizumab Phase III 
studies in other  indications . 
[IP_ADDRESS]  Cohort B (Biopsy Cohort ) 
Cohort B is designed to allow assessment of the effects of cobimetinib on immune 
therapy.   In this cohort, in Cycle 1 only,  cobimetinib will be given  for 14 days before 
initiation of atezolizumab treatment  as described in Section 3.1.  Biopsies obtained 
before treatment start and at the end of the 14 -day cobimetinib monotherapy period will 
allow  elucidation of the effects of cobimetinib on tumor immune context ure.  Additional 
biopsies taken during the combination treatment period and at radiographic progression 
will support evaluation of the effects of combination treatment  on the tumor 
micro -environment  and the identification of potential mechanisms of resistance to 
combination therapy.  
During Cycle 2 and all subsequent cycles, patients in Cohort B will receive cobimetinib 
60 mg QD 21/7 and atezolizumab 840 mg IV Q 2W, the same dose and schedule as in  
Cohort A.  
[IP_ADDRESS]  Cohort C (Atezolizumab Monotherapy C ohort)  
Atezolizumab will be administered at a dose of 1200 mg IV Q3W.  As detailed in 
Section 3.3.1 , this approved dose schedule based on average body weight  results in  
similar atezolizumab exposure after  the 840 mg Q2W  dose schedule.  
3.3.2  Rationale for Patient Population and Cohorts  
[IP_ADDRESS]  Cohort A  (Cobimetinib plus Atezolizumab with Concurrent Start)  
Cohort A will enroll patients with advanced BRAFV600 WT melanoma whose disease has 
progressed on or after treatment with an anti −PD-1 agent.   This patient population has 
limited treatment options and high unmet need .  The known effects of MAPK inhibitors, 
including cobimetinib, on tumor microenvironment ( see Section 1.3.4 ), include effects 
that may enable conversion to an immunoresponsive phenotype, sensitize refractory 
tumors to anti −PD-1/PD-L1 agents , and/or re -sensitize relapsed tumors to these agents, 
and suggest that combination therapy with cobimetinib and atezolizumab may be 
efficacious in this population.  This hypothesis is supported by [CONTACT_351848]28363 ( see Section 1.3.5 ) which indicate that combination therapy with 
cobimetinib and atezolizumab in advanced melanoma results in improved ORR and PFS 
relative to either PD -1/PD -L1 or MEK inhibitor monotherapy .  
[IP_ADDRESS]  Cohort B (Biopsy Cohort)  
The molecular mechanisms of primary and secondary resistance to anti −PD-1/PD -L1 
therapi[INVESTIGATOR_351814]−PD-1 progression require further elucidation to inform optimal development of 
combination therapy.   In order to ensure that biomarker data collected from biopsies are 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
47/Protocol CO39721, Version [ADDRESS_437391] received sufficient anti −PD-1 therapy to adequately 
assess the tumor ’s sensitivity,  and that the tumor ’s current molecular profile represents 
the molecular profile at progression, a ll patients in this cohort must have received a 
minimum of two cycles of the anti−PD-[ADDRESS_437392] progressed on or after this 
therapy within 12 weeks before study start.   
The cohort will enroll approximately 6 patients with primary resistance, defined as 
progressive disease (PD) as best response,  according to RECIST v 1.1, and 
approximately [ADDRESS_437393] v 1.1.  
[IP_ADDRESS]  Cohort C (Atezolizumab M onotherapy)  
Cohor t C will enroll approximately [ADDRESS_437394] not received previous treatment, to receive atezolizumab monotherapy . 
Data from Study  PCD4989g indicate that atezolizumab monotherapy provides ef ficacy 
benefit in advanced melanoma comparable with that reported for approved aPD -1 
monotherapi[INVESTIGATOR_351815] a comparable safety profile (Section 1.1.2 ).  However, since the 
patient population in this study was heterogeneous with respect to line of therapy and 
BRAF V600 status, evaluation of atezolizumab monotherapy in previously untreated, 
BRAF  WT melanoma, will allow more accurate understanding of the achievable 
magnitude of efficacy  in this population.  In addition, this cohort  will allow comparison of 
the potential  molecular mechanisms of resistance between the [ADDRESS_437395].  
In order to ensure that the ORR , DCR, duration of response ( DOR ), and PFS  can be 
adequately assessed, patients must have measureable disease (per RECIST v 1.1.) and 
locally advanced, unresectable or metastatic melanoma, as defined by [CONTACT_351849], Version 7 (Balch et al. 2009).  
Additional eligibility criteria have been incorporated that are pertinent to the safety profiles for cobimetinib and atezolizumab (and PD−L1-targeted therapi[INVESTIGATOR_98479] a 
therapeutic class).  These criteria have been informed by  [CONTACT_351850]28 363, the  Phase Ib study, which evaluates the combination of cobimetinib 
and atezolizumab in patients with diverse solid tumors, including advanced melanoma.  
3.3.3  Rationale for P rimary Endpoint Selection  
This study is designed to gain preliminary information on the potential for efficacy of atezolizumab in combination with cobimetinib in BRAF
V600 WT melanoma that has 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
48/Protocol CO39721, Version 5  progressed on or after treatment with an anti −PD-1 therapy and will initially enroll a 
limited number of patients ( n = 42).  Compelling evidence of anti -tumor activity in these 
patients will result in further evaluation of the combination’s activity in this indication 
The study will also enroll an additional cohort of patients with BRAFV600 WT melanoma 
who have not been previously treated to obtain additional efficacy and safety data for 
atezolizumab as monotherapy.  This will extend the efficacy data seen in melanoma in 
Study PCD4989g and clarify the magnitude of benefit achievable in previously untreated BRAF
V600 WT patients . 
The co -primary endpoints for this study are ORR and DCR at 16 weeks.  
ORR is recognized as a correlate of survival in advanced melanoma and has been used as a primary endpoint in a pi[INVESTIGATOR_351816] ( Weber et al. 2015).   DCR at 
16 weeks  is included as a co- primary efficacy endpoint because clinical experience in 
Study  GP28363 indicates that early evaluations of ORR may underestimate the 
percentage of patients who benefit from the combination.   In Study  GP283 63, of  the 
9 melanoma patients with a PR, 3 patients had prolonged SD and converted from SD to  
a PR after >
 12 months o f therapy .  Further, in a recent retrospective study that  included 
172 metastatic  melanoma patients treated with high -dose IL-2, SD and DCR w ere found 
to correlate well with survival ( Hughes et al . 2015 ).  Early compelling evidence of 
anti-tumor activity, based on a high DCR rate, will allow timely initiation of further 
evaluation of the combination.  
3.3.[ADDRESS_437396] v1.1.  Studies with immunotherapeutic agents indicate that conventional response criteria may not adequately assess the activity of immunotherapeutic agents because progressive disease (by [CONTACT_33450]) does not necessarily reflect therapeutic failure.  Initial increase in tumor burden caused by  [CONTACT_351847] a  TCR can occur with 
immunotherapy and has been termed pseudoprogression (Hales et al. 2010) .  However, 
the implications of atypi[INVESTIGATOR_900] -tumor responses in the setting of immunotherapy 
combined with targeted therapy are currently unknown.  
Clinically stable patients who have a favorable benefit -risk assessment  may continue on 
study treatment following radiographic progression per RECIST v1.1.  Approval from the 
study medical monitor must be obtained prior to continuing treatment.   Patients who 
continue treatment beyond radiographic disease progression will be closely monitored.  
Treatment may  be discontinued if clinical deterioration occurs due to disease 
progression . 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
49/Protocol CO39721, Version 5  3.3.5  Rationale for Biomarker Assessments  
Tumor tissue samples will be collected at baseline for genetic and histopathologic  
assessments at DNA, RNA, protein, and cellular levels to add to researchers' 
understanding of disease pathobiology.  Genetic alterations, immune contextures, and microenvironment of BRAF
V600 WT melanom a may have profound effects on the efficacy 
of this combination.  Biomarker data from archival/baseline tumor will be analyzed together with the treatment outcomes to explore potential factors associated with favorable response or treatment escape.  Becaus e these biomarkers may also have 
prognostic value, their potential association with disease progression will also be explored.   
Tumor biopsies are scheduled during treatment and at progression to further elucidate 
the possible mechanism of action or mechanisms of treatment escape (innate or acquired) of this regimen and may include evaluation of CD8
+ T-cell or other IC infiltrate, 
PD-L1 expression, TCR repertoires, MAPK activation, and others  involved in apoptosis 
or inflammation.  
3.3.[ADDRESS_437397] ing for Biomarker Assessments  
An exploratory objective of this study is to evaluate biomarkers (including, but no t limited 
to, whole genome sequencing (WGS), mutations in circulating -tumor DNA ), and TCR 
repertoires in blood samples.  The evaluation of blood biomarkers may provide evidence for biologic activity of atezolizumab plus cobimetinib in  patients who have been 
previously treated with anti− PD-[ADDRESS_437398] not been treated with anti -PD-1, respectively , and may allow for exploration of a 
relationship of these biomarkers with the activity of cobimetinib and atezolizumab. 
3.3.7  Rationale for Oph thalmologic  Assessments (Cohort s A and  B) 
Serous retinopathy has been observed in patients treated with MEK -inhibitors, including 
cobimetinib ( Flaherty  et al. 2012) .  Manifestations of serous retinopathy include retinal 
detachment (i.e., fluid accumulation between the neurosensory retina and the retinal pi[INVESTIGATOR_1836]) and retinopathy. Although serous retinopathy can lead to visual 
disturbanc es, in some circumstances  it may also be asymptomatic.  
Serous retinopathy was prospectively monitored in Study  GO28141 in all patients.   
Serous retinopathy was reported more frequently in patients treated with cobimetinib plus vemurafenib than placebo plus  vemurafenib (25.5% vs. 2.8%, respectively), and 
approximately half the events were asymptomatic Grade  1 events.  Few patients treated 
with cobimetinib plus vemurafenib experienced Grade
 ≥ 3 ocular events (2.8%); the 
majority of these events were managed with dose modification of both cobimetinib and vemurafenib.  Most events of serous retinopathy occurred  early in treatment  with a 
median onset of 1 month (De la Cruz -Merino et al. 2015 ). 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
50/Protocol CO39721, Version [ADDRESS_437399] two cycles of 
treatment, and then every 4 weeks  until Day 1 of Cycle 7  (Cohorts A and B) .  If serous 
retinopathy is detected at any of these visits, monitoring will be con tinued at increased 
frequency (see Section  4.4.7 ) until the adverse event resolves or [ADDRESS_437400].  
[IP_ADDRESS]  Ratio nale for Optional Whole Genome Sequencing  
Genomics is increasingly informing understanding of disease pathobiology and rationale for the development of new therapeutic approaches.  WGS provides comprehensive characterization of the genome and, along with clinical data collected in this study, may increase the opportunity for making these discoveries.  
Relevant literature on genomic analyses shows ample examples of genetic variations and their implications in immune responses.  For instance, a recent report i dentified 
20 genes linked to variability of the immune response to seasonal influenza vaccination, 
7 of which were shown to be involved in intracellular antigen transport, processing, and 
presentation (Franco et al. 2013).  Similarly, genome −wide association studies (GWAS) 
have identified specific genetic variants that are associated with differences in WBC, neutrophil, and monocyte counts among individuals (Knight 2013).  Furthermore, GWAS in autoimmune diseases have led to novel insights.  One example is the role of 
autophagy in Crohn disease, which was elucidated based on variation at two loci and has now become a major therapeutic target in this disease (Hu and Daly 2012).  
It is also established that genetic variants of drug -metabolizing enzymes and 
transporters can affect the pharmacokinetics of drugs, which affects safety and efficacy.  For example, patients who carry defective alleles of the gene encoding uridine diphosphate glucuronosyltransferase 1A1, which facilitates the metabolism and excretion of  SN-38 (the active metabolite of irinotecan), are at a higher risk for adverse 
effects associated with the use of standard doses of irinotecan (O’Dwyer  and Catalano 2006).  
In addition to the link between genetic variation in drug- metabolizing enzymes and 
transporters and pharmacokinetics, recent studies have also identified genetic variants 
that increase the likelihood of (or are protective of) developi[INVESTIGATOR_21395]− induced adverse 
events.  For example, HLA  has been demonstrated to play an important role in the 
development of drug- induced rash for some drugs (carbamazepi[INVESTIGATOR_050], abacavir, and 
allopurinol; Michels and Ostrov  2015; Shirzadi et al. 2015; Stamp et al. 2015).  In 
addition, mutations in GSTP1 , CTLA4, and FDG4  have been associated with 
development of drug− induced peripheral neuropathy of various small molecules 
(Lecomte et al. 2006 ; Ruzzo et al 2007; Favis et al. 2011; Baldwin et al. 2012).  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
51/Protocol CO39721, Version [ADDRESS_437401] genetic variation by [CONTACT_351851] a further understanding of efficacy and safety for cancer immunotherapy and other therapeutic approaches.  To this end, a blood sample may be collected from patients enrolled in this study  for DNA extraction to enable WGS 
analysis.   The WGS testing is an optional component of this study; patients can decline 
this sample collection and test.  
WGS is contingent upon the review and approval by [CONTACT_25733]'s Institutional Review 
Board/Ethics Committee ( IRB/EC ) and, if applicable, an appropriate regulatory body.  If  a 
site has not been granted approval for WGS, this assessment will not be applicable at that site.  
3.3.8  Rationale for Pharmacokinetic Assessments 
The proposed PK sampling scheme for assessment of cobimetinib and atezolizumab concentration, together with available data from other clinical studies, will be used to investigate any potential drug interactions between the two molecules by [CONTACT_351852]- agent data from previous studies.   In addition, single-
agent atezolizumab data from Cohort C will be compared to atezolizumab PK collected in the combination cohorts (Cohort A and Cohort B).  
Atezolizumab is primarily elim inated by [CONTACT_351853], therefore , 
it has a low potential for drug interactions.  Cobimetinib is metabolized primarily by 
[CONTACT_097]3A, and to a lesser extent by [CONTACT_15924]2B7, based on in vitro studies.  Because of the 
differences in metabolism, no drug −drug interaction is anticipated between cobimetinib 
and atezolizumab. 
A sparse sampling strategy will be applied in this study.  Samples for pharmacokinetic 
(PK) characterization of cobimetinib and atezolizumab will be collected as outlined in 
Appendix  2.  The pharmacokinetics of each compound each drug will be compared with 
single -agent data for each molecule from previous studies or previously developed 
population PK models.  
4. MATERIALS AND METHOD S  
4.[ADDRESS_437402] progressed on or after 
prior treatment with an anti −PD-[ADDRESS_437403] not received previous 
treatment wil l be enrolled in Cohort  C. 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
52/Protocol CO39721, Version [ADDRESS_437404] meet the following crite ria for study entry.  
[IP_ADDRESS]  Disease-S pecific Inclusion Criteria : Cohorts A and B  
• Histologically confirm ed Stage IV (metastatic) or unresectable Stage IIIc BRAFV600 
WT (locally advanced) melanoma  
• Documentation of BRAFV600 mutation− negative status in melanoma tumor tissue 
(archival [< 5 years  old] or newly obtained) through use of a clinical mutation test 
approved by [CONTACT_19407] (e.g., U.S. Food and Drug Administration 
[FDA] -approved test, CE -marked [European conformity] in vitro diagnostic in E.U. 
countries, CLIA -certified next -generation sequencing ( NGS ) test or equivalent)  
• Measurable disease according to RECIST v1.1 (see Appendix 3 ) 
• Disease progression on or after treatment with a PD-1 inhibitor  either as 
monotherapy or in combination with other agent(s)  
 
[IP_ADDRESS]  Additional Disease-Sp ecific Inclusion Criteria in Cohort B 
(Biopsy Cohort)  
• Patients in this cohort must have progressed on or after anti −PD-1 therapy within 
12 weeks before study start . 
• Patients in this cohort must have received a minimum of two cycles of anti −PD-1 
therapy . 
• Patients in this cohort  must meet criteria for primary  (n  = 6) or secondary  (n  = 6) 
resistance to an anti -PD-1 agent as outlined below:  
Primary resistance is defined as PD  as best response according to RECIST v 1.1. 
Secondary resistance  is defined as PD after initial response according to 
RECIST v1.1. 
• Patients in this cohort must c onsent to undergo tumor biopsies of accessible lesions , 
before and during treatment and at radiographic progression, for biomarker 
analyses . 
• Patients in this cohort must have at least two accessible lesions that are amenable 
to excisional or core -needle (minimum three cores and minimum diameter 18 gauge; 
however, 16 gauge is desirable) biopsy with acceptable risk of a major procedural 
complic ation.   Exceptions may be made if patient has only one lesion that allows 
multiple biopsies following discussion with Medical Monitor.  
 
[IP_ADDRESS]  Disease-S pecific Incl usion Criteria:   Cohort C   
• Histologically confirmed Stage IV (metastatic) or unresectable Stage IIIc 
BRAFV600 WT (locally advanced) melanoma  
• Naive to prior systemic anti -cancer therapy for melanoma (e.g., chemotherapy, 
hormonal therapy, targeted therapy, immunotherapy, or other biologic therapi[INVESTIGATOR_014]), 
with the following exceptions:  
– Adjuvant treatment with interferon -α (IFN-α), interleukin -2 (IL-2), or vaccine 
therapi [INVESTIGATOR_014], if discontinued at least 28 days prior to initiation of study treatment  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
53/Protocol CO39721, Version 5  – Adjuvant treatment with ipi[INVESTIGATOR_125], if discontinued at least 90 days prior to 
initiation of study treatment  
– Adjuvant treatment with herbal therapi[INVESTIGATOR_014], if discontinued at least 7 days prior to 
initiation of study treatment  
• Documentation of BRAFV600 mutation− negative status in melanoma tumor tissue 
(archival [< 5 years  old] or newly obtained) through use of a clinical mutation test 
approved by [CONTACT_19407] (e.g., U.S. Food and Drug Administration 
[FDA] -approved test, CE -marked [European conformity] in vitro diagnostic in E.U. 
countries, CLIA -certif ied next -generation sequencing [NGS]  test or equivalent)  
• A representative, formalin- fixed, paraffin -embedded (FFPE) tumor specimen in a 
paraffin block (preferred) or [ADDRESS_437405] be obtained from a biopsy performed at screening.  
• Measurable disease according to RECIST v1.1 (See Appendix 3 ) 
 
[IP_ADDRESS]  General Inclusion Criteria  
• Signed Informed Consent Form  
• Age ≥ 18 years  
• Ability to comply with the study protocol, in the investigator ’s judgment  
• ECOG  performance status of  0 or 1 (see  Appendix  5) 
• Available and adequate baseline tumor tissue sample (archival [ < 5 years  old] or 
newly obtained biopsy; see Section 3.1.1 ) 
• Life expectancy ≥  18 weeks  
• Adequate hematologic and end- organ function, defined by [CONTACT_123511], obtained within 14 days before  initiation of study treatment : 
Neutrophils (ANC ≥ 1500 cells/ µL without G- CSF support within 2 weeks before 
Cycle 1, Day  1) 
WBC counts > 2500  cells /µL and < 15,000  cells /µL 
Lymphocyte count ≥  500 cells/µL 
Platelet count ≥ 100,000 cells /µL (without transfusion within 2 weeks 
before  Cycle 1, Day  1) 
Hemoglobin ≥ 9.0 g/dL (without transfusion)  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
54/Protocol CO39721, Version 5  Serum creatinine ≤  1.5  × ULN or creatinine clearance (CrCl) ≥ 40 mL/min on the 
basis of measured CrCl from a 24 -hour urine collection or Cockcroft -Gaul t 
glomerular filtration rate estimation: 
CrCl   =  (140   −  age)  × (weight in kg)  ( × 0.85 if female)  
72  × (serum creatinine in mg/dL)  
 
AST, ALT, and alkaline phosphatase ≤ 2.5  × upper limit of normal ( ULN), with the 
following exceptions:   
– Patients with documented liver metastases:   AST and/or ALT ≤  5 × ULN   
– Patients with documented liver or bone metastases:  alkaline 
phosphatase ≤ 5 × ULN 
Serum albumin ≥ 25 g/L 
Total bilirubin ≤  1.5 × ULN; patients with known Gilbert’s disease may have a 
bilirubin  ≤ 3.0 × ULN 
For patients not receiving therapeutic anticoagulation:  INR or aPTT ≤ 1.5 × ULN 
within 28 days before  initiation of study treatment  
For patients receiving therapeutic anticoagulation:  stable anticoagulant regimen 
and stable INR during the 28 days immediately preceding initiation of study 
treatment  
For women of childbearing potential:  agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of <
 1% per year during the treatment period , within  [ADDRESS_437406] refrain from donating eggs during th is same period.  
A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state ( ≥
 12 continuous months of 
amenorrhea with no identified cause other than menopause), and has not 
undergone surgical sterilization (removal of ovaries and/or uterus).  
Examples of contraceptive methods with a fail ure rate of < 1% per year include 
bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit 
ovulation, hormone -releasing intrauterine devices, and copper intrauterine 
devices.  
The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not acceptable methods of contraception.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
55/Protocol CO39721, Version 5  •For men:  agreement to remain abstinent (refrain from heterosexual intercourse) or
use a condom, and agreement to refrain from donating sperm, as defined below:
With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at 
least [ADDRESS_437407] refrain from donating sperm during this same period.  
The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not acceptable methods of contracept ion. 
4.1.2  Exclusion Criteria  
Patients who meet any of the criteria  in the following sections  will be excluded f rom 
study entry.  
[IP_ADDRESS]  Cancer -Related Exclusion Criteria  
•Prior treatment with a MAPK inhibitor
•Ocular melanoma
•Major surgical procedure other than for diagnosis within 4 weeks before  initiation of
study treatment, or anticipation of need for a major surgical procedure during the
course of the study
•Traumatic injury within 2 weeks before  initiation of study treatmen t
•Palliative radiotherapy within 14 days before  initiation of study treatment
•Active malignancy (other than BRAFV600 mutation−negative melanoma) or
malignancy within [ADDRESS_437408]
3 years
Patients with a history of isolated elevation in prostate -specific antigen in the 
absence of radiographic evidence of metastatic prostate cancer are eligible for 
the study.  
•Treatment with any anti -cancer agent 14 days prior to Cycle, D ay 1 other than a
PD-1 based therapy
•Adverse events from prior anti -cancer therapy that have not resolved to Grade ≤ 1
Clinically stable patients with manageable immune- related adverse events 
resulting from prior cancer immunother apy may be eligible for the study after 
discussion with and approval by [CONTACT_1689] . 
•For Cohort C, specific exclusion criteria include a ny prior anti-cancer therapy  for
advanced melanoma
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
56/Protocol CO39721, Version 5  [IP_ADDRESS]  Ocular Exclusion Criteria  (Cohorts A and B)  
• History of serous retinopathy  
• History of retinal vein occlusion ( RVO ) 
• Evidence of ongoing serous retinopathy or RVO at baseline  
 
[IP_ADDRESS]  Cardiac Exclusion Criteria (Cohorts A and B)  
• History of clinically significant cardiac dysfunction, including the following:  
Unstable angina, or new -onset angina within 3 months before  initiation of study 
treatment  
Symptomatic congestive heart failure, defined as [LOCATION_001] Heart Association 
Class II or higher  
Myocardial infarction within 6 months before  initiation of study treatment  
Unstable arrhythmia  
History or presence of an abnormal ECG that is clinically significant in the 
investigator’s opi[INVESTIGATOR_1649], including complete left bundle branch block, second - or 
third-degree heart block, or evidence of prior myocardial infarction 
LVEF  below the institutional lower limit of normal or below 50%, whichever is 
lower  
 
[IP_ADDRESS]  Central Nervous System Exclusion Criteria  
• Untreated or actively progressing central nervous system ( CNS ) lesions 
(carcinomatous meningitis)  
Patients with stable and asymptomatic CNS metastases are eligible, if they 
meet all of the following:  
– Measurable disease, per RECIST v1.1, must be present outside the CNS.  
– All known CNS lesions are clinically stable . 
– CNS lesions have not been treated with whole- brain radiotherapy, except 
in patients who underwent definitive resection of or stereotactic therapy for all radiologically detectable parenchymal brain lesions.  
– Absence of interim progression must be confirmed by [CONTACT_351835] 4 weeks before  initiation of study treatment.  If new CNS metastases 
are suspected during the screening period, a confirmatory radiographic 
study is required before  initiation of study treatment.  
– Any radiotherapy or surgery must be completed ≥
 4 weeks before  initiation 
of study treatment.  
– There is no ongoin g requirement for corticosteroids, and any prior 
corticosteroid treatment must be discontinued ≥  2 weeks before  initiation of 
study treatment.  Treatment with an anticonvulsant at a stable dose is 
allowed.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
57/Protocol CO39721, Version 5  • History of metastases to brain stem, midbrain, pons, or medulla, or within 10 mm of 
the optic apparatus (optic nerves and chiasm) 
• History of leptomeningeal metastatic disease  
 
[IP_ADDRESS]  Exclusions Related to Infections  
• HIV infection  
• Active tuberculosis infection 
• Severe infections within 4 weeks prior to Day 1 of Cycle 1, including, but not limited 
to, hospi[INVESTIGATOR_33377], bacteremia, or severe pneumonia 
• Signs or symptoms of clinically relevant infection within 2 weeks prior to Day 1 of 
Cycle 1  
• Treatment with oral  or IV antibiotics within 2 weeks prior to Day 1 of Cycle 1 
Patients receiving prophylactic antibiotics (e.g., for prevention of urinary tract 
infection or chronic obstructive pulmonary disease) are eligible.  
• Active or chronic viral hepatitis B or C infect ion 
Patients with a past or resolved HBV infection, defined as having a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test at screening, are eligible for the study if quantitative HBV DNA <
  500 IU/mL at 
screening . 
Patients with hepatitis C virus (HCV) infection are eligible if polymerase chain 
reaction test for HCV RNA is negative.  
 
[IP_ADDRESS]  Exclusion Criteria Related to Autoimmune Conditions and 
Immunomodulatory Drugs  
• Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus 
erythematosus, rheumatoid arthritis, inflammatory bowel disease, anti −phospholipid 
antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain- Barré  
syndrome, or multiple sclerosis (see Appendix  [ADDRESS_437409] of 
autoimmune diseases and immune deficiencies), with the following exceptions:  
Patients with a history of autoimmune- related hypothyroidism who are on a 
stable dose of  thyroid- replacement hormone are eligible for the study.  
Patients with controlled Type 1 diabetes mellitus who are on a stable insulin 
regimen are eligible for t he study.  
Patients with a history of manageable immune- related adverse events resulting 
from prior immunotherapy may be eligible for the study after discussion with 
and approval by [CONTACT_351854], psoriasis, lichen simplex chronic us, or vitiligo with 
dermatologic manifestations only (e.g., patients with psoriatic arthritis are 
excluded) are eligible for the study provided all of following conditions are met: 
– Rash must cover <10% of body surface area . 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
58/Protocol CO39721, Version 5  – Disease is well controlled at baseline and requires only low −potency 
topi[INVESTIGATOR_11930].  
– No occurrence of acute exacerbations of the underlying condition requiring 
psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic 
agents, oral calcineurin inhibitors, or high -potency or oral corticosteroids 
within the previous 12 months . 
• Prior allogeneic stem cell or solid organ transplantation 
• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug -induced pneumonitis, or idiopathic pneumonitis, or evidence of 
active pneumonitis on screening chest CT scan  
History of radiation pneumonitis in the radiation field (fibrosis) is permitted.  
• Treatment with systemic immunosuppressive medication (including, but not limited to, prednisone, c yclophosphamide, azathioprine, methotrexate, thalidomide, and 
anti−tumor necrosis factor alpha [ TNF-α] agents) within 2 weeks before initiation of 
study treatment, or anticipation of need for systemic immunosuppressive medication 
during the course of the study  with the following exceptions:  
Patients who have received acute, low -dose systemic immunosuppressant 
medication ( ≤
 10 mg/day oral prednisone or equivalent)  or a one -time pulse 
dose of systemic immunosuppressant medication (e.g., [ADDRESS_437410] allergy) are eligible for the study  after Medical 
Monitor approval has been obtained . 
Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids 
for chronic obstructive pulmonary disease (COPD) or asthma, or low -dose 
corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible 
for the study.  
 
[IP_ADDRESS]  Additional Exclusion Criteria  
• Current severe, uncontrolled systemic disease (including, but not limited to, clinically 
significant cardiovascular, pulmonary, or renal disease) other than cancer  
• Any Grade ≥ 3 hemorrhage or bleeding event within 28 days of Day 1 of Cycle 1 
• History of stroke, reversible ischemic neurological defect, or transient ischemic 
attack within 6 months prior to Day 1 
• Any psychological, familia l, sociological, or geographic  condition that may hamper 
compliance with the protocol and follow -up after treatment discontinuation 
• Inability or unwillingness to swallow pi[INVESTIGATOR_3353]  
• History of malabsorption or other clinically significant metabolic dys function that may 
interfere with absorption of oral study treatment  
• Pregnant or breastfeeding, or intending to become pregnant during the study  
Women of childbearing potential must have a negative serum pregnancy test 
result within 14 days before initiation of study treatment.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
59/Protocol CO39721, Version 5  • Known clinically significant liver disease, including alcoholism, cirrhosis, fatty liver, 
and other inherited liver disease as well as active viral disease, including p ositive 
HIV test at screening. 
• Any other disease, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding that contraindicates the use of an investigational drug, may affect 
the interpretation of the results, or may render the patient at high risk from treatment complications  
• Treatment with a live, attenuated vaccine within 4 weeks before  initiation of study 
treatment, or anticipation of need for such a vaccine during the course of the study  
• Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary ce lls 
• Known hypersensitivity to any component of the atezolizumab or cobimetinib formulations  
• History of severe allergic, anaphylactic , or other hypersensitivity reactions to 
chimeric or humanized antibodies or fusion proteins  
• Treatment with any other investigational agent or participation in another clinical study with therapeutic intent  
• Requirement for concomitant therapy or food that is prohibited during the study, as described in Section 4.3, respectively  
 
4.2 STUDY TREATMENT  
The investigational medicinal products (IMPs) for this study are cobimetinib and 
atezolizumab.   
4.2.1  Formulation, Packaging, and Handling  
[IP_ADDRESS]  Cobimetinib 
Cobimetinib tablets  will be supplie d by [CONTACT_1034].  The 20- mg cobimetinib drug 
product is a film -coated, white, round, immediate- release tablet.  Cobimetinib will be 
packaged in blister packs.  The inactive ingredients in cobimetinib are as follows:  lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and 
magnesium stearate for the tablet core.  The tablet coating consists of polyvinyl alcohol, part hydrolyzed, titanium dioxide, polyethylene glycol 3350, and talc.  Cobimetinib should not be stored above 25°C (77°F).  If  the study drug is stored outside of the permitted 
temperature ranges, quarantine the affected supply and contact [CONTACT_2037].  
For further details, see the Cobimetinib Investigator ’s Brochure.  
[IP_ADDRESS]  Atezolizumab  
Atezolizumab will be supplied by [CONTACT_351855] 20 -mL glass vials.  
The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may 
contain more than the stated volume to enable delivery of the entire 20 -mL volume.  For 
Cohorts A and B, extraction of 14 mL of atezolizumab solution from a 1200 mg vial 
contains an 840- mg dose.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
60/Protocol CO39721, Version 5  For information on the formulation and handling of atezolizumab, refer to the 
Atezolizumab Investigator's Brochure and Pharmacy Manual.  
4.2.2  Dosage, Administration, and Compliance  
[IP_ADDRESS]  Cobimetinib 
Patients in C ohorts A and B  will receive 60  mg (3 tablets of 20 mg each) orally QD  for 
Days  1−[ADDRESS_437411] administration of cobimetinib should be noted on the Study  Drug Administration electronic Case Report Form (eCRF).  Adverse events 
associated with an overdose or incorrect administration of cobimetinib should be recorded on the Adverse  Event eCRF ( see Section [IP_ADDRESS] ). 
[IP_ADDRESS]  Atezolizumab  
Cohort A:  Patients will initiate dosing with atezolizumab concurrently with cobimetinib and will receive atezolizumab 840 mg IV Q2W on Days 1 and 15 of all cycles.  
Cohort B:  Patients will receive the first dose of atezolizumab at 840 mg IV on Day 15 of 
Cycle 1.  Thereafter, they will receive atezolizumab 840 mg IV Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles . 
Cohort C:  Patients will receive atezolizumab 1200 mg I V Q3W as monotherapy.  
All dosing schedules will be given in a monitored setting where there is immediate 
access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.   
For more detailed information on drug preparation, storage, and administration, refer to 
the Atezolizumab Investigator ’s Brochure and Pharmacy Manual.  
Atezolizumab infusions will be given per the instructions outlined in Table 2. 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
61/Protocol CO39721, Version [ADDRESS_437412] Infusion  Subsequent Infusions  
Premedication is allowed.  If patient experienced IRR during any previous 
infusion, premedication with antihistamines 
may be administered for Cycles  ≥ [ADDRESS_437413] vital signs (HR, RR, BP, and T) within 
[ADDRESS_437414] vital signs (HR, RR, BP, and T) within 60 minutes before starting infusion.  
Infuse atezolizumab (one vial in 250 mL NaCl) 
over 60 (± 15) minutes  If the patient tolerated the first infusion without 
infusion- associated AEs, the second infusion 
may be delivered over 30 ( ± 10) minutes.  
Record vital signs (HR, RR, BP, and T) during the infusion or after the infusion if clinical ly 
indicated   If the patient had an IRR during the previous infusion, the subsequent infusion must be 
delivered over 60 ( ±
 15) minutes.  
 Record patient ’s vital signs (HR, RR, BP, and 
T) during the infusion or after the infusion if 
clinically indicated or patient experienced symptoms during the previous infusion.  
Patients will be informed about the possibility of 
delayed post -infusion symptoms and instruc ted 
to contact [CONTACT_351856].   
 If no reaction occurs, continue subsequent 
infusions over 30 ( ± 10) minutes with same 
schedule for recording vital signs.  
AE  = adverse event; BP  = blood pressure; HR  = heart rate; IRR  = infusion- related reaction; 
NaCl  = sodium chloride; RR  = respi[INVESTIGATOR_697]; T  = temperature.  
 
Dose reductions of atezolizumab are not permitted.  Guidelines for treatment interruption 
or discontinuation and the management of specific adverse events relat ed to the 
combination of cobimetinib and atezolizumab are provided in Sections 5.1.3  (see 
Table 6 ).  Guidelines for treatment interruption or discontinuation and the management 
of atezolizumab- specific adverse events are provided in Section  5.1.2  and Appendix  8, 
as well as the Atezolizumab Investigator ’s Brochure.  For anaphylaxis precautions, see 
Appendix  7.  
See the Pharmacy Manual for detailed instructions on drug preparation, storage, and administration.  
Any ove rdose or incorrect administration of atezolizumab should be noted on the 
atezolizumab administration eCRF.  Adverse events associated with an overdose or incorrect administration of atezolizumab should be recorded on the Adverse Event eCRF 
(see Section [IP_ADDRESS]).  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
62/Protocol CO39721, Version [ADDRESS_437415] Accountability  
Both IMPs  required for completion of this study , cobimetinib and atezolizumab, will be 
provided by [CONTACT_76971].  The study 
site will acknowledge receipt of IMPs, using  an interactive voice - or Web- based 
response system  (IxRS ) to confirm the shipment condition and content.  Any dam aged 
shipments will be replaced.  
IMPs either will be disposed of at the study site according to the study site ’s institutional 
standard operating procedure or will be returned to the Sponsor with the appropriate documentation.  The site ’s method of IMP destruction must be agreed to by [CONTACT_1034].  
The site must obtain written authorization from the Sponsor before any IMP is destroyed, and IMP destruction must be documented on the appropriate form.  
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by [CONTACT_25729].  
4.2.[ADDRESS_437416] -trial access to the study drug s (cobimetinib and atezolizumab) 
free of charge to eligi ble patients in accordance with the [COMPANY_002] Global Policy on 
Continued Access to Investigational Medicinal Product, as outlined below.  
A patient will be eligible to receive study drug after completing  the study if all of the 
following conditions are met: 
• The patient has a life- threatening or severe medical condition and requires 
continued study drug treatment for his or her well -being.  
• There are no appropriate alternative treatments available to the patient . 
• The patient and his or her doctor comply with and satisfy any legal or regulatory 
requirements that apply to them . 
 
A patient will not  be eligible to receive study drug after completing the study if any  of the 
following conditions are met: 
• The study drug is commercially marketed in the patient's country and is reasonably 
accessible to the patient (e.g., is covered by [CONTACT_102]'s insurance or would not 
otherwise create a financial hardship for the patient) . 
• The Sponsor has discontinued development of the study drug or data suggest that the study drug is not effective for advanced melanoma that has progressed on or 
after treatment with an anti −PD-1 therapy.  
• The Sponsor has reasonable safety concerns regarding the study drug as treatment for advanced melanoma that has progressed on or after treatment with an 
anti−PD-1 therapy.  
• Provision of study drug is not permitted under the laws and regulations of the 
patient's country . 
 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
63/Protocol CO39721, Version [ADDRESS_437417] is 
available at the following web site: 
http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf  
4.3 CONCOMITANT THERAPY  
Concomitant therapy includes any medication (e.g., prescription drugs, over -the-counter 
drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a 
patient from 7  days before  initiation of study drug to treatment discontinuation visit.  All  
such medications should be reported to the investigator and recorded on the Concomitant Medications eCRF.   
4.3.1  Permitted Therapy  
The following therapi[INVESTIGATOR_40784]:  
• Hormonal therapy with gonadotropin− releasing hormone agonists or antagonists for 
prostate cancer  
• Oral contraceptives  
• Hormone- replacement therapy  
• Prophylactic or therapeutic anticoagulation therapy (such as low -molecular weight 
heparin or warfarin at a stable dose level)   
Although allowable, caution should be used when using concomitant medications 
that increase the risk of bleeding, including antiplatelet or anticoagulant therapy, 
because of the risk of hemorrhage with cobimetinib.  
• Palliative radiotherapy (e.g., treatment of known bone metastases) provided it does 
not interfere with assessment of tumor target lesions  
It is not required to withhold atezolizumab during palliative radiotherapy.   
• Inactive influenza vaccinations during influenza season only 
• M egestrol given  as an appetite stimulant  
• Inhaled corticosteroids for chronic obstructive pulmonary disease  
• Mineralocorticoids (e.g., fludrocortisone)  
 
Anti-emetic and anti -diarrheal medications should not be given  prophylactically before 
initial treatment with study drugs.  At the discretion of the investigator, prophylactic 
anti-emetic and anti -diarrheal medication(s) may be used per standard clinical practice 
before subsequent doses of study drugs.  Hematopoietic growth factors should not be 
given prophylactically before initial treatment with study drugs.   Hematopoietic growth 
factors may be given  according to local guidelines if indicated during the study.  
In general, investigators should manage a patient ’s care with supportive therapi[INVESTIGATOR_40801], as per local standards.  Patients who experience infusion- associated 
symptoms may be treated symptomatically with acetaminophen, ibuprofen, diphenhydramine, and/or famotidine or another H
2-receptor antagonist as per standard 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
64/Protocol CO39721, Version 5  practice (for sites outside the [LOCATION_002], equivalent medications may be substituted 
per local practice).  Serious infusion- associated events manifested by [CONTACT_27926], 
hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation, or respi[INVESTIGATOR_40802] (e.g., supplemental oxygen and β
2-adrenergic agonists).  
All medications must be recorded on the Concomitant Medications eCRF.  
4.3.2  Prohibited Therapy  
Any concomitant therapy intended for the  treatment of cancer, whether health 
authority -approved or experimental, is prohibited for various time periods prior to starting 
study treatment, depending on the anti -cancer agent (see Section 4.1.2 ) and during 
study treatment until disease progression is documented and patient has discontinued study treatment.   
Use of the  following concomitant therapi[INVESTIGATOR_351817] : 
• Concomitant therapy intended for the treatment of cancer (including, but not limited 
to, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, and herbal 
therapy), whether health authority −approved or experimental, is prohibited for 
various time periods prior to starting study treatment, depending on the agent, and 
during study treatment until disease progression is documented and the patient has 
discontinued study treatment, with the exception of palliative radiotherapy and local therapy under certain circumstances.  
• Any live, attenuated vaccine (e.g., FluMist
®) within [ADDRESS_437418] infusion of 
atezolizumab.  
• Prohibited therapi[INVESTIGATOR_351818]:  
Immunomodulatory agents, including , but not limited to , IFNs  or IL-2, during the 
entire study; these agents could potentially increase the risk for autoimmune 
conditions when received in combination with atezolizumab. 
Immunosuppressive medications, includi ng, but not limited to, cyclophosphamide, 
azathioprine, methotrexate, and thalidomide; these agents could potentially alter 
the activity and the safety of atezolizumab. 
Systemic corticosteroids and TNF- α inhibitors may attenuate potential beneficial 
immunologic effects of treatment with atezolizumab.  Therefore, in situations 
where systemic corticosteroids or TNF- α inhibitors would be routinely given , 
alternatives, including antihistamines, should be considered first by [CONTACT_1963].  If the alternatives are not feasible, systemic corticosteroids and TNF-α inhibitors may be administered at the discretion of the treating physician 
(see Section 4.3.2 ). 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
65/Protocol CO39721, Version 5  • For patients receiving  cobimetinib:  
Concomitant use of strong and moderate inhibitors of CYP3A 
(e.g.,  clarithromycin, grapefruit juice, itraconazole, ketoconazole, posaconazole, 
telithromycin, and voriconazole) should be avoided as cobimetinib is a sensitive 
substrate of CYP3A and exposures will be increased in presence of these agents 
(approximately 7- fold increase in presence of itraconazole in healthy subjects).  
Avoid strong and moderate CYP3A inducers (e.g., rifampin, phenytoin, carbamazepi[INVESTIGATOR_050], phenobarbital, and St. John’ s wort) as they increase the 
metabolism of cobimetinib.  Strong inducers of CYP3A4 should be avoided, or 
selection of an alternate concomitant medicinal product, with no or minimal 
potential to induce CYP3A4 should be considered.  
 
The above lists of medications are not necessarily comprehensive.  Thus, the 
investigator should consult the prescribing information for any concomitant medication when determining whether a certain medication is metabolized by [CONTACT_40865]3A.  In  addition, the investigator should contact [CONTACT_351857].  
4.3.3  Cautionary Therapy for Atezolizumab- Treated Patients  
[IP_ADDRESS]  Corticosteroids and Tumor Necrosis Factor -α Inhibitors  
Systemic co rticosteroids and TNF- α inhibitors may attenuate potential beneficial 
immunologic effects of treatment with atezolizumab.  Therefore, in situations in which systemic corticosteroids or TNF- α inhibitors would be routinely administered, alternatives, 
includi ng antihistamines, should be considered.  If the alternatives are not feasible, 
systemic corticosteroids and TNF- α inhibitors may be administered at the discretion of 
the investigator (see Section 4.3.2 ). 
Systemic corticosteroids are recommended, at the discretion of the investigator, for the treatment of specific adverse events when associated with atezolizumab therapy (refer to Appendix  8 for details).  
4.[ADDRESS_437419] be performed and documented for each patient.  Patients will be closely monitored for safety and tolerability throughout the study.  Patients should be assessed for toxicity prior to each dose; dosing will occur only if the clinical assessment and local laboratory test values are acceptable.  Safety assessments specified in this section are for the purposes of monitoring and management of toxicities known to be associated with study drugs included in this study (see Section  5 for further information) . 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
66/Protocol CO39721, Version [ADDRESS_437420] 
reasons for screening failure, as applicable. 
Screening Window Extension and R e-screening  
The screening window may be extended for an agreed upon and acceptable period to allow re-evaluation of assessments after discussion and agreement with the 
Medical  Monitor.  
Patients may be eligible for re- screening up to two additional times, with all inclusion and 
exclusion criteria being re-assessed. 
4.4.2  Medical History and Demographic Data  
Medical history, including clinically significant diseases and surgeries within 5 years before  initiation of study treatment, cancer history (including prior cancer therapi[INVESTIGATOR_014], 
surgeries, and procedures), and use of alcohol, will be recorded at baseline.  In addition, all medications (e.g., prescription drugs, over -the-counter drugs, herbal or homeopathic 
remedies, nutritional supplements) used by [CONTACT_25701] 7 days before  initiation of 
study treatment will be recorded.  At the time of each follow -up physical examination, an 
interval medical history should be obtained and any changes in medications and allergies should be recorded.  
Demographic data will include age, sex, and self -reported race/ethnicity (where 
permissible).  
4.4.3  Physical Examinations 
A comp lete physical examination, performed at screening and other specified visits, 
should include an evaluation of the head, eyes, ears, nose, and throat (HEENT), neck, and the cardiovascular, dermatologic, musculoskeletal, respi[INVESTIGATOR_696], gastrointestinal, genitourinary, and neurological systems.  HEENT examination should include visual inspection and/or palpation of the oral cavity and oropharynx, and palpation of the draining lymph nodes of the neck.  Any abnormality identified at baseline should be recorded on the General Medical History and Baseline Conditions eCRF.  
Limited, symptom -directed physical examinations, consisting of an evaluation of the oral 
cavity, oropharynx, head and neck (including lymph nodes), lungs, heart, abdomen, and skin, should be performed at specified post -baseline visits and as clinically indicated.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
67/Protocol CO39721, Version [ADDRESS_437421] while the patient is in a seated position.  Resting oxygen saturation 
will be measured during screening.  
Vital signs should be measured within 60 minutes before  each atezolizumab infusion 
and, if clinically indicated, during or after the infusion.  In addition, vital signs should be measured at other specified timepoints as  outlined in the schedule of activities 
(see Appendix  1). 
For patients in the atezolizumab arm who experienced an infusion- related reaction (IRR) 
during the previous atezolizumab infusion, refer to Section [IP_ADDRESS]) . 
4.4.[ADDRESS_437422] be documented at screening (within 
28 days before initiation of study treatment).  Evaluation of tumor response conforming 
to RECIST v1.[ADDRESS_437423] then be documented every 8 weeks ( ± 1 week ); from the date of 
first study drug administration until investigator -determined disease progression 
(according to RECIST v1.1 that is confirmed 4 weeks after initial documentation of 
progression)  or death, whichever occurs first.   Thus, tumor assessments are to continue 
accordi ng to schedule for  patients who discontinue treatment for reasons other than 
disease progression.  At the investigator ’s discretion, tumor assessments may be 
repeated at any time if disease progression is suspected.    
Tumor assessments must be performed independently of changes to the study treatment administration schedule (i.e., when treatment is withheld).  If a tumor assessment has to be performed early or late, subsequent assessments should be conducted according to the original schedule based on the date of first study treatment .  
Tumor assessments will include contrast -enhanced CT or MRI scans of the chest, 
abdomen, and pelvis.  Imaging of the neck should be included if clinically indicated.  In 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
68/Protocol CO39721, Version 5  the event a positron emission tomography (PET)/CT scanner is used for tumor 
assessments, the CT portion of the PET/CT  scanner  must meet criteria for diagnostic 
quality.   
A CT or MRI scan of the head must be performed at screening to assess CNS 
metastasis.  An MRI scan of the brain is required to confirm or refute the diagnosis of CNS metastases at baseline in the event of an equivocal scan.  Patients with untreated or actively progressing CNS metastases are not eligible for the study (see Section 4.1.2 ).  St able brain metastases (as defined in Appendix  1) must be evaluated at 
each tumor assessment with the same radiographic procedure as the baseline study.  Patients without brain metastases do not need brain scans for tumor assessment unless clinically warranted.   Clinical disease assessments by [CONTACT_351858]/superficial lesions.  Tumor measurements for each patient should be made by [CONTACT_351859], if feasible, using the same assessment technique or procedure throughout the study.  
Tumor response and progression will be evaluated according to RECIST v1.1 (see 
Appendix  3) and immune -modified RECIST (see Appendix  4).  Objective response 
(a CR or PR) must be confirmed by [CONTACT_294862] ≥ [ADDRESS_437424] meet criteria for 
SD ≥ [ADDRESS_437425] be performed at the following 
timepoints:  
• Screening  
• Cycle 2 , Day 1  ± 1 week  
• Day 1 of every three treatment cycles thereafter,  starting at C ycle 5  (± 2 weeks )  
• The treatment discontinuation visit evaluation of LVEF does not need to be 
performed at the treatment discontinuation visit if an evaluation has been performed 
within the last 12  weeks , and there are no clinically significant findings and/or 
changes from baseline.  
• All patients restarting treatment with a dose reduction of cobimetinib because of a 
decrease in LVEF should have LVEF measurements taken after approximately 2, 4, 
10, and [ADDRESS_437426] be performed by [CONTACT_40872] (ECHO or MUGA  scan ) for each patient.  It is strongly encouraged that the same 
laboratory and operator perform ECHO/MUGA scans for each patient.  Investigators 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
69/Protocol CO39721, Version [ADDRESS_437427] be aware of local institution regulations regarding repeat MUGA scans.  The repeat 
administration of radioisotopes is limited in some nuclear medicine laboratories, and some patients in this study could require monitoring on four or more occasions.  
4.4.7  Ophthalmologic  Examination (Cohorts A and B)  
All patients in Cohorts A and B  will require an ophthalmologic examination at screening 
and subsequent ophthalmologic examinations.   The objective of  a baseline 
ophthalmologic examination is to evaluate for evidence of retinal abnormalities .  An 
ophthalmologic examination must be performed by a qualified ophthalmologist.   
Baseline and serial surveillance ophthalmologic examinations will include visual acuity 
testing  using a standard Snellen chart , intraocular pressure measurement by [CONTACT_26554], 
slit-lamp biomicroscopy , indirect ophthalmoscopy, spectral −domain optical coherence 
tomography  (OCT) , and automatic visual field testing.   Spectral -domain OCT , if not 
available, may be substituted with time -domain OCT .  Ophthalmol ogic examinations 
must be performed according to the schedule in Table [ADDRESS_437428] ophthalmoscopy  
Cycle s 1 and 2  Q2W (± 1) day of the 
scheduled visit , if serous 
retinopathy is not detected  Visual acuity test , OCT, indirect 
ophthalmoscopy  a 
Increase to QW  (± 1) day, if 
serous retinopathy is 
detected, until resolution or 
until C ycle 2, Day 28, 
whichever occurs first  Visual acuity test , VF b, OCT, indirect 
ophthalmoscopy  
Cycles 3 to 6 Q4W  ± [ADDRESS_437429] 
ophthalmoscopy  a 
Increase to Q2W  ± [ADDRESS_437430] 
ophthalmoscopy  
 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
70/Protocol CO39721, Version 5  Table  3 Ophthalmologic Examination Schedule (cont.)   
From Cycle  7  Every 3 cycles ( ± 2 weeks ) Visual acuity test , indirect ophthalmoscopy  c 
Treatment 
discontinuation d One time Visual acuity test , VF b, slit-lamp 
biomicroscopy, IOP measurement, OCT, 
indirect ophthalmoscopy  
IOP  = intraocular pressure; OCT  = optical coherence tomography; Q2W  = every two weeks; 
Q4W  = every 4 weeks;  VF  = visual field.   
Note:  Exam inations should be performed prior to dosing . 
a If serous retinopathy is diagnosed at any visit, patients  must also have visual field testing if not 
already performed at this visit .   
b Perform  Swedish Interactive Threshold Algorithm  Fast strategy (or equivalent):  
• 10-[ADDRESS_437431] if serous retinopathy is detected only within the macula 
• 24-[ADDRESS_437432] the right to voluntarily withdraw from the study at any time for any reason.  
In addition, the investigator has the right to withdraw a patient from the study at any time.  
Reasons for withdrawal from the study may include, but are not limited to, the following:  
• Patient withdrawal of consent at any time  
• Any medical condition that the investigator or Sponsor determines may jeopardize 
the patient ’s safety if he or she continues i n the study  
• Investigator or Sponsor determines it is in the best interest of the patient  
• Patient non -compliance, defined as  failure to comply with protocol requirements as 
determined by [CONTACT_351860].  The primary reason for withdrawal from the study should be documented on the appropriate eCRF.  However, patients will not be followed for any reason after consent has been withdrawn.  Patients who withdraw from the study will not be replaced.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
71/Protocol CO39721, Version 5  4.5.2  Laboratory, Biomarker, and Other Biologic Samples  
[IP_ADDRESS]  Local Laboratory Assessments  
Samples for the following laboratory tests will be sent to the study site's local laboratory 
for analysis:  
• Hematology:  WBC count, RBC count, hemoglobin, hematocrit, platelet count, 
reticulocyte count, and differential count (neutrophils, bands, eosinophils, basophils, 
monocytes, and lymphocytes)  
• Chemistry panel (serum or plasma):  sodium, potassium, magnesium, chloride, bicarbonate (or t otal carbon dioxide), BUN or urea, creatinine, albumin, phosphorus, 
calcium, direct and total bilirubin, ALP, ALT, AST, LDH, CPK, and glucose (non-
fasting), total protein, and uric acid  
• Fasting blood glucose (after a minimum [ADDRESS_437433]), at screening only 
• Fasting lipi[INVESTIGATOR_805]:  total cholesterol, LDL cholesterol, and triglycerides (after a minimum 
8-hour fast), at screening only  
• Coagulation:  INR, aPTT 
• Thyroid- function testing:  thyroid- stimulating hormone, free triiodothyronine (T3;  or 
total T3 for sites where free T3 is not performed), and free thyroxine  
• Urinalysis (specific gravity, pH, glucose, protein, ketones, blood and microscopic 
examination)  
• HIV serology  
• HBV serology:  HBsAg, and total HBcAb and (if HBsAg test is negative and total 
HBcAb test is positive) HBV DNA  
If a patient has a negative HBsAg test and a positive total HBcAb test at 
screening, an HBV DNA test must also be performed to determine if the patient 
has an HBV infection. 
• HCV serology:  HCV antibody and (if HCV antibody test is positive) HCV RNA  
If a patient has a positive HCV antibody test at screening, an HCV RNA test must 
also be performed to determine if the patient has an active HCV infection.  
• Pregnancy test  
All women of childbearing potential will have a serum pregnancy test at screening , within [ADDRESS_437434].  
A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state ( ≥
 12 continuous months of amenorrhea 
with no identified cause other than menopause), and has not undergone surgical 
sterilization (removal of ovaries and/or uterus).   
 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
72/Protocol CO39721, Version 5  [IP_ADDRESS]  Central Laboratory Assessments  
The following samples will be sent to one or several central laboratories or to the 
Sponsor for analysis:  
• Serum samples for atezolizumab PK analysis through use of a validated assay  
• PBMC and plasma samples for cobimetinib PK analysis  through use of a validated 
assay  
• Serum samples for assessment of anti -drug antibodies ( ADAs ) to atezolizumab 
through use of a validated assay  
• Plasma and blood samples for exploratory research on biomarkers  
• Archival (most recently obtained [< 5 years  old]) or fresh tumor tissue sample 
consistent with the patient's diagnosis, collected at baseline for determination of 
BRAFV600-mutation status and for exploratory research on biomarkers  
A representative formalin- fixed paraffin- embedded tumor specimen in a paraffin 
block (preferred) or [ADDRESS_437435] contain a minimum of 50 viable tumor cells that preserve cellular 
context and tissue architecture regardless of needle gauge or retrieval method.  
Tumor tissue should be of good quality based on total and viable tumor content.   
Acceptable samples include those from resections, core- needle biopsies (at 
least three cores, embedded in a single paraffin block), or excisional, incisional, 
or forceps biopsies.  Fine -needle aspi[INVESTIGATOR_1516] (defined as samples that do not 
preserve tissue architecture and yield cell suspension and/or smears), brushing, 
cell pellets from pleural effusion, and lavage samples are not acceptable.  Tumor tissue from bone metastases that have been decalcified is not 
acceptable.  
If 20 slides are not available or the tissue block is not of sufficient size, the patient may still be eligible for the study after discussion with and approval by 
[CONTACT_1689].  If archival tissue is unavailable or unacceptable, a 
pretreatment tumor biopsy is required.   
For archival samples (< 5 years  old), remaining tumor tissue blocks for enrolled 
patients will be returned to the  site upon request or [ADDRESS_437436].  Remaining tumor tissue blocks for patients who are not enrolled in the study will be returned to the site no later than 3 months after eligibility determination.  Slides will not be returned.  
• For patients in Cohorts A and C, optional tumor tissue samples collected at the time of progression, if deemed clinically feasible by [CONTACT_093], for exploratory 
research on biomarkers  
Biopsies should be performed at the time of progression, preferably within [ADDRESS_437437] does of study treatment.  Acceptable samples include 
those from resections, core- needle biopsies (three cores preferred), or 
excisional, incisional, or forceps biopsies.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
73/Protocol CO39721, Version 5  • For Cohort A patients, an optional biopsy can also be collected 4 −[ADDRESS_437438] atezolizumab dose.   
• For patients enrolled in Cohort B, the biopsy cohort will undergo biopsies according 
to the following schedule:  
A mandatory predose biopsy will be obtained before Cycle 1, Day 1.  
A mandatory on- treatment biopsy will be obtained between Days 10 and 14 of 
Cycle 1.  
A second, optional, on- treatment biopsy will be obtained during Cycle 2, after 
the second dose  of atezolizumab, to assess the combined effects of 
cobimetinib and atezolizumab.  
A mandatory biopsy at the time of progression  
 
Biomarker research may include, but will not be limited to, analysis of S100, ctDNA, 
genes or gene signatures associated with tumor immunobiology, tumor immune profiles (e.g., CD8, MHC, an d PD -L1), lymphocytes, or TCR repertoire and may involve DNA or 
RNA extraction, analysis of somatic mutations, and use of NGS (see Table  4).  An 
optional blood sample for WGS may also be obtained.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
74/Protocol CO39721, Version 5  Table  4 Proposed Biomarkers for Exploratory Research  
Sample Type  Timing  Proposed Biomarker(s)  
Plasma  Predose  on Day 1 of Cycles 
1, 2, at time of subsequent 
radiologic tumor assessments, and at 
disease progression  • S100  
• ctDNA  
PBMC  Predose on Day 1 of Cycles 
1, 2, and at time of 
subsequent radiologic tumor assessments, and at 
disease progression  • TCR repertoires  
Tumor tissues  Prior to study: archival (<  5 
years  old) or at baseline 
(required)  • Tumor mutations  
• Tumor -immune contexture, 
such as PD -L1, MHCI, and 
CD8+ T cells  
Tumor biopsy  On-treatment (optional) and 
time of disease progression 
(required if clinically 
feasible)  • Tumor -immune contexture, 
such as PD -L1, MHCI, and 
CD8+ T cells  
DNA and RNA extracted 
from tumor tissues, 
plasma and PBMC  Same as tumor tissue and 
biopsy  • Mutation load/profiles in DNA  
• TCR profiles in DNA  
• Immuno- signatures by [CONTACT_351861]  = circulating tumor DNA; MHCI  = major histocompatibility complex class I; 
PBMC  = peripheral blood mononuclear cell; PD -L1  = programmed death− ligand 1; 
TCR  = T-cell receptor.  
 
NGS may be performed by [CONTACT_33430].  If performed by [CONTACT_33430], 
the investigator can obtain results from these analyses in the form of an NGS report, which is available upon request directly from Foundation Medicine.  The investigator may share and discuss the results with the patient, unless the patient choo ses 
otherwise.  The Foundation Medicine NGS assay has not been cleared or approved by [CONTACT_21652].  The NGS report is generated for research purposes and is not provided for the purpose of guiding future treatment decisions.  
For sampling procedures,  storage conditions, and shipment instructions, see the 
laboratory manual.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
75/Protocol CO39721, Version 5  Biologic samples will be destroyed when the final Clinical Study Report has been 
completed, with the following exceptions:  
• Plasma and serum samples collected for PK analysis or immunogenicity analysis 
may be needed for additional immunogenicity characterization and PK and 
immunogenicity assay development and validation; therefore, these samples will be destroyed no later than 5 years after the final Clinical Study Report has been 
completed.  
• Blood samples collected for WGS will be stored until they are no longer needed or until they are exhausted.  
• Blood and tissue samples collected for biomarker analyses will be destroyed no later than [ADDRESS_437439] to the confidentiality standar ds 
described in Section 8.4. 
Given the complexity and exploratory nature of exploratory biomarker analyses, data derived from these analyses will generally not be provided to study investigators or patients unless required by [CONTACT_2371] (with the exception of the report from Foundation Medicine).  The aggregate results of any conducted research will be available in accordance with the effective Sponsor policy on study data publication.  
4.5.[ADDRESS_437440] permanently discontinue study treatment if they experience any of the 
following:  
• Clinical deterioration due to disease progression  
• Any adverse event that requires study treatment discontinuation per the guidelines 
in Appendix  7. 
• Use of a non −protocol -specified anti -cancer therapy  
• Intolerance of study treatment despi[INVESTIGATOR_351819] -defined dose reduction 
• Pregnancy  
• Withdrawal of consent  
• Any medical condition that the investigator or Sponsor determines may jeopardize 
the patient ’s safety if he or she continues to receive study treatment  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
76/Protocol CO39721, Version 5  • Investigator or Sponsor determines it is in the best interest of the patient 
(e.g.,  unwillingness to comply with study assessments that compromise their safety)  
 
Patients who discontinue study drug for any reason will be asked to return to the clinic 
for a treatment discontinuation visit 30 ( ± 3) days  after the last dose of study drug.  The 
visit at which response assessment shows  disease progression may be used as the 
treatment discontinuation visit, provided all required assessments have been performed and it is 30 ( ±
 3) days  after the last dose of study drug.  The primary reason for study 
treatment discontinuation should be documented on the appropriate eCRF.  Patients who discontinue study treatment will not be replaced.  
After treatment discontinuation, information on survival follow -up and subsequent 
anti-cancer therapy will be collected via telephone calls, patient medical records, and/or 
clinic visits approximately every 12 weeks until death (unless the Sponsor terminates the study).  If the patient withdraws from the study, the study staff may use a public information source (e.g., county records) to obtain information about survival status only as is permissible per local laws and regulations . 
4.5.4  Study and Site Discontinuation 
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include, but are not limited to, the following:  
• The incidence or severity of adverse events in this or other studies indicates a 
potential health hazard to patients. 
• Patient enrollment is unsatisfactory. 
 
The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.  
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include, but are not limited to, the following:  
• Excessively slow recruitment  
• Poor protocol adherence  
• Inaccurate or incomplete data recording 
• Non-compliance with the International Co uncil for Harmonisation (ICH) guideline for 
Good Clinical Practice  
• No study activity (i.e., all patients have completed the study and all obligations have 
been fulfilled)  
 
5. ASSESSMENT OF SAFETY   
5.1 SAFETY PLAN  
The safety plan for patients in this study is based on clinical experience with cobimetinib 
and atezolizumab in completed and ongoing studies and on published data from similar 
molecules.  The anticipated important safety risks for cobimetinib and atezolizumab are 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
77/Protocol CO39721, Version 5  outlined below.  Refer to the Cobimetinib Investigator's Brochure and Atezolizumab 
Investigator ’s Brochure for a complete summary of safety information.  
Measures will be taken to ensure the safety of patients participating in this study, 
including the use of stringent inclusion and exclusion cri teria and close monitoring of 
patients during the study. Eligibility criteria have been designed to exclude patients at higher risk for toxicities.  Administration of atezolizumab will be performed in a monitored setting in which there is immediate access to trained personnel and adequate equipment and medicine to manage potentially serious reactions.   
Patients will undergo safety monitoring during the study, including assessment of the nature, frequency, and severity of adverse events.  In addition, guidelines for managing adverse events, including criteria for dosage modification, and treatment interruption or discontinuation, are provided below.  There are separate guidelines for the three 
different arms as the toxicities and management guidelines are di stinct.  Refer to the 
specific guidelines for each arm individually.  
The ris ks associated with cobimetinib and atezol izumab are detailed in Section 5.1.1  and 
5.1.2 , respectively.   Additional information on the risks of atezolizumab and management 
of atezolizumab- related adverse events are outlined in Appendix  8 
Adverse events will be reported as described in Sections  5.2−5.4. Oversight  will be  
provided by [CONTACT_351862] . 
5.1.1  Risks Associated with Cobimetinib  
The information related to the risks attributed to cobimetinib is based on safety data from Studies GO28141, NO25395, and MEK4592g.  Additional clinical experience has been obtained through postmarketing experience and clinical studies with cobimetinib in combination with other agents.  The safety data are  also based on postmarketing 
experience.  For further information regarding clinical safety, refer to the current Cobimetinib Investigator ’s Brochure.  
[IP_ADDRESS]  Important Identified Risks Associated with Cobimetinib 
[IP_ADDRESS].[ADDRESS_437441] been reported.  
In Study GO28141, Grade 1− 4 hemorrhagic events were reported in 13.0% of patients 
treated with cobimetinib plus vemurafenib and in 7.3% of patients treated with placebo 
plus vemurafenib.  The majority of hemorrhagic events were Grade 1 or 2 and 
non-serious.  Grade 3 and 4 hemorrhage events were reported in 1.2% of patients 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
78/Protocol CO39721, Version 5  receiving cobimetinib plus vemurafenib and in 0.8% of patients receiving placebo plus 
vemurafenib.  
Caution should be used in patients with additional risk factors for bleeding, such as brain metastases, and/or in patients that use concomitant medications that increase the risk of bleeding (including antiplatelet or anticoagulant therapy).  
Instructions for dose modification for hemorrhagic events are included in Section [IP_ADDRESS] . 
[IP_ADDRESS].[ADDRESS_437442] of cobimetinib and has also been observed 
with other MEK inhibitors  (refer to Section 3.3.7  for details) . 
To address serous retinopathy with cobimetinib treatment, all patients are required to undergo ophthalmologic examination at baseline and at specified timepoints throughout 
the study.  Details regarding baseline and subsequent ophthalmologic examinations are provided in Section 4.4.7 . 
Guidelines for management of patients who develop Grade ≥
 2 visual disorders or 
retinopathy are provided in Section [IP_ADDRESS] . 
[IP_ADDRESS].[ADDRESS_437443] been reported in patients receiving cobimetinib.  Left ventricular dysfunction may occur with signs and symptoms of cardiac failure, or reduction in LVEF events may be asymptomatic. 
Left ventricular dysfunction has been characterized in Study GO28141.  The study 
incorporated prospective serial LVEF evaluations in all patients.  With active surveillance, 
measured Grade  2 or 3 re ductions in LVEF were observed more frequently in patients 
treated with cobimetinib plus vemurafenib than placebo plus vemurafenib (8.5% vs. 3.7%, respectively).  Of the patients treated with cobimetinib plus vemurafenib, 2 patients (0.8%) had symptomatic reduction in LVEF and the remaining patients were 
asymptomatic.  Most LVEF reduction events in patients on cobimetinib plus vemurafenib (62%) improved or resolved with management according to dose modification guidelines (see in Section [IP_ADDRESS] ).  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
79/Protocol CO39721, Version 5  [IP_ADDRESS].[ADDRESS_437444] been observed in patients who received cobimetinib 
monotherapy as well as when administered with other agents.  The majority of CPK elevations reported was  asymptomatic, non- serious, and resolved with or without study 
drug interruption.  One event of rhabdomyolysis was reported in the Phase III study GO28141 (cobimetinib plus vemurafenib), and rhabdomyolysis has been reported in the postmarketing experience. 
In Study GO28141, elevated CPK was reported as an adverse event more frequently in 
patients treated with cobimetinib plus vemurafenib (32.4% all grades, 11.3% Grade ≥
 3 
events) than placebo plus vemurafenib (8.1% all grades, 0% Grade ≥  3 events).  
CPK will be monitored at baseline and monthly during treatment or as clinically indicated.  
[IP_ADDRESS].[ADDRESS_437445] been observed in patients treated with cobimetinib and vemurafenib.  
Liver laboratory tests should be monitored before initiation of treatment and monthly during treatment, or  more frequently as clinically indicated.  
Grade 3 and 4 liver laboratory abnormalities should be managed with dose interruption, reduction, or discontinuation of cobimetinib.  
[IP_ADDRESS].[ADDRESS_437446] reported events were considered to be non- serious and of low severity grade.  In Study  GO28141, 
pneumonitis events were reported more frequently in patients treated with cobimetinib plus vemurafenib than placebo plus  vemurafenib (1.6% vs. 0.4%; all grades).  
There  were no reported Grade ≥
 3 events in either study arm.  Serious events were 
reported for 2 patients (0.8%) treated with cobimetinib plus vemurafenib.  
[IP_ADDRESS]  Potential Risks Associated with Cobimetinib  
[IP_ADDRESS].1  Severe Hepatotoxicity (Grade ≥ 3) 
Liver la boratory test abnormalities, including increases in ALT, AST, and ALP, have 
been reported as adverse events and serious adverse events in patients treated with cobimetinib.  
Generally, elevations in liver laboratory tests were managed effectively with dose modification guidelines and the majority of Grade ≥
 [ADDRESS_437447] abnormalities 
resolved.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
80/Protocol CO39721, Version [ADDRESS_437448]/ALT 
and total bilirubin in Study GO28141 were reported.  However, the causality assessment 
for cobimetinib was confounded by [CONTACT_351863]/or the presence of liver metastases.  Therefore, severe hepatotoxicity is a potential risk for cobimetinib.  
[IP_ADDRESS].[ADDRESS_437449] been conducted with cobimetinib in animals, degenerative changes observed in reproductive tissues included increased apoptosis/necrosis of corpora lutea and seminal vesicle, epi[INVESTIGATOR_351820], and epi[INVESTIGATOR_40807].  These changes were reversible upon discontinuation of cobimetinib administration.  
[IP_ADDRESS].3  Teratogenicity and Developmental Toxicity  
In a dedicated embryofetal toxicity study, cobimetinib produced fetal toxicity (resorptions and reductions in fetal weight) and teratog enicity (malformations of the great vessels and 
skull) at similar systemic exposures to those observed in patients administered the 60-mg dose.  
[IP_ADDRESS]  Other Risks with Cobimetinib  
[IP_ADDRESS].1  Rash  
In Study  GO28141, combined rash events of all types and grades were reported m ore 
frequently in patients treated with cobimetinib plus vemurafenib than placebo plus vemurafenib (71.7% vs. 66.7%, respectively), although Grade ≥
 3 events (approximately 
16% of patients) and types of rash reported were similar between study arms.  Speci fic 
events in patients treated with cobimetinib plus vemurafenib included rash (39% all grades, 5.9% Grade
 ≥ 3, and 1.6% serious adverse events) and maculopapular rash 
(14.6% all grades, 6.3% Grade  ≥ 3, and 1.2% serious adverse events).  
Generally, Grade  ≥ 3 rash events were effectively managed with dose modification 
guidelines.  In Study  GO28141, approximately 90% of Grade ≥ 3 rash events resolved in 
both arms.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
81/Protocol CO39721, Version 5  [IP_ADDRESS].[ADDRESS_437450] common adverse event reported.   Diarrhea 
events of all severity grades were reported in 59.9% of patients and Grade 3 or 4 events  
were reported in 6.5% of patients treated with cobimetinib plus vemurafenib versus 
30.9%  (Grade  3) and 0.8% (Grade 4) in the patients treated with placebo plus 
vemurafenib.   No Grade [ADDRESS_437451] been reported.   Serious adverse 
events of diarrhea were reported for 1.2% of patients treated with cobimetinib plus 
vemurafenib.  
Nausea and vomiting have been reported in association with cobimetinib.   Most nausea 
and vomiting events were considered to be non -serious and of low  severity grade.  In 
Study GO28141, nausea and vomiting events were reported more frequently in the 
active cobimetinib arm than the control arm (nausea, 41.3% vs. 25.2%; vomiting, 24.3% vs. 12.6%).  However, of patients treated with cobimetinib plus vemurafenib, few experienced G rade 3 events (nausea, 0.8% ; vomiting, 1.2%).  
In the Phase  I single -agent study (MEK4592g), all grades of nausea and vomiting were 
both reported as 33.9%, with 0.9% reported for Grade ≥
 3 nausea and none reported for 
vomiting. 
The combination of diarrhea, nausea, and vomiting has the potential to contribute to 
clinically significant volume depletion/dehydration from the combination of fluid losses with decreased oral intake.   In the majority of cases, diarrhea has been effectively 
managed with anti -diarrheal agents and supportive care.  Routine anti -emetic 
prophylaxis is not recommended.  
[IP_ADDRESS].[ADDRESS_437452] been few reports of hypersensitivity and/or anaphylaxis in clinical trials with patients who have been exposed to cobimetinib monotherapy or cobimetinib when used with other agents.  These have appeared to be isolated reports, and in some cases, occurred in patients with history of drug allergies.  Thus, the relationship of cobimetinib to these events is unclear.  
In Study GO28141, Grade 3 hypersensitivity events were reported for 3 patients in the 
cobimetinib plus vemurafenib arm compared with no such events in the placebo plus vemurafenib arm.  All events required hospi[INVESTIGATOR_351821].  
Investiga tors should promptly evaluate and treat patients who are suspected of 
experiencing a hypersensitivity reaction.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
82/Protocol CO39721, Version 5  5.1.2  Risks Associated with Atezolizumab  
Atezolizumab has been associated with risks such as the following:  IRRs and 
immune- related hepatitis, pneumonitis, colitis, pancreatitis, diabetes mellitus, 
hypothyroidism, hyperthyroidism, adrenal insufficiency, Guillain- Barré  syndrome, 
myasthenic syndrome or myasthenia gravis, meningoencephalitis , myocarditis, 
hypophysitis , and nephritis .  In addition, systemi c immune activation is a potential risk 
associated when atezolizumab is given in combination with other immunomodulating 
agents .  Ref er to Appendix  8 of the protocol  and Section 6 of the Atezolizumab 
Investigator's Brochure for a detailed description of anticipated safety risks for 
atezolizumab.  
Systemic immune activation is a rare condition characterized by [CONTACT_33970].  Given the mechanism of action of atezolizumab, systemic immune activation is considered a potential risk  when administered in combination with other 
immunomodulating agents.  Systemic immune activation should be included in the differential diagnosis for patients who, in the absence of an alternative etiology, develop a sepsis -like syndrome after administration of atezolizumab, and the initial evaluation 
should include the following:  
• CBC with peripheral smear  
• PT, PTT, fibrinogen, and D -dimer  
• Ferritin  
• Triglycerides  
• AST, ALT, and total bilirubin 
• LDH 
• Complete neurologic and abdominal examination (assess for hepatosplenomegaly)  
 
If systemic immune activation is still suspected after the initial evaluation, contact [CONTACT_33472].   See Appendix  8 for additional 
information on the diagnosis and management of systemic immune activation.  
5.1.3  Management of Patients Who Experience Specific 
Adverse Events  
[IP_ADDRESS]  Cobimetinib Dose Modifications  
General dose modifications for cobimetinib are provided in Table 5 .  Dose modifications 
for specific adverse events are provided in Table  6. 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
83/Protocol CO39721, Version 5  Table  5 Recommended Cobimetinib Dose Modifications  
Grade  
(NCI CTCAE)  Recommended 
Cobimetinib Dose  
Grade 1 or Grade 2 (tolerable)  No dose reduction.  Maintain cobimetinib at the same dose 
of 60 mg QD (3 tablets)  
Grade 2 (intolerable) or Grade 3 
or 4 (any)   
First appearance  Interrupt treatment  until Grade ≤ 1, restart treatment at 
40 mg QD (2 tablets)  
Second appearance  Interrupt treatment until Grade ≤ 1, restart treatment at  
20 mg QD (1 tablet)  
Third appearance  Consider permanent discontinuation.  
NCI CTCAE  = National Cancer Institute Common Terminology  Criteria for Adverse Events; 
QD  = once daily.  
 
[IP_ADDRESS]  Atezolizumab Dose Modifications  
There will be no dose reduction for atezolizumab in this study.  
[IP_ADDRESS]  Management of Cobimetinib- and Atezolizumab- Specific 
Adverse Events  
Toxicities associated or possibly associated with cobimetinib plus atezolizumab 
treatment should be managed according to standard medical practice.  See Appendix  8 
for management of adverse events related to atezolizumab. 
For management of cobimetinib- and atezolizumab- specific toxicities, including IRRs, 
gastrointestinal toxicity, dermatologic toxicity, hepatotoxicity, pulmonary toxicity, potential 
eye toxicity, reductions in LVEF from baseline, rhabdomyolysis, elevated CPK, and hemorrhage, see Table  6. 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
84/Protocol CO39721, Version 5  Table  6 Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  
Event  Action to Be Taken  
General guidance for dose 
modifications and treatment 
delays and discontinuation  • There will be no dose modifications for atezolizumab.   
• If atezolizumab is withheld and corticosteroids are initiated for 
an atezolizumab- related toxicity, corticosteroids must be 
tapered over ≥  1 month to ≤  10 mg/day oral prednisone or 
equivalent before atezolizumab can be resumed. a, b, c 
The dose of cobimetinib can be reduced by 20 mg (one dose 
level) up to two times  (i.e., from 60 mg to 40 mg and then from 
40 mg to 20 mg).  If further dose reduction is indicated after 
two dose reductions , the patient mu st discontinue cobimetinib 
but may continue treatment with atezolizumab at the 
investigator ’s discretion.  
• If atezolizumab is discontinued, treatment with cobimetinib 
may be continued at the investigator ’s discretion and after 
discussion with the Medical Mo nitor.  
• If cobimetinib is  withheld for >  28 days because of toxicity, the 
patient should be discontinued from cobimetinib, unless resumption of treatment is approved by [CONTACT_351864].  
• If atezolizumab is  withheld for >  105 days because of toxicity, 
the patient should be discontinued from atezolizumab, unless resumption of treatment is approved by [CONTACT_351864].  
IRRs, anaphylaxis, and hypersensitivity reaction  • Guidelines for management of IRRs are provided in 
Appendix  8. 
• For anaphylaxis precautions, see Appen dix 7. 
• For severe hypersensitivity reactions, permanently discontinue all study treatment.  
IRR  = infusion- related reaction.  
a If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day oral 
prednisone or equivalent before atezolizumab can be resumed.  
b Atezolizumab may  be withheld for a period of time beyond 105 days  to allow for 
corticosteroids to be reduced to ≤  10 mg/day oral prednisone or equivalent.  The acceptable 
length of the extended period of time must be agreed upon by [CONTACT_40904].  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have 
fully recovered from the immune- related event.  Patients  can be rechallenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor.   
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
85/Protocol CO39721, Version 5  Table  6 Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  (cont.)  
Event  Action to Be Taken  
Gastrointestinal toxicity  
Gastrointestinal  events:  
general guidance  • All events of diarrhea or colitis should be thoroughly evaluated for 
more common etiologies other than drug- induced effects.  
• For events of significant duration or severity or associated with 
signs of systemic inflammation or acute- phase reactants, check for 
immune- related colitis.  
• Administer anti -diarrheal agents and other maximal supportive care 
per institutional guid elines , such as at the first report of watery 
diarrhea or loose stool, initiate maximal anti -diarrheal supportive 
care (Lomotil ® and loperamide).  
• Suggested regimen:  
– Loper amide: Initiate dose with 4 mg and then 4 mg/6 hr  around 
the clock, alternating with Lomotil. ® 
– Lomotil® (diphenoxylate and atropi[INVESTIGATOR_050]):  2 tablets (diphenoxylate 
5 mg, atropi[INVESTIGATOR_050] 0.05 mg) every 6 hours around the clock  
– Continue Lomotil® and loperamide until no loose stools for 
24 hours.  
– If Grade ≤ 2 diarrhea persists after 48 hours of total treatment 
with Lomotil® and loperamide, consider second- line agents 
(e.g., octreotide, budesonide, tincture of opi[INVESTIGATOR_1890]).   
• Oral supplementation:  
– Initiate oral supplementation of potassium and/or magnesium if  
serum levels are <  LLN.  
– Consider oral rehydration therapy (e.g., Pedialyte®) for 
Grade ≥ 1 diarrhea or vomiting.  
• Dietary modifications:  
– Stop all lactose- containing products and encourage eating small 
meals.  
– The BRAT (banana, rice, apples, toast) diet, without fiber (other 
vegetables and fruits), may be helpful.  
– Encourage adequate hydration with salt -containing liquids, such 
as broth or Gatorade®. 
Diarrhea, Grade 1 or 
Grade 2 (tolerable)  • Continue atezolizumab and cobimetinib.  
• Investigate etiology, referring patient to GI specialist for evaluation 
of possible colitis if appropriate.  
• Initiate supportive care and monitor patient closely.  
GI  = gastrointestinal; LLN  = lower limit of normal.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
86/Protocol CO39721, Version 5  Table  6 Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  (cont.)  
Event  Action to Be Taken  
Gastrointestinal toxicity (cont.) 
Diarrhea, Grade 2 
(intolerable) or Grade 3  • Withhold atezolizumab and cobimetinib.  
• Initiate supportive care and monitor patient closely.  
• Discontinue medications that may exacerbate colitis (e.g., NSAIDs) while investigating etiology.  
• Investigate etiology, referring patient to GI specialist for evaluation of possible colitis,  including biopsy if appropriate.  
• If event resolves to Grade 1 or better within 105 days , resume 
atezolizumab at fixed dose.  If not, permanently discontinue atezolizumab and cobimetinib. 
a, b, c 
• If event resolves to Grade 1 or better within 28 days , resume 
cobimetinib with dose reduced by [CONTACT_12691].  If not, permanently  
discontinue cobimetinib . 
Diarrhea, Grade 4  • Permanently discontinue atezolizumab and cobimetinib,  and 
contact [CONTACT_25290]. c 
• Initiate supportive care and monitor patient closely.  
• Discontinue medications that may exacerbate colitis (e.g., NSAIDs) 
while investigating etiology.  
• Rule out bowel perforation.  
• Investigate etiology, referring patient to GI specialist for evaluation 
of possible colitis, including biopsy if appropriate.  
Colitis, Grade 1  • Continue atezolizumab and cobimetinib.  
• Initiate supportive care and monitor patient closely.  
• Discontinue medications that may exacerbate colitis (e.g., NSAIDs).  
• Refer patient to GI specialist for evaluation and confirmatory biopsy 
if symp toms persist for > 7 days.  
GI  = gastrointestinal; NSAID  = non-steroidal anti -inflammatory drug.  
a If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day oral 
prednisone or equivalent before atezolizumab can be resumed.  
b Atezolizumab may  be withheld for a period of time beyond 105 days  to allow for corticosteroids 
to be reduced to ≤  10 mg/day oral prednisone or equivalent.  The acceptable length of the 
extended period of time must be agreed upon by [CONTACT_33495].  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have 
fully recovered from the immune- related event.  Patients can be rechallenged with atezolizumab 
only after approval has been documented by [CONTACT_33494] (or an appropriate delegate) 
and the Medical Monitor.   
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
87/Protocol CO39721, Version 5  Table  6 Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  (cont.)  
Event  Action to Be Taken  
Gastrointestinal toxicity (cont.) 
Colitis, Grade 2  • Withhold atezolizumab and cobimetinib.  
• Initiate supportive care and monitor patient closely.  
• Discontinue medications that may exacerbate colitis 
(e.g.,  NSAIDs).  
• Refer patient to GI specialist for evaluation and confirmatory 
biopsy.  
• For recurrent events or events that persist  > 5 days, initiate 
treatment with 1− 2 mg/kg/day oral prednisone or equivalent.  
• If event resolves to Grade 1 or better within 105 days , resume 
atezolizumab at fixed dose.  If not, permanently discontinue atezolizumab and cobimetinib. 
a, b, c 
• If event resolves to Grade 1 or better within 28 days , resume 
cobimetinib with dose reduced by [CONTACT_12691].  If not, permanently  
discontinue cobimetinib . 
Colitis, Grade 3  • Withhold atezolizumab and cobimetinib.  
• Initiate supportive care and monitor patient closely.  
• Discontinue medications that may exacerbate colitis (e.g.,  NSAIDs).  
• Refer patient to GI  specialist for evaluation and confirmatory 
biopsy.  
• Initiate treatment with 1−2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 1−2 mg/kg/day oral prednisone or 
equivalent  upon improvement.  
• If event resolves to Grade 1 or better within 105 days , resume 
atezolizumab at fixed dose.  If not, permanently discontinue atezolizumab and cobimetinib. 
a, b, c  
• If event resolves to Grade 1 or better within 28 days , resume 
cobimetinib with dose reduced by [CONTACT_12691].  If not, permanently  
discontinue cobimeti nib. 
GI  = gastrointestinal; IV = intravenous; NSAID  = non-steroidal anti -inflammatory drug.  
a If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day oral 
prednisone or equivalent before atezolizumab can be resumed.  
b Atezolizumab may  be withheld for a period of time beyond 105 days  to allow for corticosteroids 
to be reduced to ≤  10 mg/day oral prednisone or equivalent.  The acceptable length of the 
extended period of time must be agreed upon by [CONTACT_33495].  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have 
fully recovered from the immune- related event.  Patients can be rechallenged with atezolizumab 
only after approval has been documented by [CONTACT_33494] (or an appropriate delegate) 
and the Medical Monitor.  
 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
88/Protocol CO39721, Version 5  Table  6 Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  (cont.)  
Event  Action to Be Taken  
Gastrointestinal toxicity (cont.) 
Colitis, Grade 4  • Permanently discontinue atezolizumab and cobimetinib,  and 
contact [CONTACT_25290]. a 
• Initiate supportive care and monitor patient closely.  
• Discontinue medications that may exacerbate colitis (e.g., NSAIDs).  
• Refer patient to gastrointestinal specialist for evaluation and 
confirmatory biopsy.  
• Initiate treatment with 1− 2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 1 −2 mg/kg/day oral prednisone or 
equivalent upon improvement.  
• If event does not improve within 48 hours after initiating corticosteroids, consider adding an immunosuppressive agent.  
• If event resolves to Grade 1 or better, taper corticosteroids over ≥
 1 month.  
IV = intravenous; NSAID  = non-steroidal anti -inflammatory drug.  
a Resumption of atezolizumab may be considered in patients who are deriving benefit and have 
fully recovered from the immune- related event.  Patients can be rechallenged with atezolizumab 
only after approval has been documented by [CONTACT_33494] (or an appropriate delegate) 
and the Medical Monitor.   
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
89/Protocol CO39721, Version 5  Table  6 Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  (cont.)  
Event  Action to Be Taken  
Dermatologic toxicity   
General guidance  • A dermatologist should evaluate persistent and/or severe 
rash or pruritus.  A biopsy should be considered unless 
contraindicated.  
Dermatologic event,  
Grade 1 or 2  • Continue atezolizumab and cobimetinib.  
• Initiate supportive care (e.g., antihistamines, topi[INVESTIGATOR_030]).  If event does not improve, consider 
treatment with higher -potency topi[INVESTIGATOR_11930].  
• For Grade [ADDRESS_437453].  
Acneiform rash:  
• Consider topi[INVESTIGATOR_11930] ( e.g., hydrocortisone 2.5%, 
alclometasone) and oral antibiotics (minocycline, doxycycline, or antibiotics covering skin flora) as clinically indicated.  
Dermatologic event,  
Grade 3  • Withhold atezolizumab and cobimetinib.  
• Refer patient to dermatologist.  A biopsy should be performed if appropriate.  
• Consider initiating treatment with 10 mg/day oral prednisone 
or equivalent, increasing dose to 1− 2 mg/kg/day if event does 
not improve within 48− 72 hours.  
• If event resolves to Grade 2 or better within 105 days , 
resume atezolizumab
 at fixed dos e.  If not, permanently 
discontinue atezolizumab and cobimetinib. a, b 
• Permanently discontinue atezolizumab and cobimetinib and contact [CONTACT_246791] 1 
or better within 105 days.
 a, b, c  
• If event resolves to Grade 2 or  better within 28 days , resume 
cobimetinib with dose reduced by [CONTACT_12691] .  If not, 
permanently  discontinue cobimetinib.  
Acneiform rash:  
• Consider continuation of topi[INVESTIGATOR_11930] (e.g., 2.5% 
alclometasone) and oral antibiotics (e.g., minocycline, doxycycline , or antibiotics covering skin flora) when restarting 
cobimetinib.  
Dermatologic event,  
Grade 4  • Permanently discontinue atezolizumab and cobimetinib,  and 
contact [CONTACT_25290]. c 
a If corticosteroids have been initiated, they must be tapered over ≥ 1 month to ≤ 10 mg/day oral 
prednisone or equivalent before atezolizumab can be resumed.  
b Atezolizumab may  be withheld for a period of time beyond 105 days to allow for corticosteroids to be 
reduced to ≤ 10 mg/day oral prednisone or equivalent.  The acceptable length of the extended period of 
time must be agreed upon by [CONTACT_33495].  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune-related event.  Patients can be rechallenged with atezolizumab only after approval has been documented by [CONTACT_33494] (or an appropriate delegate) and the Medical 
Monitor.   
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
90/Protocol CO39721, Version 5  Table  6 Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  (cont.)  
Event  Action to Be take  
Elevations in ALT, AST, 
and/or bilirubin   
AST/ALT  > ULN to  ≤ 3 × ULN 
with total bilirubin  < 2 × ULN 
(Grade 1)  • Continue atezolizumab and cobimetinib.  
• Continue with the standard monitoring plan (i.e., LFTs Q4W 
before dosing).  
AST/ALT  > 3 × baseline values 
to < 5 × ULN with total 
bilirubin  < 2 × ULN  
(Grade 2)  • Continue all study treatment.  
• Monitor LFTs at least weekly.   
• Consider referral to a hepatologist and liver biopsy.  
• For suspected immune- related events of >  5 days duration  
– Consider withholding atezolizumab a 
– Consider administering 1− 2 mg/kg/day oral prednisone or 
equivalent followed by ≥  1 month taper  
– Restart atezolizumab if event resolves to Grade 1 or better within 105 days . 
b, c 
– Permanently discontinue atezolizumab and cobimetinib if 
event does not resolve to Grade [ADDRESS_437454]/ALT  > 5 × baseline values 
to < 10  × ULN with  total 
bilirubin  < 2 × ULN  
(Grade 3)  • Continue all study treatment.  
• Monitor LFTs at least weekly.   
• Consider referral to a hepatologist and liver biopsy.  
• For suspected immune- related events:  
– Withhold atezolizumab  
– Consider administering 1 −2 mg/kg/day oral prednisone or 
equivalent followed by ≥ 1 month taper  
– If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent. If event resolves to Grade 1 or better, taper 
corticosteroids over 
≥ 1 month.  
– Permanently discontinue atezolizumab and cobimetinib if 
event does not resolve to Grade 1 or better within  
105 days . a, b, c 
LFT  = liver function test; Q4W  = every 4 weeks; ULN  = upper limit of normal.  
a Resumption of atezolizumab may be considered in patients who are deriving benefit and have 
fully recovered from the immune- related event.  Patients can be rechallenged with atezolizumab 
only after approval has been documented by [CONTACT_33494] (or an appropriate delegate) 
and the Medical Monitor.  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day oral 
prednisone or equivalent before atezolizumab can be resumed.  
c Atezolizumab may  be withheld for a period of time beyond 105 days to allow for corticosteroids 
to be reduced to ≤  10 mg/day oral prednisone or equivalent.  The acceptable length of the 
extended period of time must be agreed upon by [CONTACT_33495].   
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
91/Protocol CO39721, Version 5  Table  6 Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  (cont.)  
Event  Action to Be take  
Elevations in ALT, AST, 
and/or bilirubin (cont.)  
AST/ALT  > 3 × ULN with 
bilirubin  > 2  × ULN  • Withhold atezolizumab and cobimetinib.  
• Consult hepatologist and consider liver biopsy.  
• Consider administering 1− 2 mg/kg/day oral prednisone or 
equivalent followed by  ≥ 1 month taper  (for possible autoimmune 
hepatitis).  
• If LFTs do not decrease within 48 hours after initiation of systemic steroids, consider adding an immunosuppressive 
agent (e.g., mycophenolate mofetil or TNF -α antagonist).  
• Monitor LFTs every 48− 72 hours until decreasing and then 
follow weekly.  
• Restart atezolizumab at fixed dose and cobimetinib at [ADDRESS_437455]/ALT
 < 3 × ULN with bilirubin  < 2 × ULN and steroid 
dose  < 10 mg oral prednisone equivalent per day. a, b, c 
• Permanently discontinue atezolizumab and cobimetinib for 
life-threatening hepatic events, and contact [CONTACT_1689].  
AST/ALT  > 10  × ULN • Permanently discontinue atezolizumab and cobimetinib.  c 
• Consult hepatologist and consider liver biopsy.  
• Consider administering 1−2 mg/kg/day oral prednisone or 
equivalent (for possible autoimmune hepatitis).  If event resolves to Grade 1 or better, taper corticosteroids over ≥
 1 month.  
• If LFTs do not decrease within 48 hours after initiation of 
systemic steroids, addition of an alter native immunosuppressive 
agent (e.g., mycophenolate mofetil or TNF -α antagonist) or dose 
escalation of corticosteroids may be considered.  
• Monitor LFTs every 48− 72 hours until decreasing and then 
follow weekly.  
LFT  = liver function test; TNF -α = tumor necrosis factor −alpha; ULN  = upper limit of normal.  
a If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day oral 
prednisone or equivalent before atezolizumab can be resumed.  
b Atezolizumab may  be withheld for a period of time beyond 105 days to allow for corticosteroids 
to be reduced to ≤  10 mg/day oral prednisone or equivalent.  The acceptable length of the 
extended period of time must be agreed upon by [CONTACT_33495].  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have 
fully recovered from the immune- related event.  Patients can be rechallenged with atezolizumab 
only after approval has been documented by [CONTACT_33494] (or an appropriate delegate)  
and the Medical Monitor.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
92/Protocol CO39721, Version 5  Table  6 Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  (cont.)  
Event  Action to Be take  
Pulmonary events  
General guidance  Mild-to-moderate events of pneumonitis have been reported with 
atezolizumab and cobimetinib.  All pulmonary events should be 
thoroughly evaluated for other commonly reported etiologies such as pneumonia/infection, lymphangitic carcinomatosis, pulmonary embolism, heart failure, chronic obstructive pulmonary disease, or 
pulmonary hypertension.  
For events concerning for pneumonitis, consider comprehensive infectious evaluation including viral etiologies.  
Pneumonitis, Grade 1 (asymptomatic)  • Continue atezolizumab and cobimetinib.  
• Re-evaluate on serial imaging.  
• Consider patient referral to pulmonary specialist.  
Pneumonitis, Grade 2  • Withhold atezolizumab and cobimetinib.  
• Refer patient to pulmonary and infectious disease specialists and consider bronchoscopy or BAL.  
• If bronchoscopy is consistent with immune- related etiology, 
initiate treatment with 1−2 mg/kg/day oral prednisone or equivalent.  
• Resume atezolizumab and cobimetinib if event resolves to Grade 1 or better within 105 days .
 a, b 
• Permanently discontinue atezolizumab and cobimetinib and 
contact [CONTACT_246791] 1 or 
better within 105 days . a, b, c 
• For recurrent events, treat as a Grade 3 or 4 event.  
Pneumonitis, Grade 3 or 4  • Permanently discontinue atezolizumab and cobimetinib. c 
• Refer patient to pulmonary and infectious disease specialists 
and consider bronchoscopy or BAL.  
• If bronchoscopy is consistent with immune- related etiology, 
initiate treatment with 1−2 mg/kg/day oral prednisone or equivalent.  
• If pulmonary event does not improve within 48 hours or worsens, consider adding an immunosuppressive agent 
(e.g.,  infliximab, cyclophosphamide, IVIg, or mycophenolate).  
• If event resolves to Grade 1 or better, taper corticosteroids over ≥
 1 month.  
BAL = bronchoscopic alveolar lavage; IVIg = intravenous immunoglobulin.  
a If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day oral prednisone 
or equivalent before atezolizumab can be resumed.  
b Atezolizumab may  be withheld for a period of time beyond 105 days  to allow for corticosteroids to be 
reduced to ≤  10 mg/day oral prednisone or equivalent.  The acceptable length of the extended period of 
time must be agreed upon by [CONTACT_33495].  
c Resumptio n of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune-related event.  Patients can be rechallenged with atezolizumab only after 
approval has been documented by [CONTACT_33494] (or an appropriate delegate) and the Medical 
Monitor.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
93/Protocol CO39721, Version 5  Table  6 Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  (cont.)  
Event  Action to Be Taken 
Ocular toxicity  
General guidance  • An ophthalmologist should evaluate visual complaints.  
• Uveitis or epi[INVESTIGATOR_351822]− mediated ocular 
disease may be associated with atezolizumab and may be 
treated with topi[INVESTIGATOR_351823].  Atezolizumab 
should be permanently discontinued for immune- related 
ocular event that is unresponsive to local 
immunosuppressive therapy.  
• Serous retinopathy is associated with cobimetinib.  In clinical trials, most events were Grade 1 (asymptomatic) or 2 
(symptomatic).  Most events in clinical trials resolved or improved to asymptomatic Grade 1 following dose 
interruption or reduction.  If serous retinopathy is diagnosed, 
cobimetinib should be withheld until visual symptoms improve to Grade ≤
 1.   Serous retinopathy can be managed 
with treatm ent interruption, dose reduction, or treatment 
discontinuation.  
• RVO has been reported in patients treated with MEK inhibitors other than cobimetinib.  
Serous retinopathy  
 
Severity grade assessment 
based on NCI  CTCAE v4 0 
“Eye Disorders –Other” scale a, 
b, c, d Serous retinopathy, Grade 1 a or 2 b (tolerable):  
• Continue cobimetinib and atezolizumab without dose change.  
• Follow the monitoring schedule detailed in Section 4.4.7.  
Serous retinopathy, Grade 2 b (intolerable) or Grade 3 or 4:c, d 
• Interrupt cobimetinib until Grade  ≤ 1.  
• Continue atezolizumab as clinically indicated.  
• Consult ophthalmology and undergo complete ophthalmologic examination, which includes visual acuity testing, intra -ocular 
pressure measurements, slit lamp ophthalmoscopy, indirect 
ophthalmoscopy, visual field, and OCT.  Consider a fluorescein 
angiogram and/or indocyanine green angiogram, if clinically 
indicated.  
• Follow  the monitoring schedule detailed in Section 4.4.7.  
• The dose of cobimetinib should be reduced by [CONTACT_351865].  
• Consider  permanent discontinuation of cobimetinib if serous 
retinopathy recurs despi[INVESTIGATOR_351824] . 
ADL  = activities of daily living; NCI  CTCAE v4.0  = National Cancer Institute Common Terminology 
Criteria for Adverse Events, Version 4.0; OCT  = optical coherence tomography; RVO  = retinal vein 
occlusion. 
a Grade 1:  Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention 
not indicated . 
b Grade 2:  Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental ADL
. 
c Grade 3:  Severe or medically significant but not immediately sight threatening; hospi[INVESTIGATOR_40822]; disabling; limiting self -care ADL
. 
d Grade 4:  Sight -threatening consequences; urgent intervention indicated; blindness (20/200 or 
worse) in the affected eye .  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
94/Protocol CO39721, Version 5  Table  6 Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  (cont.)  
Event  Action to Be Taken  
Ocular toxicity (cont.)   
Potential immune- related 
ocular toxicity (e.g.,  uveitis, 
iritis, epi[INVESTIGATOR_227], or retinitis)  • Follow guidelines provided in Appendix  8. 
• Continue cobimetinib as clinically indicated.  
RVO (any grade)  • If RVO (any grade) is diagnosed, cobimetinib dosing should be 
permanently discontinued and RVO treated per institutional 
guidelines . 
• Continue atezolizumab.  
RVO  = retinal vein occlusion.  
 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
95/Protocol CO39721, Version 5  Table  6 Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  (cont.)  
Event  Action to Be Taken  
LVEF Decrease from Baseline  
Patient  LVEF  
Value  Recommended 
Action with Cobimetinib 
and Atezolizumab LVEF Value  
following  
Treatment Break  Recommended 
Cobimetinib 
Daily Dose  
Asymptomatic  ≥ 50% 
(or 
40%−49% 
and  < 10% 
absolute decrease 
from baseline)  Continue atezolizumab and cobimetinib at current 
dose. NA NA 
< 40% (or 
40%−49% 
and 
≥ 10% 
absolute decrease from 
baseline)
 Interrupt cobimetinib treatment for 2 weeks . 
 
Continue atezolizumab as 
clinically indicated . <
 10% absolute 
decrease from  
baseline  First 
occurrence:  
40 mg 
Second  
occurrence:  
[ADDRESS_437456] occurrence:  
permanent 
discontinuation  
< 40% (or ≥  10% 
absolute decrease 
from baseline)  Permanent 
discontinuation  
Symptomatic   NA Interrupt cobimetinib 
treatment for 4 weeks . Asymptomatic and <
 10% absolute 
decrease from baseline  First occurrence:  
40 mg  
Second  
occurrence:  
[ADDRESS_437457] occurrence:  
permanent discontinuation  
Consider withholding atezolizumab.  
Discuss with Medical 
Monitor regarding 
resumption of 
atezolizumab.  Asymptomatic and 
<
 40% ( or ≥  10% 
absolute decrease 
from baseline)  Permanent 
discontinuation  
Cardiology consultation is 
strongly recommended.  Symptomatic 
regardless of 
LVEF  Permanent 
discontinuation  
LVEF  = left ventricular ejection fraction; NA  = not applicable.  
 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
96/Protocol CO39721, Version 5  Table  6 Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  (cont.)  
Event  Action to Be Taken  
Rhabdomyolysis or CPK  elevation  
General guidance  • Rule out cardiac cause (check electrocardiogram, serum 
cardiac troponin, and CPK -isoforms M and B fraction) and 
rule out rhabdomyolysis  (clinical examination; serum 
creatinine, potassium, calcium, phosphorus, uric acid, and 
albumin; and urine myoglobin).  
• Assess patient for any history of strenuous physical activity, 
blunt trauma, or recent intramuscular injections.  
For Grade  ≤ 3 CPK el evations 
that are asymptomatic and 
deemed not clinically significant  • Cobimetinib and atezolizumab dosing does not need to be 
modified or interrupted to manage asymptomatic Grade ≤  3 
CPK elevations.  
• Recheck CPK at least once a week.  
For Grade 4 CPK elevations that 
are asymptomatic and deemed 
not clinically significant   • Interrupt cobimetinib and atezolizumab treatment.  
• If improved to Grade ≤  3 within 4 weeks, restart cobimetinib 
at a dose reduced by 20 mg, if clinically indicated.  
• If CPK elevations d o not improve to Grade ≤  3 within 
4 weeks following dose interruption, permanently 
discontinue cobimetinib treatment.  
• Resumption of atezolizumab may be considered in patients 
who are deriving benefit.  
Rhabdomyolysis or symptomatic 
CPK elevations  • Interrupt cobimetinib and atezolizumab treatment.   
• If severity is improved by [CONTACT_351866] 4 weeks, restart cobimetinib at a dose 
reduced by 20 mg, if clinically indicated.   
• If rhabdomyolysis or symptomatic CPK elevations do not  
improve within 4 weeks, permanently discontinue cobimetinib treatment    
• Resumption of atezolizumab may be considered in patients 
who are deriving benefit after discussion with the Medical 
Monitor.  
CPK  = creatine phosphokinase.   
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
97/Protocol CO39721, Version 5  Table  6 Guidelines for Management of Patients Who Experience 
Specific  Adverse Events (Cobimetinib and Atezolizumab)  (cont.)  
Event  Action to Be Taken  
Hemorrhage  
Grade 3 hemorrhage  • Interrupt cobimetinib treatment.  There are no data on the 
effectiveness of cobimetinib dose modification for hemorrhage events.  Clinical judgment should be applied when 
considering restarting cobimetinib treatment.  
• Continue atezolizumab treatment.  
Grade 4 hemorrhage or any 
grade cerebral hemorrhage  • Interrupt cobimetinib treatment.  Permanently discontinue 
cobimetinib for hemorrhage events attributed to cobimetinib.  
• Continue atezolizumab treatment.  
Grade 3 or 4 or intolerable 
Grade 2 treatment -related 
toxicities not described 
above and in Table 5  (dose 
modifications for 
cobimetinib) • Withhold all study treatment.  
• If event resolves to Grade 1 or better within 105 days , resume 
atezolizumab at fixed dose.  If not, permanently di scontinue 
atezolizumab. a, b, c  
• If event resolves to Grade [ADDRESS_437458] be tapered over ≥ 1 month to ≤ 10 mg/day oral 
prednisone or equivalent before atezolizumab can be resumed.  
b Atezolizumab may  be withheld for a period of time beyond 105 days to allow for corticosteroids to be 
reduced to ≤  10 mg/day oral prednisone or equivalent.  The acce ptable length of the extended period of 
time must be agreed upon by [CONTACT_33495].  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune-related event.  Patients can be rechallenged with atezolizumab only after approval has been documented by [CONTACT_33494] (or an appropriate delegate) and the Medical 
Monitor.   
5.[ADDRESS_437459], regardless of causal attribution.  An adverse event can 
therefore be any of the following:  
• Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
98/Protocol CO39721, Version 5  • Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a know n condition), except  as described in 
Section [IP_ADDRESS]  
• Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline 
• Any deterioration in a laboratory value or other clinical test (e.g., ECG, X -ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study drug 
• Adverse events that are related to a protocol -mandated intervention, including those 
that occur prior to assignment of study treatment (e.g.,  screening invasive 
procedures such as biopsies)  
 
5.2.2  Serious Adverse Events (Immediately Reportable to the 
Sponsor ) 
A serious adverse event is any adverse event that meets any of the following criteria:  
• Is fatal (i.e., the adverse event actually causes or leads to death)  
• Is life threatening (i.e.,  the adverse event, in the view of the investigator, places the 
patient at immediate risk of death)  
This does not include any adverse event that had it occurred in a more severe form or was allowed to continue might have caused death.  
• Requires or prolongs inpatient hospi[INVESTIGATOR_059] (see Section [IP_ADDRESS] ) 
• Results in persistent or significant disability/incapacity (i.e., the adverse event 
results in substantial disruption of the patient ’s ability to conduct normal life 
functions)  
• Is a congenit al anomaly/birth defect in a neonate/infant born to a mother exposed to 
study drug 
• Is a significant medical event in the investigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the outcomes listed above)  
 
The terms " severe" and "serious " are not synonymous.  Severity refers to the intensity of 
an adverse event ( e.g., rated as mild, moderate, or severe, or according to NCI CTCAE  
v4.0; see Section 5.3.3 ); the event itself may be of relatively minor medical significance 
(such as severe headache without any further findings).  
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the eCRF.  
Serious adverse events are required to be reported by [CONTACT_13657] (i.e., no more than 24 hours after learning of the event; see Section 5.4.2  for 
reporting instructions).  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
99/Protocol CO39721, Version [ADDRESS_437460] (Immediately Reportable to 
the Sponsor ) 
Adverse events of special interest are required to be reported by [CONTACT_33473] (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2  for reporting instructions).  Adverse events of special interest for this study 
include the following: 
• Significant liver toxicity  
• Cases of potential drug- induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by 
[CONTACT_25742]’s Law (see Section  [IP_ADDRESS] ) and based on t he following observations:  
Treatment -emergent ALT or AST >  3 × baseline value in combination with total 
bilirubin > 2 × ULN (of which  ≥ 35% is direct bilirubin)  
Treatment -emergent ALT or AST >  3 × baseline value in combination with 
clinical jaundice 
Hepatitis, including AST or ALT > 10  × ULN 
• Suspected transmission of an infectious agent by [CONTACT_5257], as defined below  
Any organism, virus, or infectious particle (e.g., prion protein− transmitting 
transmissible spongiform encephalopathy), pathogenic or non- pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate  an 
infection in a patient exposed to a medicinal product.  This term applies only  
when a contamination of the study drug is suspected. 
• Pneumonitis  
• Colitis  
• Endocrinopathies:  diabetes mellitus, pancreatitis, adrenal insufficiency, hyperthyroidism, and hypophysitis  
• Systemic lupus erythematosus  
• Neurologic  disorders : Guillain -Barré syndrome, myasthenic syndrome or  
myasthenia gravis,  and meningoencephalitis  
• Nephritis  
• Events suggestive of hypersensitivity, infusion -related reactions, cytokine- release 
syndrome, influenza- like illness, systemic inflammatory response system  
• Ocular toxicities  
Uveitis  
RVO  
Serous retinopathy  
Myositis  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
100/Protocol CO39721, Version 5  • Cardiac disorders for the following events : 
Grade ≥ 2 cardiac disorders, including atrial fibrillation, myocarditis, 
and pericarditis  
Symptomatic heart failure or Grade ≥ 3 reduction in LVEF  
• Vasculitis  
• Myopathies, including rhabdomyolysis or Grade ≥ 3 CPK elevation 
• Grade  ≥ 3 hemorrhage or any -grade cerebral hemorrhage  
• Grade  ≥ 3 rash  
• Grade  ≥ 3 diarrhea  
 
5.3 METHODS AND TIMING FOR CAPTURING AND ASS ESSING 
SAFETY  PARAMETERS  
The investigator is responsible for ensuring that all adverse events (see Section 5.2.1  for 
definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in 
accordance with instructions provided in this section and in Sections  5.4−5.6. 
For each adverse event recorded on the Adverse Event eCRF, the investigator will make 
an assessment of seriousness (see Section 5.2.2  for seriousness criteria), severity (see 
Section 5.3.3 ), and causality (see Section 5.3.4 ).   
5.3.[ADDRESS_437461].  All adverse events, whether reported by [CONTACT_25743], will be recorded in the patient ’s medical record and on the Adverse Event eCRF.  
After informed consent  has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol -mandated intervention (e.g., invasive 
procedures such as biopsies, discontinuation of medications) should be reported (see Section 5.4.2  for ins tructions for reporting serious adverse events). 
After initiation of study drug, all  adverse events will be reported until [ADDRESS_437462] dose of study drug.  After this period, the investigator should report any serious adverse events that are believed to be related to prior study drug treatment (see Section 5.6).  
5.3.2  Eliciting Adverse Event Information 
A consistent methodology of non- directive questioning should be adopted for eliciting 
adverse event information at all patient evaluation timepoints.  Examples of non -directive 
questions include the following:  
"How have you felt since your last clinic visit?" 
"Have you had any new or changed health problems since you were last here?"  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
101/Protocol CO39721, Version 5  5.3.3  Assessment of Severity of Adverse Events 
The adverse event severity grading scale for the NCI CTCAE (v 4.0) will be used for 
assessing adverse event severity.  Table 7  will be used for assessing severity for 
adverse events that are not specifically listed in the NCI CTCAE.  
Table  7 Adverse Event Severity Grading Scale for Events Not Specifically 
Listed in NCI CTCAE  
Grade  Severity 
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
or intervention not indicated 
2 Moderate; minimal, local, or non- invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily living a 
3 Severe or medically significant, but not immediately life- threatening; 
hospi[INVESTIGATOR_3111]; disabling; or 
limiting  self-care activities of daily living b, c 
4 Life-threatening consequences or urgent intervention indicated d 
5 Death related to adverse event d 
NCI CTCAE  = National Cancer Institute Common Terminology Criteria for Adverse Events . 
Note:  Based on the most recent version of NCI CTCAE (v 4.0), which can be found at:   
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  
a Instrumental activities of daily living refer to preparing meals, shoppi[INVESTIGATOR_19640], using the telephone, managing money, etc.  
b Examples of self -care activities of daily living include bathing, dressing and undressing, 
feeding oneself, using the toilet, and taking medications, as performed by [CONTACT_27947].  
c If an event is assessed as a "significant medical event," it must be reported as a serious 
adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious 
adverse event in Section 5.2.2. 
d Grade [ADDRESS_437463] be reported as serious adverse events (see Section 5.4.2  for 
reporting instructions), per the definition of serious adverse event in Section 5.2.2 . 
 
5.3.4  Assessment of Causality of Adverse Events 
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether an adverse event is considered to be related to the study drug, indicating " yes" or "no" 
accordingly.  In addition to Table 7 , the following guidance should be taken into 
consideration: 
• Temporal relationship of event onset to the initiation of study drug 
• Course of the event, with special consideration of the effects  of dose reduction, 
discontinuation of study drug, or reintroduction of study drug ( as applicable)  
• Known association of the event with the study drug or with similar treatments  
• Known association of the event with the disease under study  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
102/Protocol CO39721, Version 5  • Presence of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event  
• Presence of non −treatme nt-related factors that are known to be associated with the 
occurrence of the event  
 
For patients receiving combination therapy, causality will be assessed individually for 
each protocol- mandated therapy.  
5.3.[ADDRESS_437464] medical terminology/concepts when recording adverse events on the Adverse Event eCRF.  Avoid colloquialisms and abbreviations.  
Only one adverse event term should be recorded in the event field on the Adverse Event eCRF.  
[IP_ADDRESS]  Infusion- Related Reactions  
Adverse events that occur during or within 24 hours after study drug administration and are jud ged to be related to study drug infusion  should be captured as a diagnosis 
(e.g.,  "infusion -related reaction" on the Adverse Event eC RF.  If possible, avoid 
ambiguous terms such as "systemic reaction."  Associated signs and symptoms should be recorded on the dedicated Infusion- Related Reaction eCRF.  If a patient experiences 
both a local and systemic reaction to the same dose of study drug, each reaction should be recorded separately on the Adverse Event eCRF, with signs and symptoms also recorded separately on the dedicated Infusion- Related Reaction eCRF. 
[IP_ADDRESS]  Diagnosis versus Signs and Symptoms  
A diagnosis (if known) should be recorded on the Adverse Event eCRF rather than 
individual signs and symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated transaminases).  However, if a constellation of signs and/or symptoms cannot be medically characterized as a single diagnosis or syndrome at the time of reporting, each individual event should be recorded on the Adverse Event eCRF.  If a diagnosis is subsequently established, all previously reported adverse events based on signs and symptoms should be nullified and replaced by [CONTACT_25746], with a starting date that corresponds to the starting date of the first symptom of the eventual diagnosis. 
[IP_ADDRESS]  Adverse Events That Are  Secondary to Other Events  
In general, adverse  events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by [CONTACT_5252], with the exception of severe or serious secondary events.  A medically significant secondary adverse event that is separated  in time from the initiating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example:  
• If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
103/Protocol CO39721, Version 5  • If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF.  
• If a severe gastrointestinal hemorrhage leads to renal failure, both events should be 
reported separately on the eCRF. 
• If dizziness leads to a fall and consequent fracture, all three events should be reported separately on the eCRF. 
• If neutropenia is accompanied by [CONTACT_25747], both events should be reported 
separately on the eCRF.  
 
All adverse events should be recorded separately on the Adverse Event eCRF if it  is 
unclear as to whether the events are associated.  
[IP_ADDRESS]  Persistent or Recurrent Adverse Events  
A persistent adverse event is one that extends continuously, without resolution, between 
patient evaluation timepoints.  Such events should only be recorded once on the 
Adverse Event eCRF.  The initial severity (intensity or grade) of the event will be recorded at the time the event is first reported.  If a persistent adverse event becomes more severe, the most extreme severity should also be recorded on the Adverse Event eCRF.  If the event becomes serious, it should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning that the event became serious; see Section 5.4.2  for reporting instructions).  The Adverse Event eCRF should be updated 
by [CONTACT_25748] "non- serious" to "serious," providing the date that the event 
became serious, and completing all data fields related to ser ious adverse events.  
A recurrent adverse event is one that resolves between patient evaluation timepoints and subsequently recurs.  Each recurrence of an adverse event should be recorded as a separate event on the Adverse Event eCRF.  
[IP_ADDRESS]  Abnormal Laboratory Values 
Not every laboratory abnormality qualifies as an adverse event.  A laboratory test result 
must  be reported as an adverse event if it meets any of the following criteria:  
• Is accompanied by [CONTACT_4659]  
• Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation) 
• Results in a medical intervention (e.g., potassium supplementation for hypokalemia) or a change in concomitant therapy  
• Is clinically significant in the investigator ’s judgment  
Note:  For oncology trials, certain abnormal values may not qualify as adverse 
events.  
 
It is the investigator ’s responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laborato ry 
abnormality should be classified as an adverse event.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
104/Protocol CO39721, Version 5  If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g.,  alkaline phosphatase and bilirubin 5  × ULN associated with cholestasis), only the 
diagnosis (i.e.,  cholest asis) should be recorded on the Adverse Event eCRF.  
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, the abnormality itself should be recorded on the Adverse Event eCRF, along with a descriptor indicating whether  the test result is above or below the normal range 
(e.g.,  "elevated potassium, " as opposed to " abnormal potassium ").  If the laboratory 
abnormality can be characterized by a precise clinical term per standard definitions, the clinical term should be recorded as the adverse event.  For example, an elevated serum 
potassium level of 7.0 mEq/L should be recorded as "hyperkalemia. " 
Observations of the same clinically significant laboratory abnormality from visit to visit should only be recorded once on the Adverse Event eCRF (see Section [IP_ADDRESS]  for 
details on recording persistent adverse events).  
[IP_ADDRESS]  Abnormal Vital Sign Values  
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must  
be reported as an adverse event if it meets any of the following criteria:  
• Is accompanied by [CONTACT_4659]  
• Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation) 
• Results in a medical intervention or a change in concomitant therapy 
• Is clinically significant in the investigator ’s judgment  
 
It is the investigator ’s responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event.  
If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g.,  high blood pressure), only the diagnosis (i.e.,  hypertension) should be recorded on 
the Adverse Event eCRF.  
Observations of the same clinically significant vital sign abnormality from visit to visit should only be recorded once on the Adverse Event eCRF (see Section [IP_ADDRESS]  for 
details on recording persistent adverse events).  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
105/Protocol CO39721, Version 5  [IP_ADDRESS]  Abnormal Liver Function Tests  
The finding of an elevated ALT or AST ( > 3 × baseline value) in combination with either 
an elevated total bilirubin ( > 2 × ULN) or clinical jaundice in the absence of cholestasis or 
other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury  
(as defined by [CONTACT_25742]'s law) .  Therefore, investigators must report as an adverse event the 
occurrence of either of the following:  
• Treatment -emergent ALT or AST >  3 × baseline value in combination with total 
bilirubin > 2 × ULN (of which ≥ 35% is direct bilirubin)  
• Treatment -emergent ALT or AST >  3 × baseline value in combination with clinical 
jaundice  
 
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see  Section [IP_ADDRESS] ) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event), either as a serious adverse event or a n adverse event o f special interest (see 
Section 5.4.2 ). 
[IP_ADDRESS]  Deaths  
For this protocol, mortality is an efficacy endpoint.  Deaths that occur during the protocol -
specified adverse event reporting period (see Section 5.3.1 ) that are attributed by [CONTACT_351867] t he 
Death Attributed to Progressive Disease eCRF.   All other on -study deaths, regardless of 
relationship to study drug, must be recorded on the Adverse Event eCRF and immediately reported to the Sponsor (see Section  5.4.2). 
Death should be considered an outcome and not a distinct event.  The event or condition that caused or contributed to the fatal outcome should be recorded as the single medical concept on the Adverse Event eCRF.  Generally, only one such event should be reported.  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, "unexplained death"  should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes available (e.g., after autopsy), "unexplained death " should 
be replaced by [CONTACT_25749].   The term  "sudden death " should not be 
used unless combined with the presumed cause of death (e.g., "sudden cardiac death").  
Deaths that occur after the adverse event reporting period should be reported as 
described in Section 5.6 . 
[IP_ADDRESS]  Preexisting Medical Conditions  
A preexisting medical condition is one that is present at the screening visit for this study.  Such conditions should be recorded on the General Medical History and Baseline Conditions eCRF.  
A preexisting medical condition should be recorded as an adverse event only  if the 
frequency, severity, or character of  the condition worsens during the study.  When 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
106/Protocol CO39721, Version 5  recording such events on the  Adverse Event eCRF, it is important to convey the concept 
that the preexisting condition has changed by [CONTACT_9672] 
(e.g.,  "more frequent headaches "). 
[IP_ADDRESS]  Lack of Efficacy or Worsening of Melanoma  
Events that are clearly consistent with the expected pattern of progression of the underlying disease should not  be recorded as adverse events.  These data will be 
captured as efficacy assessment data only.  In most cases, the expected pattern of progression will be based on RECIST  v1.1.  In rare cases, the determination of clinical 
progression will be based on symptomatic deterioration.  However, every effort should be made to document progression through use of  objective criteria.  If there is any 
uncertainty as to whether an event is due to disease progression, it should be reported as an adverse event.  
[IP_ADDRESS]  Hospi[INVESTIGATOR_226804] (i.e., inpatient  admission to a hospi[INVESTIGATOR_307])  
or prolonged hospi[INVESTIGATOR_25676] a serious adverse event (per the definition of serious adverse event in Section 5.2.2 ), except as outlined 
below.   
An event that leads to hospi[INVESTIGATOR_26664] a serious adverse event:  
• Hospi[INVESTIGATOR_351825]  
• Planned hospi[INVESTIGATOR_33402] (e.g., for study drug administration 
or insertion of access device for study drug administration) 
• Hospi[INVESTIGATOR_272] a preexisting condition, provided that all of the following criteria are met: 
The hospi[INVESTIGATOR_351826]  
• Hospi[INVESTIGATOR_123443] a serious adverse event, but should be reported as an adverse event 
instead:  
• Hospi[INVESTIGATOR_351827]  
 
[IP_ADDRESS]  Adverse Events Associated with an Overdose  or Error in Drug 
Administration  
An overdose is the accidental or intentional use of a drug in an amount higher than the 
dose being studied.  An overdose or incorrect administration of study treatment is not 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
107/Protocol CO39721, Version [ADDRESS_437465] administration of study drug should be recorded on the Adverse Event eCRF.  If the associated adverse event fulfills seriousness  criteria, the event should be reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2 ). 
There is no clinical experience with an overdose of cobimetinib, and thus , no safety data 
related to overdosing are available.  Please see the C obimetinib Investigat or’s Brochure 
for more details.  
There is no clinical experience with an overdose of atezolizumab, and thus , no safety 
data related to overdosing are available.  Please see the Atezolizumab Investigator’s 
Brochure for more details . 
5.[ADDRESS_437466] report such events to the Sponsor immediately; under no circumstances should reporting take place more than [ADDRESS_437467] report to the Sponsor within 24 hours after learning 
of the event, regardless of rel ationship to study drug:  
• Serious adverse events  (see Section 5.4.2  for further details)  
• A dverse events of special interest  (see Section 5.4.2  for further details)  
• Pregnancies  (see Section 5.4.3  for further details)  
 
The investigator must report new significant follow -up information for these events to the 
Sponsor immediately (i.e., no more than 24 hours after becoming aware of the 
information).  New significant information includes the following:  
• New signs or symptoms or a change in the diagnosis  
• Significant new diagnostic test results  
• Change in causality based on new information  
• Change in the event ’s outcome, including recovery  
• Additional narrative information on the clinical course of the event  
 
Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority and IRB/EC. 
  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
109/Protocol CO39721, Version 5  5.4.3  Reporting Requirements for Pregnancies  
[IP_ADDRESS]  Pregnancies in Female Patients  
Female patients of childbearing potential will be instructed to immediately inform the 
investigator if they become pregnant during the study or within [ADDRESS_437468] dose of cobimetinib.  A Clinical 
Trial Pregnancy Reporting Form should be completed and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the pregnancy), either by [CONTACT_25750].  Pregnancy should not be recorded on the Adverse Event eCRF.  The investigator should discontinue study drug and counsel the patient, 
discussing the risks of the pregnancy and the possible effects on the fetus.  Monitoring of the patient should continue until conclusion of the pregnancy.  Any serious adverse events associated with the pregnancy (e.g., an event in the fetus, an event in the mother during or after the pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the Adverse Event eCRF.  In addition, the investigator will submit a Clinical Trial Pregnancy Reporting Form when updated information on the course and outcome of the pregnancy becomes available.   
[IP_ADDRESS]  Pregnancies in Female Partners of Male Patients  
Male patients will be instructed through the Informed Consent Form to immediately inform the investigator if their partner becomes pregnant during the study or within [ADDRESS_437469] dose of stu dy drug.  A Clinical Trial Pregnancy Reporting Form 
should be completed and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the pregnancy), either by [CONTACT_25750].  Attempts should be made to collect and report details of the course and outcome of any pregnancy in the partner of a male patient exposed to study drug.  When permitted by [CONTACT_779] , the pregnant partner would need to sign an Authorization for Use and 
Disclosure of Pregnancy Health Information to allow for follow -up on her pregnancy.  If 
the authorization has been signed, the investigator shoul d submit a Clinical Trial 
Pregnancy Reporting Form when updated information on the course and outcome of the pregnancy becomes available.  An investigator who is contact[CONTACT_27951], to support an informed decision in cooperation with the treating physician and/or obstetrician.  
[IP_ADDRESS]  Abortions  
Any abortion should be classified as a serious adverse event (as the Sponsor considers 
abortions to be medically significant), recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event;  see Section 5.4.2 ).   
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
110/Protocol CO39721, Version 5  [IP_ADDRESS]  Congenital Anomalies /Birth Defects  
Any congenital anomaly/birth defect in a child born to a female patient exposed to study 
drug or the female partner of a male patient exposed to study drug should be classified 
as a serious adverse event, recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Secti on 5.4.2 ). 
5.[ADDRESS_437470] to follow -up, or the patient withdraws consent.  Every effort should be made to follow all 
serious adverse events considered to be related to study drug or trial -related procedures 
until a final outcome can be reported.  
During the study period, resolution of adverse events (with dates) should be documented on the Adverse Event eCRF and in the patient ’s medical record to facilitate source data 
verifica tion. 
All pregnancies reported during the study should be followed until pregnancy outcome.  
5.5.[ADDRESS_437471], and pregnancies, the Sponsor or a designee may follow  up by [CONTACT_756], fax, electronic mail, and/or a 
monitoring visit to obtain additional case details and outcome information (e.g.,  from 
hospi[INVESTIGATOR_8838], consultant reports, autopsy reports) in order to perform an independent medical assessment of the reported case.  
5.6 ADVERSE EVENTS THAT OCCUR AFTER THE ADVERSE 
EVENT REPORTING PERI OD 
After the end of the adverse event reporting period (defined as  [ADDRESS_437472] 
dose of  study drug), all deaths, regardless of cause, should be reported through use of 
the Long- Term Surviv al Follow -Up eCRF .  In addition, if the investigator becomes aware 
of a serious adverse event that is believed to be related to prior study drug treatment, the event should be reported through use of the Adverse Event eCRF.  
5.[ADDRESS_437473] experience to identify and expeditiously communic ate possible new safety findings to investigators, IRBs, ECs, and applicable 
health authorities based on applicable legislation.  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
111/Protocol CO39721, Version 5  To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events using the following reference document s: 
•Cobimetinib Investigator's Brochure
•Atezolizumab Investigator's Brochure
The
 Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency  reported in the 
applicable reference document.  
Reporting requirements will also be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by [CONTACT_25753].  
6. STATISTICAL CONSIDERA TIONS AND ANALYSIS PLAN
This study evaluates the preliminary  efficacy, safety , and pharm acokinetics  of 
atezolizumab plus cobimetinib in patients with BRAFV600 WT metastatic or unresectable 
locally advanced melanoma who have progressed on prior anti -PD-1 therapy (Cohorts A 
and B), and atezolizumab monotherapy in patients with BRAF V600 WT metastatic or 
unresectable locally advanced melanoma who have not been previously treated 
(Cohort  C). 
The p rimary analysis will be conducted in Cohort s A and B  approximately [ADDRESS_437474] response rates of less than 17%.  
For example, w ith 102 patients  in Cohort s A and B , observing 26 patients with objective 
response corresponds to ORR (95% CI) of 25.5% (17.4%, 35.1%) and observing 
60 patients with disease control corresponds to  a DCR (95% CI) of 58.8 % (48.6% , 
68.52% ).   
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
112/Protocol CO39721, Version [ADDRESS_437475] not been previously treated to allow for an accurate 
understanding of the achievable magnitude of efficacy in this population.   
For example, observing 17 patients with objective response corresponds to ORR 
(95%  CI) of 34.0% (21.1 %, 48.8 %) and observing 32 patients with disease control 
corresponds to DCR (95% CI) of 64% (49.2% , 77.1 %).  Enrolling [ADDRESS_437476] one dose of study drug.  
6.4.1  Primary Efficacy Endpoint  
ORR is  defined as the proportion of patients whose objective response is a CR or a PR .  
Objective response is defined as a CR or PR on two  consecutive occasions ≥  [ADDRESS_437477] v1.1.  A 95% Clopper -Pearson 
CI will be calculated for the ORR. 
DCR is defined as the proportion of patients with a CR, PR, or SD at [ADDRESS_437478] 
treatment date.  Kaplan- Meier methodology will be used to estimate the median PFS, 
and the 95% CI of the median DOR arm will be constructed using the Brookmeyer and 
Crowley method (Brookmeyer and Crowley 1982) . 
PFS is defined as the time from Cycle [ADDRESS_437479] v1.1, or death from 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
113/Protocol CO39721, Version [ADDRESS_437480]  (see Appendix  4) will be analyzed using the same methods as described above.  
6.[ADDRESS_437481] study drug dose will be summarized by [CONTACT_210079].  In addition, serious adverse events, severe adverse events (Grades ≥
 3), 
adverse events of special interest, and adverse events leading to study drug discontinuation or interruption will be summarized accordingly.  Multiple occurrences of the same event will be counted once at the maximum severity.  The proportion of patients who experience at least one adverse event will b e reported by [CONTACT_351868] .  
Study drug exposure, including treatment duration, number of doses, and dose intensi ty, 
will be summarized using descriptive statistics.  
All deaths and causes of death will be summarized. 
Laboratory data with values outside the normal ranges will be identified.  In addition, 
relevant laboratory data and vi tal signs will be summarized . 
6.[ADDRESS_437482] one evaluable PK sample (actual dose and actual sampling time 
recorded for each sample) is collected.  Since only a few samples are collected from patients, data will be analyzed using the existing population PK model for post hoc 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
114/Protocol CO39721, Version 5  estimates of apparent clearance or systemic clearance for cobimetinib and atezolizumab 
respectively.  Maximum or minimum concentration (Cmax or C min) will be reported for 
individual patients and summarized by [CONTACT_53813], as data permit .  In addition, the 
relationship between drug exposure (cobimetinib or atezolizumab) and safety and 
efficacy endpoints will be explored for exposure- response relationship.  
Additional PK analyses will be conducted as appropriate on the basis of the available data.  
6.7 IMMUNOGENICIT Y ANALYSES  
The immunogenicity analyses for atezolizumab will include patients with any  ADA result , 
with patients grouped by [CONTACT_9084]. 
The numbers and proportions of A DA-positive patients and A DA-negative patients 
during both the treatment and follow -up periods will be summarized by [CONTACT_9084].  Patients 
are considered to be A DA positive if they are A DA negative or are missing data at 
baseline but develop an A DA response following study drug administration 
(treatment -induced AD A response), or if they are AD A positive at baseline and the titer 
of one or more post -baseline samples is at least 4- fold greater (i.e., ≥ 0.60 titer unit ) than 
the titer of the baseline sample (treatment -enhanced AD A response).  Patients are 
considered to be AD A negative if they are A DA negative or are missing data at baseline 
and all post -baseline samples  are negative, or if they are ADA positive at baseline but do 
not have any post -baseline samples with a titer that is at least 4 -fold greater than the 
titer of the baseline sample (treatment unaffected). 
The relationship between ADA status and safety, efficacy, PK, and biomarker endpoints 
may be analyzed and reported descriptively in subgroup analyses.  
6.8 BIOMARKER ANALYSES  
Descriptive statistics will be used to explore the biomarkers and their relations to 
response or escape of combined treatment in patients, these biomarkers include: PD-L1 expression, CD8 T -cell density, NRAS  or NF-1 mutation status , and other 
significant biological markers warranted by [CONTACT_351869].  
NGS data will be analyzed in the context of this study and explored in aggregate with data from other  studies to increase researcher s’ understanding of disease pathobiology 
and guide the development of new therapeutic approaches . 
6.[ADDRESS_437483] an optional interim analysis 
and the timing of the analysis will be documented in the Sponsor ’s trial master file prior 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
115/Protocol CO39721, Version [ADDRESS_437484] data clarification from the sites, which the sites 
will resolve electronically in the EDC system.  
The Sponsor  will produce an EDC Study Specification document that describes the 
quality checking to be performed on the data.   Central laboratory data and other 
non− EDC system -captured data will be sent directly to the Sponsor, using the Sponsor ’s 
standard procedures to handle and process the electronic transfer of these data.  
eCRFs and correction documentation will be maintained in the EDC system ’s audit trail.  
System backups for data stored by [CONTACT_351870] ’s standard procedures.  
7.[ADDRESS_437485] disc is required.  
7.3 SOURCE DATA DOCUMENT ATION  
Study monitors will perform ongoing source data verification to confirm that critical protocol data (i. e., source data) entered into the eCRFs by [CONTACT_26831], complete, and verifiable from source documents.  
Source documents (paper or electronic) are those in which patient data are recorded and documented for the first time.  They  include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, patient -reported outcomes, 
evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_351828] t hat are certified after verification as being accurate 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
116/Protocol CO39721, Version 5  and complete, microfiche, photographic negatives, microfilm or magnetic media, X -rays, 
patient files, and records kept at pharmacies, laboratories, and medico- technical 
departments involved in a clinic al trial. 
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and considered source data. 
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per the policy for retention of records described in Section 7.5. 
To facilitate source data verification, the investigators and institutions must provide the Sponsor direct access to applicable source documents and reports for trial -related 
monitoring, Sponsor audits, and IRB/EC review.  The study  site must also allow 
inspection by [CONTACT_25756].  
7.4 USE OF COMPUTERIZED SYSTEMS 
When clinical observations are entered directly into a  study site’s computerized medical 
record system (i.e., in lieu of original hardcopy records), the electronic record can serve as the source document if the system has been validated in accordance with health authority requirements pertaining to computerized systems used in clinical research.  An acceptable computerized data collection system allows preservation of the original entry of data.  If original data are modified, the system should maintain a viewable audit trail that shows the original data as well as the reason for the change, name [CONTACT_25773], and date of the change.  
7.[ADDRESS_437486] to local regulations.   
No records may be disposed of without the written approval of the Sponsor .  Written 
notification should be provided to t he Sponsor  prior to transferring any records to 
another party or moving them to another location.  
[COMPANY_002] will retain study data for 25 years after the final Clinical Study Report has been completed or for the length of time required by [CONTACT_109851], whichever is longer. 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
117/Protocol CO39721, Version 5  8. E THICAL CONSIDERATION S 
8.1 COMPLIANCE WITH LAWS  AND REGULATIONS  
This study will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice  and the principles of the Declaration of Helsinki, or the laws and 
regulations of the country in which the research is conducted, whichever affords the greater protection to the individual.  The study will comply with the requirements of the ICH E2A guideline (Clinical Safety Data Management:  Definitions and Standards for Expedited Reporting).  Studies conducted in the [LOCATION_002] or under a U.S. Investigational New Drug (IND ) Application will comply with U.S. FDA regulations and 
applicable local, state, and federal laws.  Studies conducted in the European Union or 
European Economic Area will comply with the E.U.  Clinical Trial Directive (2001/20/EC).  
8.2 INFORMED CONSENT  
The Sponsor ’s sample Informed Consent Form (and ancillary sample Informed Consent 
Forms such as a Child’ s Informed Assent Form or Mobile Nursing Informed Consent 
Form, if  applicable) will be provided to each site.  If applicable, it will be provided in a 
certified translation of the local language.  The Sponsor or its designee must review and approve any proposed deviations from the Sponsor's sample Informed Consent Forms or any alternate consent forms proposed by [CONTACT_779] (collectively, the "Consent Forms") before IRB/EC submission.  The final IRB/EC -approved Consent Forms must be 
provided to the Sponsor for health authority submission purposes according to local requirements.  
If applicable, the Informed Consent Form will contain separate sections for any optional procedures.  The investigator or authorized designee will explain to each patient the objectives, methods, and potential risks associated with each optional procedure.  Patients will be told that they are free to refuse to participate and may withdraw their consent at any time for any reason.  A separate, specific signature [CONTACT_22862] a patient's agreement to participate in optional procedures.  Patients who decline to participate will not provide a separate signature.  
The Consent Forms must be signed and dated by [CONTACT_12718] ’s legally 
authorized representative before his or her participation in the study.  The case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained prior to participation in the study.  
The Consent Forms should be revised whenever there are changes to study pr ocedures 
or when new information becomes available that may affect the willingness of the patient to participate.  The final revised IRB/EC -approved Consent Forms must be provided to 
the Sponsor for health authority submission purposes.  
Patients must be re -consented to the most current version of the Consent Forms (or to a 
significant new information/findings addendum in accordance with applicable laws and 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
118/Protocol CO39721, Version 5  IRB/EC policy) during their participation in the study.  For any updated or revised 
Consent Forms, the  case history or clinical records for each patient shall document the 
informed consent process and that written informed consent was obtained using the updated/revised Consent Forms for continued participation in the study.  
A copy of each signed Consent Form must be provided to the patient or the patient ’s 
legally authorized representative.  All signed and dated Consent Forms must remain in each patient ’s study file or in the site file and must be available for verification by [CONTACT_33483].  
For sites in the [LOCATION_002], each Consent Form may also include patient authorization to allow use and disclosure of personal health information in compliance with the U.S. Health Insurance Portability and Accountability Act (HIPAA) of 1996.  If the site utilizes a 
separate Authorization Form for patient authorization for use and disclosure of personal health information under the HIPAA regulations, the review, approval, and other 
processes outlined above apply except that IRB review and approval may not be required per study site policies.  
8.[ADDRESS_437487] be submitted to the IRB/EC by [CONTACT_079] [INVESTIGATOR_25684]/EC before the study is initiated.  
In addition, any patient recruitment materials must be approved by [CONTACT_1201]/EC.  
The Principal Investigator [INVESTIGATOR_226809]/EC annually or more frequently in accordance with the requirements, 
policies, and procedures established by [CONTACT_1201]/EC.  Investigators are also responsible for promptly informing the IRB/EC of any protocol amendments (see Section 9.6 ). 
In addition to the requirements for reporting all adverse events to the Sponsor, investigators must comply with requirements for reporting serious adverse events to the local health authority and IRB/EC.  Investigators may receive written IND safety reports or other safety -related communications from the Sponsor.  Investigators are responsible 
for ensuring that such reports are reviewed and processed in accordance with health authority requirements and the policies and procedures established by [CONTACT_11577]/EC, and archived in the site’ s study file.  
8.[ADDRESS_437488] parties only as permitted by [CONTACT_25734] (or  separate 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
119/Protocol CO39721, Version 5  authorization for use and disclosure of personal health information) signed by [CONTACT_102], 
unless permitted or required by [CONTACT_2371].  
Medical information may be given to a patient ’s personal physician or other appropriate 
medical personnel responsible for the patient ’s welfare, for treatment purposes. 
Given the complexity and exploratory nature of the analyses, data derived from exploratory biomarker specimens will generally not be provided to study investigators or patients unless required by [CONTACT_2371].  The aggregate results of any conducted research will be available in accordance with the effective [COMPANY_002] policy on study data publication 
(see Section 9.5). 
Data generated by [CONTACT_351871], Sponsor  monitors, 
representatives, and collaborators, and the IRB/EC for each study site, as appropriate.  
8.5 FINANCIAL DISCLOSURE  
Investigators will provide the Sponsor with sufficient, accurate financial information in accordance with local regulations to allow the Sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate health authorities.  Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study (i.e., l ast patient, 
last visit). 
9. S TUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRATION  
9.[ADDRESS_437489] of the study to be fully documented, including, but not limited to , the protocol, protocol 
amendments, Informed Consent Forms, and documentation of IRB/EC and governmental approval.  In addition,  at the end of the study, the investigator will receive 
the patient data, including an audit trail containing a complete record of all changes to 
data.  
9.[ADDRESS_437490] on patient safety and data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC policies and procedures.  The Sponsor will review all protocol deviations and as sess 
whether any represent a serious breach of Good Clinical Practice guidelines and require reporting to health authorities.  As per the Sponsor's standard operating procedures, prospective requests to deviate from the protocol, including requests to waive protocol eligibility criteria, are not allowed.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
120/Protocol CO39721, Version 5  9.3 SITE INSPECTIONS  
Site visits will be conducted by [CONTACT_26833], patients ’ medical records, and eCRFs.  The investigator will 
permit national and local health authorities; Sponsor monitors, representatives, and collaborators; and the IRBs/ECs to inspect facilities and records relevant to this study.  
9.4 ADMINISTRATIVE STRUC TURE  
This study is sponsored by F. Hoffmann -La [COMPANY_002] Ltd.  Approximately  60 study centers 
will participate in this study globally and enroll a total of approximately  152 patients.   The 
Sponsor will provide clinical operations oversight, data management support, and medical monitoring.
 
An IxRS will be used to manage site drug supply.   For patients not previously tested for 
tumor mutati on status, testing will be performed at screening.   Plasma and serum will be 
sent to a central laboratory for analysis and sample storage.  Routine sample analysis 
will be performed by [CONTACT_351872] ’s local laboratory; 
central and local laboratory ranges will be collected.  
9.5 PUBLICATION OF DATA AND PROTECTION OF TR ADE 
SECRETS  
Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing information on the trial to healthcare professionals and to the public, both at scientific congresses and in peer -reviewed journals.   The Sponsor will comply with all 
requirements for publication of study results.   For more information, refer to the [COMPANY_002] 
Global Policy on Shar ing of Clinical Trials Data at the following web site: 
http://www.roche.com/roche_global_policy_on_sharing_of_clinical_study_information.pdf 
The results of this study may be published or presented at scientific congresses.  For all 
clinical trials in patien ts involving an IMP for which a marketing authorization application 
has been filed or approved in any country, the Sponsor aims to submit a journal manuscript reporting primary clinical trial results within [ADDRESS_437491] 
propriet ary information and to provide comments based on information from other 
studies that may not yet be available to the investigator. 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
121/Protocol CO39721, Version [ADDRESS_437492] editorial and ethical practice, the Sponsor  will generally 
support publication of multicenter trials only in their entirety and not as individual center 
data.  In this case, a coordinating investigator [INVESTIGATOR_12992].  
Authorship will be determined by [CONTACT_351873] E ditors authorship requirements.  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by [CONTACT_351874].  
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of data from this study will become and remain the exclusive and unburdened property of the Sponsor, except where agreed otherwise.  
9.6 PROTOCOL AMENDMENTS  
Any protocol amendments will be prepared by [CONTACT_1034].  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local regulatory requirements.  
Approval must be obtained from the IRB/EC and regulatory authorities ( as locally 
required) before implementation of any changes, except for changes necessary to eliminate an immediate hazard to patients or changes that involve logistical or administrative aspects only (e.g.,  change in Medical Monitor or contact [CONTACT_3031]).  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
122/Protocol CO39721, Version 5  10. REFERENCE S 
American Cancer Society.  Melanoma Skin Cancer [resource on the Internet]. 2016  
[updated  20 May 2016; cited  17 July 2016].  Available from:  
http://www.cancer.org/cancer/skincancer -melanoma/detailedguide/melanoma- skin-
cancer -key-statistics . 
Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2099 AJCC melanoma 
staging and classification. J Clin Oncol 2009;27:6199− 206. 
Baldwin RM, Owzar K, Zembutsu H, et al. A  genome- wide association study identifies 
novel loci  for paclitaxel -induced sensory  peripheral neuropathy in CALGB [ZIP_CODE]. 
Clin Cancer Res 2012;18:5099− 109. 
Bedikian Ay, Millward M,  Pehamberger H,  et al.  Bcl-2 antisense (oblimersen sodium) 
plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma 
Study Group. J Clin Onc ol 2006;24:4738 −45. 
Bendell JC, Kim TW, Goh BC, et al. Clinical activity and safety of cobimetinib (cobi) and 
atezolizumab in colorectal cancer (CRC)  [abstract] . J Clin Oncol 2016;34: 3502A. 
Boni A, Cogdill AP, Dang P, et al. Selective BRAF V600E inhibition enhances T -cell 
recognition of melanoma without affecting lymphocytes function. Cancer Res 2010;70:5213 −9. 
Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 
1982;38:29 −41. 
[CGAN] Cancer Genome Atlas N etwork. Genomic classification of cutaneous melanoma. 
https://www.ncbi.nlm.nih.gov/pubmed/26091043  Cell 2015;161:1681 −96. 
Chang LH, Pan SL, Lai CY, et al. Activated PAR- 2 regulates pancreatic cancer 
progression through ILK/HIF- α-induced TGF -α expression and 
MEK/VEGF -A-mediated angiogenesis. Am J Pathol  2013;183:566 −75. 
Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of 
the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745− 51. 
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in 
melanoma with BRAF  V600E mutation. N Engl J Med 2011;364:2507− 16. 
Chen L, Flies DB. Molecular mechanisms of T cell co- stimulation and co- inhibition. Nat 
Rev Immunol 2013;13 :227−42. doi: 10.1038/nri3405. Epub 8 Mar 2013. Review. 
Erratum in:  Nat Rev Immunol 2013;13:542. 
Ciuffreda L, Del Bufalo D, Desideri M, et al. Growth -inhibitory and antiangiogenic activity 
of the MEK inhibitor PD0325901 in malignant melanoma with or without BRA F 
mutations. Neoplasia 2009;11:720 −31. 
Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in 
melanoma. N Engl J Med 2005;353: 2135− 47. 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
123/Protocol CO39721, Version 5  Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF  gene in human cancer. 
Nature 2002;  417:949−54. 
De L a Cruz -Merino L , Di Guardo L, Grob J -J, et al. Clinical features of cobimetinib-
associated serous retinopathy in BRAF -mutated melanoma patients treated in the 
coBRIM study  [abstract] . J Clin Oncol 2015;33: 9033A. 
Diepgen TL, Mahler V. The epi[INVESTIGATOR_351829]. Br J Dermatol 2002;146(Suppl 
61):1−6. 
Dummer R, Schadendorf D, Ascierto PA, et al.  Results of NEMO: a  phase III trial of 
binimetinib (BINI) vs dacarbazine (DTIC) in NRAS -mutant cutaneous melanoma 
[abstract] . J Clin Oncol 2016;34:9500A. 
Ebert PJ, Cheung J, Yang Y, et al. MAP kinase inhibition promotes T cell and anti -tumor 
activity in combination with PD -L1 checkpoint blockade . Immunity 2016;44:609− 21. 
Favis R, Sun Y, van de Velde H, et al. Genetic variation as sociated with bortezomib-
induced peripheral neuropathy. Pharmacogenet Genomics 2011;21:121 −9. 
Fehrenbacher  L, Spi[INVESTIGATOR_20116] A, Ballinger M,  et al., for the POPLAR Study Group. 
Atezolizumab versus docetaxel for patients with previously treated non- small -cell 
lung cancer (POPLAR): a multicentre, open -label, phase 2 randomised controlled 
trial. Lance 2016;387: 1837− 46. 
Ferlay J, Steliarova- Foucher E, Lortet -Tieulent J, et al. Cancer incidence and mortality 
patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 
2013;49:1374 −1403. 
Flaherty  KT, Robert C, Hersey P, et al. METRIC Study Group. Improved survival with 
MEK inhibition in BRAF -mutated melanoma. N Engl J Med 2012;367:107 −14. 
Franco LM, Bucasas KL, Wells JM , et al Integrative genomic analysis of the human 
immune response to influenza vaccination. Elife. 2013;2:e00299.  
Frederick DT, Pi[INVESTIGATOR_56989] A, Cogdill AP, et al. BRAF  inhibition is associated with enhanced 
melanoma antigen expression and a more favorable tumor microenvironment in 
patients with metastatic melanoma. Clin Cancer Res 2013;19:1225− 31. 
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD -1 immunoinhibitory receptor 
by a novel B7 family member leads to negative regulation of lymphocyte activation. 
J Exp Med 2000;192:1027− 34. 
Garbe C, Leiter U. Melanoma epi[INVESTIGATOR_351830].  Clin Dermatol 2009;27:3 −9. 
Haas NK, Sproesser K, Nguyen TK, et al. The mitogen- activated protein/extracellular 
signal -regulated kinase kinase inhibitor AZD6244 (ARRY -142886) induces growth 
arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008;14:230− 9. 
Hales RK, Banchereau J, Ribas A, et al. Assessing oncologic benefit in clinical trials of 
immunotherapy agents. Ann Oncol 2010;21:1944 −51. 
 
C o bi m eti ni b a n d At e z oli z u m a b —F.  H off m a n n -L a  R o c h e Lt d  
1 2 4 /Pr ot o c ol C O 3 9 7 2 1, V er si o n 5  H o di F S, O ’D a y  S J, M c D er m ott D F, et  al. I m pr o v e d s ur vi v al wit h i pi[INVESTIGATOR_45769] m u m a b i n  p ati e nt s 
wit h m et a st ati c m el a n o m a. N E n gl J M e d 2 0 1 0; 3 6 3: 7 1 1 2 3.  
H o di F S, Kl u g er H, S z n ol M, et al. D ur a bl e, l o n g -t er m s ur vi v al i n pr e vi o u sl y tr e at e d 
p ati e nt s wit h a d v a n c e d m el a n o m a ( M E L) w h o r e c ei v e d ni v ol u m a b ( NI V O) 
m o n ot h er a p y i n a p h a s e I tri al [ a b str a ct C T 0 0 1]. I n A m eri c a n A s s o ci ati o n of 
C a n c er R e s e ar c h a n n u al m e eti n g [ADDRESS_437493] ati c m el a n o m a: u p d at e d p h a s e 1 d at a. Pi g C ell M el R e s 
2 0 1 4; 2 7: 1 1 9 8.  
H u X, D al y M. W h at h a v e w e l e ar n e d fr o m si x y e ar s of G W A S i n a ut oi m m u n e di s e a s e s, 
a n d w h at i s n e xt ? C urr O pi n I m m u n ol 2 0 1 2; 2 4 : 5 7 1 −5. 
H u g h e s T, Kl air m o nt M, Br o u c e k J, et al. T h e pr o g n o sti c si g nifi c a n c e of st a bl e di s e a s e 
f oll o wi n g hi g h d o s e i nt erl e u ki n -2 (I L -2) tr e at m e nt i n p ati e nt s wit h m et a st ati c 
m el a n o m a a n d r e n al c ell c ar ci n o m a. C a n c er I m m u n ol I m m u n ot h er 2 0 1 5; 6 4: 4 5 9 -6 5.  
H u -Li e s k o v a n S, M o k S, H o m et M or e n o B, et al. I m pr o v e d a ntit u m or a cti vit y of  
i m m u n ot h er a p y wit h B R A F  a n d M E K i n hi bit or s i n B R A F ( V 6 0 0 E) m el a n o m a. S ci 
Tr a n sl M e d 2 0 1 5; 7: [ADDRESS_437494] ati c m el a n o m a: a m et a- a n al y si s of 1 8 tri al s i n v ol vi n g 2, 6 2 1 
p ati e nt s. J Cli n O n c ol 2 0 0 7; 2 5 : 5 4 2 6 −[ADDRESS_437495] ati c m el a n o m a. C a n c er  2 0 1 2; 1 1 8: 4 0 1 4 −2 3.  
J o h n s o n  G L, L a p a d at R. Mit o g e n a cti v at e d pr ot ei n ki n a s e p at h w a y s m e di at e d b y E R K, 
J N K a n d p 3 8 pr ot ei n ki n a s e s. S ci e n c e 2 0 0 2; 2 9 8: 1 9 1 1 −2.  
K a k a v a n d H, Wil m ott J S, M e n zi e s A M, et al. P D -L 1 E x pr e s si o n a n d t u m or -i nfiltr ati n g 
ly m p h o c yt e s d e fi n e diff er e nt s u b s et s of M A P K  i n hi bit or -t r e at e d mel a n o m a p ati e nt s. 
Cli n C a n c er R e s 2 0 1 5; 2 1: 3 1 4 0 −8.  
K ni g ht J C . G e n o mi c m o d u l at or s of t h e i m m u n e r e s p o n s e. Tr e n d s G e n et  2 0 1 3; 2 9: 7 4 −[ADDRESS_437496] e n o B, et al. C o m bi n e d v e m ur af e ni b a n d c o bi m eti ni b i n  B R A F -
m ut at e d m el a n o m a. N  E n gl J M e d 2 0 1 4; 3 7 1: 1 8 6 7 −7 6.  
L ar ki n J, C hi ari o n -Sil e ni V, G o n z al e z R, et al. C o m bi n e d ni v ol u m a b a n d i pi[INVESTIGATOR_45769] m u m a b or 
m o n ot h er a p y i n u ntr e at e d m el a n o m a. N E n gl J M e d  2 0 1 5; 3 7 3: 2 3 −[ADDRESS_437497] ol o gi c al t y p e s a n d sit e s of ori gi n of c ut a n e o u s m el a n o m a: a m et a -a n al y si s. 
Briti s h J D er m 2 0 1 1; 1 6 4: 7 7 6 -8 4.  
L e c o mt e T, L a n di B, B e a u n e P, et al. Gl ut at hi o n e S -tr a n sf er a s e s P 1  p ol y m or p hi s m 
(ll 3 1 0 5 V al) pr e di ct s c u m ul ati v e n er u o p at h y i n p ati e nt s r e c ei v ei n g o x ali pl ati n -b a s e d 
c h e m ot h er a p y.  Cli n C a n c er R e s 2 0 0 6; 1 2: 3 0 5 0 .  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
125/Protocol CO39721, Version 5  Liu I, Mayes PA, Eastman S, et al. The BRAF  and MEK inhibitors dabrafenib and 
trametinib: effects on immune function and ombination with immunomodulatory 
antibodies targeting PD -1, PD- L1, and CTLA -4. Clin Cancer Res 2015;21:1639− 51. 
Loi S, Dushyanthen S, Beavis PA, et al. RAS/MAPK activation is associated with 
reduced tumor -infiltrating lymphocytes in triple -negative breast cancer: therapeutic 
cooperation between MEK and PD -1/PD -L1 immune checkpoint inhibitors. Clin 
Cancer  Res 2016;22:1499− 509. 
Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF  and MEK inhibition versus 
BRAF  inhibition alone in melanoma. N Engl J Med. 2014;371:1877− 88. 
Michels  AW, Ostrov DA .  New approaches to predicting T cell -mediated drug reactions: 
a role for inducible and potentially preventable autoimmunity. J Allergy Clin 
Immu nol 2015;136:252 −7. 
Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide 
versus  dacarbazine in the treatment of patients with advanced metastatic 
malignant m elanoma. J Clin Oncol 2000;18 :158−66.  
Miller WH, Kim TM, Lee CB , et al. Atezolizumab (A) + cobimetinib  (C) in metastatic 
melanoma  (mel) : updated safety and clinical activity.  J Clin Onc 2017 ; 3057.  
Mohan S, Vander Broek R, Shah S, et al. MEK i nhibitor PD -0325901 overcomes 
resistance to PI3K/mTOR inhibitor PF- 5212384 and potentiates antitumor effects 
in human head and neck squamous cell carcinoma. Clin Cancer Res 
2015;21:3946 −56. 
O'Dwyer PJ, Catalano  RB. Uridine  diphosphate  glucuronosyltransferase (ugt) 1a1 and 
irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin 
Oncol  2006;24:4534 −8. 
Phan VT, Wu X, Cheng JH, et al. Oncogenic RAS pathway activation promotes 
resistance to anti -VEGF therapy through G -CSF−induced neutrophil recruitment. 
Proc Natl Acad Sci [LOCATION_003] 2013;110:6079 −84. 
Richman J, Martin- Liberal J, Diem S, et al. BRAF  and MEK inhibition for the treatment of 
advanced BRAF  mutant melanoma.  Expert Opin Pharmacother  2015;16;1285– 97. 
Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma 
with combined dabrafenib and trametinib. N Engl J Med. 2015a;372:30- 9. 
Robert C,  Long GV,  Brady B, et al. Nivolumab in previously untreated melanoma without 
BRAF  mutation. N Engl J Med.  2015b;22;372:320 –30.  
Robert C, Ribas A, Hamid O , et al. Three -year overall survival for patients with advanced 
melanoma treated with pembrolizumab in KEYNOTE -001 [abstract] . J Clin Oncol 
2016;34:9503A. 
Robert C, Thomas L, Bondarenko I, et al. Ipi[INVESTIGATOR_80049]. N Engl J Med 2011;364:2517 −26. 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
126/Protocol CO39721, Version 5  Roberts PJ, Der CJ. Targeting the Raf -MEK -ERK mitogen -activated protein kinase 
cascade for the treatment of cancer. Oncogene 2007;26:3291 −310. 
Rosenberg JE, Hoffman- Censits J, Powles T, et al. Atezolizumab in patients with locally 
advanced and metastatic urothelial carcinoma who have progressed following 
treatment with platinum -based chemotherapy: a single- arm, multicentre,  phase 2 
trial. Lancet 2016;387:1909− 20. 
Ruzzo A, Graziano F, Loupakis  F, et al. Pharmacogenetic profiling  in patients  with 
advanced colorectal cancer  treated with first -line FOLFOX -4 chemotherapy . J Clin 
Oncol 2007;25:1247 −54. 
Shirzadi M,  Thorstensen K,  Helde G, et al.  Do Hla-A markers predict skin- reactions from 
aromatic antiepi[INVESTIGATOR_40819] a Norwegian population? A case control study . 
Epi[INVESTIGATOR_5612]. 2015;118:5 −9. 
Stamp LK, Day RO, Yun J,  et al.  Allopurinol hypersensitivity: investigating the cause and 
minimizing the risk. Nat Rev Rheumatol 2015;12:235− 42. 
Solit DB, Garraway LA, Pratilas CA, et al. BRAF  mutation predicts sensitivity to M EK 
inhibition. Nature 2006; 358−62. 
Weber JS, D'Angelo SP, Mi nor D , et al. Nivolumab versus chemotherapy in patients with 
advanced melanoma who progressed after anti -CTLA -4 treatment (CheckMate 
037): a randomised, controlled, open- label, Phase  3 trial. Lancet Oncol  
2015;16:375 −84. 
Wilmott JS, Long GV, Howle JR, et a l. Selective BRAF  inhibitors induce marked T- cell 
infiltration into human metastatic melanoma. Clin Cancer Res  2012;18:1386− 94. 
Zhu Z, Liu W, Gotlieb V. The rapi[INVESTIGATOR_351831] towards immunotherapy, molecular targeted therapy, and beyond. Crit 
Rev Oncol Hematol 2016;99:91 −9.
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
127/Protocol CO39721, Version 5  Appendix  1  
Schedule of Activities  
Cohort A  
Day (window)  Screening a Cycle 1  Cycle 2  Cycle 3+  Treatment Discontinuation b Unplanned Visit c Survival  FU d 
–35 to –1 1 15 1 15 1 15 30 (± 3) d after last dose   Q3M  
Informed consent e x           
Demographic data  x          
Medical history  x          
Vital signs f, g x x x x x x x x x  
ECOG PS  x x  x  x   x  
Weight  x x  x  x  x   
Height  x          
Complete physical examination  x       x   
Limited physical examination  x h  x  x     
Hematology i x x  x  x  x x  
Coagulation (INR and aPTT)  x          
BRAFV600 WT mutation status  x          
PK/ADA sample for atezolizumab See Appendix  2 x  
PK sample for cobimetinib  See Appendix  2   
Serum samples for auto antibody 
tests j  x         
Optional WGS   x         
 
Appendix 1  
Schedule of Activities (cont.)  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
128/Protocol CO39721, Version 5  Cohort A  
Day (window)  Screening a Cycle 1  Cycle 2  Cycle 3+  Treatment 
Discontinuation b Unplanned Visit c Survival FU d 
–35 to –1 1 15 1 15 1 15 30 (± 3) days after last 
dose   Q3M  
Chemistry k x x  x  x  x x  
Tumor assessments l x Scans will be done every 8 weeks  ± 7 days  
ECHO/MUGA  scan  x   x  x m  x x  
ECG  (average of  triplicate  measurements)  x        x  
Serology n x          
Thyroid function o x x  x  x o  x   
Ophthalmologic exam  x Perform ophthalmology investigations as per Section 4.4.[ADDRESS_437498] p x x  x  x p  x x  
Urinalysis q x          
Concomitant medications r x r x r  x  x  x r   
Adverse events s x s x s x x x x x x s  x s 
Tumor biopsy t x   x   x   
Biomarker blood samples   See Appendix  2   
Atezolizumab administration u  x x x x x x    
Dispense cobimetinib v  x  x  x     
Survival and anti -cancer therapy FU           x 
 
Appendix 1  
Schedule of Activities (cont.)  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
129/Protocol CO39721, Version 5  ADA  = anti-drug antibody; CPK  = increased creatine phosphokinase; ECHO  = echocardiogram; ECOG PS  = Eastern Cooperative Oncology Group 
performance status; eCRF  = electronic Case Report Form; FU  = follow -up; HBcAb  = hepatitis B core antibody; HBcAg  = hepatitis B core antigen;  
HBsAg  = hepatitis B surface antigen;  HBV  = hepatitis B virus; HCV  = hepatitis C virus;  LVEF  = left ventricular ejection fraction; MUGA  = multiple -gated 
acquisition; PD  = progressive disease;  PK  = pharmacokinetic; Q3M  = every 3 months; RECIST  = Response Evaluation Criteria in Solid Tumors; 
T3  = triiodothyronine; T4  = thyroxine; TSH  = thyroid -stimulating hormone; WGS  = whole genome sequencing; WT  = wild type.  
Notes:  All assessments should be performed within ± [ADDRESS_437499]- of-care tests or examinations performed before obtaining informed consent and within 35 days before Day 1 may be used; 
such tests do not need to be repeated for screening.  BRAFV600 status must be known before performing study -specific screening assessments.  
The 35- day window begins at the time of the first standard- of-care screening assessment or the first study -specific screening assessment after 
the BRAFV600 mutation test result is available, whichever is earlier.  Test results should be reviewed before study treatment  is given .   
b Patients who discontinue study drug will return to the clinic for  a treatment discontinuation visit at 30 ( ± 3) days.  The visit at which response 
assessment shows PD may be used as the study discontinuation visit.  
c Visit not specified by [CONTACT_760].  Assessments (possibly including PK sample collection) should be performed as clinically indicated.  
d Required follow -up information will be collected via telephone calls and/or clinic visits every [ADDRESS_437500] be documented before an y study -specific screening procedure is performed and may be obtained up to 35 days before 
initiation of study treatment.  
f Includes respi[INVESTIGATOR_697], heart  rate, and systolic and diastolic blood pressure (after  patient has been in a seated position for 5 minutes)  and 
temperature (oral or tympanic); resting oxygen saturation may be measured at screening.  Record abnormalities observed at baseline on the 
General Medical History and Baseline Conditions eCRF.  At subsequent visits, record new or worsened clinically significant abnormalities on the 
Adverse Event eCRF.  
g Vital signs at the first atezolizumab infusion will be collected within 60 min before the infusion, every 15 ( ± 5) min during the atezolizumab 
infusion, and 30 (± 10) min after the infusion.  For subsequent infusions, vital signs will be collected within 60 min before infusion and during the 
infusion ( if clinically indicated or if symptoms occurred in the prior infusion) , and 30 ( ± 10) min after the infusion.  
h Perform a limited, symptom -directed examination at specified timepoints or as clinically indicated.  Record new or worsened clinically significant 
abnormalities on the Adverse Event eCRF.  If physical examinations are assessed within [ADDRESS_437501] to 
be repeated at Day 1.  
 
Appendix 1  
Schedule of Activities (cont.)  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
130/Protocol CO39721, Version 5  i Hematology includes WBC count, RBC count, hemoglobin, hematocrit, platelet count, reticulocyte count,  differential count (neutrophils, 
eosinophils, basophils, monocytes, and lymphocytes).  
j Includes anti -nuclear antibody, anti− double- stranded DNA, circulating anti- neutrophil cytoplasmic antibody, and perinuclear anti -neutrophil 
cytoplasmic antibody.  
k Chemistry panel (serum  or plasma) includes sodium, potassium, chloride, bicarbonate (or total carbon dioxide) , BUN or urea, creatinine, 
total protein, magnesium, phosphorus, calcium, total and direct bilirubin, ALP, ALT, AST, CPK, LDH,  uric acid; al bumin, non- fasting glucose 
(fasting blood glucose after a minimum 8- hour fast, at screening only ), lipi[INVESTIGATOR_805], (Fasting lipi[INVESTIGATOR_805]:  total cholesterol, LDL cholesterol, and triglycerides 
after a minimum 8- hour fast, at screening only ).  
l Tumor assessments will continue until disease progression per RECIST v1.1, loss of clinical benefit (patients who continue tr eatment  after 
disease progression according to RECIST v1.1), consent withdrawal, study termination by [CONTACT_1034], or death, whichever occurs first.  At the 
investigator's discretion, tumor assessments may be repeated at any time if disease progression is suspected.  Patients who discontinue treatment for reasons other than disease progression (e.g., toxicity) will continue scheduled tumor assessments until disease progression, 
withdrawal of consent, study termination by [CONTACT_2728], or death, whichever occurs first.  
m All patients will undergo evaluation of left ventricular dysfunction, either by [CONTACT_351875] , at screening.  Evaluation of LVEF by [CONTACT_351876]:  
• Cycle 2, Day 1 ( ± 1 week ) 
• Day 1 of Cycles 5, 8, 11, 14, 17, etc. (every three treatment cycles) ±  2 weeks  
• Treatment discontinuation visit evaluation of LVEF does not need to be performed at treatment discontinuation visit if an evaluation has been 
performed within the last 12 weeks and there are no clinically significant findings and/or changes from baseline.  
• All patients restarting treatment with a dose reduction of cobimetinib because of a decrease in LVEF should have LVEF measurements taken after approximately 2, 4, 10, and 16 weeks, and then resume monitoring LVEF every three treatment cycles.  
n All patients will be tested for HIV prior to the inclusion into the study and HIV -positive patients will be excluded from the clinical study.  
• HBV serology will include HBsAg, t otal HBcAg antibody (anti -HBcAb).  HBV DNA should be obtained prior to study start if patient has a 
negative serology for HBsAg and a positive serology for anti -HBcAb.  
• HCV serology will include HCV antibody (anti- HCV).  HCV RNA should be obtained prior to study start if patient tests positive for anti -HCV.  
o Thyroid function testing (TSH, free T3 [or total T3 for sites where free T3 is not performed, free T4) collected at Day 1 of Cycles 1 −5, and every 
second cycle thereafter (e.g., Day 1 of Cycles 7, 9, 11, etc.) for patients on atezolizumab only.  
p All women of childbearing potential will have a serum pregnancy test at screening  within [ADDRESS_437502].  
Appendix 1  
Schedule of Activities (cont.)  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
131/Protocol CO39721, Version 5  q Includes dipstick (pH, specific gravity, glucose, protein, ketones, blood) and microscopic examination (sediment, RBCs, WBCs,  casts, crystals,  
epi[INVESTIGATOR_1663], bacteria).  
r Includes any medication (e.g., prescription drugs, over -the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by a 
patient from  [ADDRESS_437503].  After this period, all deaths, regardless of cause, should be reported.   After this 
period, the Sponsor should be notified if the investigator becomes aware of any serious adverse event that is believed to be related to prior study 
drug treatment (see Section 5.6) .  The investigator should follow each adverse event until the event has resolved to baseline grade or better, the 
event is assessed as stable by [CONTACT_093], the patient is lost to follow- up, or the patient withdraws consent.  Every effort should be made to 
follow all serious adverse events  or adverse events of special interest  considered to be related to study drug or trial -related procedures until a 
final outcome can be reported.  
t Archival (< 5 years  old) or fresh baseline tumor tissue collected during screening.   If a patient provides a fresh biopsy for BRAFV600 testing, this 
sample will be used also as baseline for biomarker analysis. Therefore predose specimens are not required for patients who provide a fres h 
biopsy before treatment start .  If archival tissue is used availability of adequate tumor tissue must be confirmed prior to any screening procedures 
(paraffin- embedded tumor block or a minimum of 20 unstained slides).  Submit archival tissue and associated pathology report within [ADDRESS_437504] 
atezolizumab administration; an additional optional biopsy may be collected at the time of radiographic progression if clinically feasible. See 
Section 3.1.1  and the laboratory manual  for further details.   
u In Cohort A, atezolizumab will be given on Days 1 and 15 of all c ycles.  The initial dose will be delivered over 60 ( ± 15) minutes.  If the first 
infusion is well tolerated, all subsequent infusions will be delivered over 30 ( ± 10) minutes until loss of clinical benefit.  Study drug administration 
may be ±  3 days from the scheduled Day 1 and 15 of each cycle.  
v Cobimetinib 60 mg/day by [CONTACT_351877] a 21/7  dosing schedule.  
  
Appendix 1  
Schedule of Activities (cont.)  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
132/Protocol CO39721, Version 5  Cohort B:  Biopsy Cohort  
 Screeninga Cycle 1  Cycle 2  Cycle 3+  Treatment 
Discontinuation b Unplanned 
Visit c Survival 
FU d 
Day (window)  –35 to –1 1 15 1 15 1 15 30 (±3) days after last 
dose   Q3M  
Informed consent e x           
Demographic data  x          
Medical history  x          
Vital signs f,g x x x x x x x x x  
ECOG PS  x x  x  x   x  
Weight  x x  x  x  x   
Height  x          
Complete physical examination  x       x   
Limited physical examination  x h  x  x     
Hematology i x x  x  x  x x  
Coagulation (INR and aPTT)  x          
BRAFV600 WT mutation status  x          
PK and ADA sample for atezolizumab See Appendix  2 x x 
PK sample for cobimetinib  See Appendix  2   
Serum samples for auto- antibody tests j  x         
Appendix 1  
Schedule of Activities (cont.)  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
133/Protocol CO39721, Version 5  Cohort B:  Biopsy Cohort  
 Screening a Cycle 1  Cycle 2  Cycle 3+  Treatment Discontinuation b Unplanned Visit c Survival FU d 
Day (window)  –35 to –1 1 15 1 15 1 15 <30 (± 3) days after last dose   Q3M  
Optional WGS   x         
Chemistry k x x  x  x  x x  
Tumor assessments l x Scans will be done every 8 weeks  ± 7 days  
ECHO/MUGA  scan  x   x  x m  x x  
ECG   (average of  triplicate  measurements)  x        x  
Serology n x          
Thyroid function o x x  x  x o  x   
Ophthalmologic exam  x Perform ophthalmology investigations as per Section 4.4.[ADDRESS_437505] p x x  x  x p  x x  
Urinalysis q x          
Concomitant medications r x r x r  x  x  x r   
Adverse events s x s x s x x x x x x s  x s 
Tumor biopsy t x  x u x   x   
Biomarker blood samples   See Appendix  2   
Atezolizumab administration v   x x x x x    
Dispense cobimetinib w  x  x  x     
Survival and anti -cancer therapy FU           x 
 
Appendix 1  
Schedule of Activities (cont.)  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
134/Protocol CO39721, Version 5  ADA  = anti-drug antibody; CPK  = increased creatine phosphokinase; ECHO  = echocardiogram; ECOG PS  = Eastern Cooperative Oncology 
Group performance status; eCRF  = electronic Case Report Form; FU  = follow -up; HBcAb  = hepatitis B core antibody; HBcAg  = hepatitis B core 
antigen;  HBsAg  = hepatitis B surface antigen;  HBV  = hepatitis B virus; HCV  = hepatitis C virus;  LVEF  = left ventricular ejection fraction; 
MUGA  = multiple -gated acquisition; PD  = progressive disease;  PK  = pharmacokinetic; Q3M  = every 3 months; RECIST  = Response Evaluation 
Criteria in Solid Tumors; T3  = triiodothyronine; T4  = thyroxine; TSH  = thyroid -stimulating hormone; WGS  = whole genome sequencing; 
WT  = wild type.  
Notes:  All assessments should be performed within ±  [ADDRESS_437506]- of-care tests or examinations performed before obtaining informed consent and within 35 days before Day 1 may be 
used; such tests do not need to be repeated for screening.  BRAFV600 status must be known prior to performing study -specific screening 
assessments.  The 35- day window begins at the time of the first standard- of-care screening assessment or the first study -specific 
screening assessment after the BRAFV600 mutation test result is available, whichever is earlier.  Test results should be reviewed before 
study treatment  is given . 
b Patients who discontinue study drug will return to the clinic for a treatment discontinuation visit at 30 ( ± 3) days.  The visit at which 
response assessment shows PD may be used as the study discontinuation visit.  
c Visit not specified by [CONTACT_760].  Assessments (possibly including PK sample collection) should be performed as clinically indicated.  
d Required follow -up information will be collected via telephone calls and/or clinic visits every [ADDRESS_437507] be documented before any study -specific screening procedure is performed and may be obtained up to 35 days 
before initiation of study treatment.  
f Includes respi[INVESTIGATOR_697], heart  rate, and systolic and diastolic blood pres sure (monitored after  the patient has been in a seated position for 
5 min), and temperature (oral or tympanic) .  Resting oxygen saturation may be measured at screening. Record abnormalities observed at 
baseline on the General Medical History and Baseline Conditions eCRF.  At subsequent visits, record new or worsened clinically 
significant abnormalities on the Adverse Event eCRF.  
g Vital signs at the first atezolizumab infusion will be collected within 60 minutes  before the infusion, every 15 ( ± 5) min during the 
atezolizumab infusion , and 30 (± 10) min after the infusion.  For subsequent infusions, vital signs will be collected within 60 min before the 
infusion and during the infusion (if clinically indicated or if symptoms occurred in the prior infusion) , and 30 ( ± 10) min after the infusion.  
 
 
Appendix 1  
Schedule of Activities (cont.)  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
135/Protocol CO39721, Version [ADDRESS_437508] to be repeated at Day 1.  
i Hematology includes WBC count, RBC count, hemoglobin, hematocrit, platelet count,  reticulocyte count,  differential count (neutrophils, 
eosinophils, basophils, monocytes, and lymphocytes).  
j Includes: anti -nuclear antibody, anti− double- stranded DNA, circulating anti- neutrophil cytoplasmic antibody, perinuclear anti -neutrophil 
cytoplasmic antibody.  
k Chemistry panel (serum  or plasma) includes sodium, potassium, chloride, bicarbonate (or total carbon dioxide), BUN or urea, creatinine, 
total protein, magnesium, phosphorus, calcium, total and direct bilirubin, ALP, ALT, AST, CPK,  LDH,  uric acid; al bumin, non- fasting 
glucose (f asting blood glucose after a minimum 8- hour fast, at screening only), and lipi[INVESTIGATOR_805] ( fasting lipi[INVESTIGATOR_805]:  total cholesterol, LDL cholesterol, 
and triglycerides after a minimum 8- hour fast, at screening only) . 
l Tumor assessments will continue until disease progression per RECIST v1.1, loss of clinical benefit (patients who continue treatment after 
disease progression according to RECIST v1.1), consent withdrawal, study termination by [CONTACT_1034], or death, whichever occurs first.  
At the investigator's discretion,  tumor assessments may be repeated at any time if disease progression is suspected.  Patients who 
discontinue treatment for reasons other than disease progression (e.g., toxicity) will continue scheduled tumor assessments until disease progression, withdra wal of consent, study termination by [CONTACT_2728], or death, whichever occurs first.  
m All patients will undergo evaluation of left ventricular dysfunction, either by [CONTACT_351875] , at screening.  Evaluation of LVEF by 
[CONTACT_351878]:  
• Cycle 2, Day 1 ±  1 week  
• Day 1 of Cycles 5, 8, 11, 14, 17, etc. (every three treatment cycles;  ± 2 weeks ) 
• Treatment discontinuation visit evaluation of LVEF does not need to be performed at  treatment discontinuation visit if an evaluation 
has been performed within the last 12 weeks and there are no clinically significant findings and/or changes from baseline.  
• All patients restarting treatment with a dose reduction of cobimetinib because of a  decrease in LVEF should have LVEF 
measurements taken after approximately 2, 4, 10, and 16 weeks, and then resume monitoring LVEF every three treatment cycles.  
n All patients will be tested for HIV prior to the inclusion into the study and HIV -positive patients will be excluded from the clinical study.  
• HBV serology will include HBsAg, total HBcAg antibody (anti- HBcAb).  HBV DNA should be obtained before study start if patient has a 
negative serology for HBsAg and a positive serology for anti -HBcAb.  
• HCV serology will include HCV antibody (anti- HCV).  HCV RNA should be obtained prior to study start if patient tests positive for 
anti-HCV.  
 
Appendix 1  
Schedule of Activities (cont.)  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
136/Protocol CO39721, Version 5  o Thyroid function testing (TSH, free T3 [or total T3 for sites where free T3 is not performed] , free T4) collecte d at Day 1 of Cycles 1− 5, and 
every second cycle thereafter (e.g., Day 1 of Cycles 7, 9, 11, etc.) for patients on atezolizumab only.  
p All women of childbearing potential will have a serum pregnancy test at screening  within [ADDRESS_437509].  
q Includes dipstick (pH, specific gravity, glucose, protein, ketones, blood) and microscopic examination (sediment, RBCs, WBCs, casts, 
crystals, epi[INVESTIGATOR_1663], bacteria).  
r Includes any medication (e.g., prescription drugs, over -the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used 
by a patient from [ADDRESS_437510].  After this period, all deaths, regardless of cause, should be reported.  
After this period, the Sponsor should be notified if the investigator becomes aware of any serious adverse event that is believed to be 
related to prior study drug treatment (see Section 5.6).  The investigator should follow each adverse event until the event has resolved to 
baseline grade or better, the event is assessed as stable by [CONTACT_093], the patient is lost to follow -up, or the patient withdraws 
consent.  Every effort should be made to follow all serious adverse events  or adverse events of special interest considered to be related to 
study drug or trial- related procedures until a final outcome can be reported.  
t In Cohort B. If a patient provides a fresh biopsy for BRAFV600 test, this sample will be used also as baseline for biomarker analysis.  
Therefore, predose specimens are not required for patients who provide a fresh biopsy before treatment start .. 
A subsequent mandatory biopsy will be performed between Days 10 and 14 of Cycle 1.  An additional optional biopsy may be collected 
during Cycle 2, approximately 4− [ADDRESS_437511] atezolizumab administration.   A mandatory biopsy will be collected at the time of 
radiographic progression, if clinically feasible.  
u Days 10−14. 
v In Cohort B, atezolizumab will be given  on Cycle 1, Day 15 and on Days 1 and 15 of all subsequent c ycles.  The initial dose will be 
delivered over 60 ( ± 15) minutes.  If the first infusion is well tolerated all subsequent infusions will be delivered over 30 ( ± 10) minutes until 
a loss of clinical benefit.  Study drug administration may be ±  3 days from the scheduled Day 1 and 15 of each cycle. 
w Cobimetinib 60 mg/day by [CONTACT_351879] a 21/[ADDRESS_437512] 
atezolizumab administration.  
Appendix 1  
Schedule of Activities (cont.)  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
137/Protocol CO39721, Version 5  Cohort C :  Atezolizumab M onotherapy  (21-Day C ycle)  
Day (window)  Screening a Cycle 1  Cycle 2  Cycle 3+  Treatment 
Discontinuation b Unplanned Visit 
c Survival FU 
d 
–35 to –1 1 
 1 
 1 
 30 (± 3) d after last 
dose   Q3M  
Informed consent e x        
Demographic data  x       
Medical history  x       
Vital signs f, g x x x x x x  
ECOG PS  x x x x  x  
Weight  x x x x x   
Height  x       
Complete physical examination  x    x   
Limited physical examination  x h x x    
Hematology i x x x x x x  
Coagulation (INR and aPTT)  x       
BRAFV600 WT mutation status  x       
PK/ADA sample for 
atezolizumab  See Appendix  2 
Serum samples for auto antibody tests 
j  x       
Optional WGS   x      
 
Appendix 1  
Schedule of Activities (cont.)  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
138/Protocol CO39721, Version 5  Cohort C :  Atezolizumab M onotherapy (21-Day C ycle)  
Day (window)  Screening a Cycle 1  Cycle 2  Cycle 3+  Treatment 
Discontinuation b Unplanned Visit c Survival FU d 
–35 to –1 1 
 1 
 1 
 30 (± 3) days after last 
dose   Q3M  
Chemistry k x x x x x x  
Tumor Assessments l x Scan assessments every 8 weeks± 7 days  
ECHO/MUGA scan m x       
ECG  (average 
of triplicate  measurements)  x     x  
Serology n x       
Thyroid function o x x x x o x   
Pregnancy test p x x x x p x x  
Urinalysis q x       
Concomitant medications r x r x r x x x r   
Adverse events s x s x s x x x s  x s 
Collection of archival tissue or t umor 
biopsy t x    x   
Biomarker blood samples   See Appendix  2   
Atezolizumab administration u  x x x    
Survival and anti -cancer therapy FU        x 
 
Appendix 1  
Schedule of Activities (cont.)  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
139/Protocol CO39721, Version 5  ADA  = anti-drug antibody; CPK  = increased creatine phosphokinase; ECHO  = echocardiogram; ECOG PS  = Eastern Cooperative Oncology Group 
performance status; eCRF  = electronic Case Report Form; FU  = follow -up; HBcAb  = hepatitis B core antibody; HBcAg  = hepatitis B core antigen;  
HBsAg  = hepatitis B surface antigen;  HBV  = hepatitis B virus; HCV  = hepatitis C virus;  LVEF  = left ventricular ejection fraction; MUGA  = multiple -gated 
acquisition; PD  = progressive disease;  PK  = pharmacokinetic; Q3M  = every 3 months; RECIST  = Response Evaluation Criteria in Solid Tumors; 
T3  = triiodothyronine; T4  = thyroxine; TSH  = thyroid -stimulating hormone; WGS  = whole genome sequencing; WT  = wild type.  
Notes:  All assessments should be performed within ±  [ADDRESS_437513]- of-care tests or examinations performed before obtaining informed consent and within 35 days before Day 1 may be used; 
such tests do not need to be repeated for screening.  BRAFV600 status must be known before performing study -specific screening assessments.  
The 35- day window begins at the time of the first standard- of-care screening assessment or the first study -specific screening assessment after 
the BRAFV600 mutation test result is available, whichever is earlier.  Test results should be reviewed before study treatment is given.   
b Patients who discontinue study drug will return to the clinic for a treatment discontinuation visit at 30 ( ± 3) days.  The visit at which response 
assessment shows PD may be used as the study discontinuation visit.  
c Visit not specified by [CONTACT_760].  Assessments (possibly including PK sample collection) should be performed as clinically  indicated.  
d Required follow -up information will be collected via telephone calls and/or clinic visits every 3 months until death, loss to follow -up, or study 
termination by [CONTACT_1034].   PK/ADA sample is required 120 days +/ - [ADDRESS_437514] be documented before any study -specific screening procedure is performed and may be obtained up to 35 days before 
initiation of study treatment.  
f Includes respi[INVESTIGATOR_697], heart rate, and systolic and diastolic blood pressure (after patient has been in a seated position for 5 minutes) and 
temperature (oral or tympanic); resting oxygen saturation may be measured at screening.  Record abnormalities observed at baseline on the 
General Medical History and Baseline Conditions eCRF.  At subsequent visits, record new or worsened clinically significant abnormalities on the 
Adverse Event eCRF.  
g Vital signs at the first atezolizumab infusion will be collected within 60 min before the infusion, every 15 ( ± 5) min during the atezolizumab 
infusion, and 30 ( ± 10) min after the infusion.  For subsequent infusions, vital signs  will be collected within 60 min before infusion and during the 
infusion (if clinically indicated or if symptoms occurred in the prior infusion), and 30 ( ± 10) min after the infusion.  
h Perform a limited, symptom -directed examination at specified timepoints or as clinically indicated.  Record new or worsened clinically significant 
abnormalities on the Adverse Event eCRF.  If physical examinations are assessed within [ADDRESS_437515] to be repeated at Day 1.  
 
Appendix 1  
Schedule of Activities (cont.)  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
140/Protocol CO39721, Version 5  i Hematology includes WBC count, RBC count, hemoglobin, hematocrit, platelet count, reticulocyte count, differential count (neutrophils, 
eosinophils, basophils, monocytes, and lymphocytes).  
j Includes anti -nuclear antibody, anti− double- stranded DNA, circulating anti- neutrophil cytoplasmic antibody, and perinuclear anti -neutrophil 
cytoplasmic antibody.  
k Chemistry panel (serum or plasma) includes sodium, potassium, chloride, bicarbonate (or total carbon dioxide), BUN or urea, c reatinine, 
total protein, magnesium, phosphorus, calcium, total and direct bilirubin, ALP, ALT, AST, CPK, LDH, uric acid; albumin, non- fasting glucose 
(fasting blood glucose after a minimum 8- hour fast, at screening only), lipi[INVESTIGATOR_805], (Fasting lipi[INVESTIGATOR_805]:  total cholesterol, LDL cholesterol, and triglycerides 
after a minimum 8- hour fast, at screening only).  
l Tumor assessments will continue until disease progression per RECIST v1.1, loss of clinical benefit (patients who continue treatment after 
disease progression according to RECIST v1.1), consent withdrawal, study termination by [CONTACT_1034], or death, whichever occurs f irst.  At the 
investigator's discretion, tumor assessments may be repeated at any time if disease progression is suspected.  Patients who d iscontinue 
treatment for reasons other than disease progression (e.g., toxicity) will continue scheduled tumor assessments until disease progression, withdrawal of consent, study termination by [CONTACT_2728], or death, whichever occurs first.  
m All patients will undergo evaluation of left ventricular dysfunction, either by [CONTACT_123550], at screening.  Treatment discontinu ation visit 
evaluation of LVEF does not need to be performed at treatment discontinuation visit if an evaluation has been performed withi n the last 12 weeks 
and there are no clinically significant findings and/or changes from baseline.  
n All patients will be tested for HIV prior to the inclusion into the study and HIV -positive patients will be excluded from the clinical study.  
• HBV serology will include HBsAg, total HBcAg antibody (anti- HBcAb).  HBV DNA should be obtained prior to study start if patient has a 
negative serology for HBsAg and a positive serology for anti -HBcAb.  
• HCV serology will include HCV antibody (anti- HCV).  HCV RNA should be obtained prior to study start if patient tests positive for anti -HCV.  
o Thyroid function testing (TSH, free T3 [or total T3 for sites where free T3 is not performed, free T4) collected at Day 1 of Cycles 1− 5, and every 
second cycle thereafter (e.g., Day 1 of Cycles 7, 9, 11, etc.) for patients on atezolizumab only.  
p All women of childbearing potential will have a serum  pregnancy test at screening within [ADDRESS_437516].  
q Includes dipstick (pH, specific gravity, glucose, protein, ketones, blood) and microscopic examination (sediment, RBCs, WBCs,  casts, crystals, 
epi[INVESTIGATOR_1663], bacteria).  
r Includes any medication (e.g., prescription drugs, over -the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by a 
patient from   [ADDRESS_437517] dose of study drug.  
 
Appendix 1  
Schedule of Activities (cont.)  
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
141/Protocol CO39721, Version [ADDRESS_437518].  After this period, all deaths, regardless of cause, should be reported.   After this 
period, the Sponsor should be notified if the investigator becomes aware of any serious adverse event that is believed to be related to prior study 
drug treatment (see Section 5.6).  The investigator should follow each adverse event until the event has resolved to baseline grade or better, the 
event is assessed as stable by [CONTACT_093], the patient is lost to follow- up, or the patient withdraws consent.  Every effort should be made to 
follow all serious adverse events or adverse events of special interest considered to be related to study drug or trial -related procedures until a 
final outcome can be reported.  
t Archival (<5 years)  or fresh baseline tumor tissue collected during screening.  If a patient provides a fresh biopsy for BRAF  test, this sample will 
be used also as baseline for biomarker analysis.   Therefore predose specimens are not required for patients who provide a fresh biopsy before 
treatment start.  
If archival tissue is used availability of adequate tumor tissue must be confirmed prior to any screening procedures (paraffin- embedded tumor 
block or a minimum of 20 unstained slides).  Submit archival tissue and associated pathology report within [ADDRESS_437519] consented to optional biopsies; an additional optional biopsy may be collected at the time of radiographic progression if clinically fea sible. See Section 3.1.1 and the laboratory manual  for further details.  
u In Cohort C, atezolizumab (1200  mg) will be given on Cycle 1, Day 1 IV Q3W.  The initial dose will be delivered over 60 ( ± 15) minutes.  If the 
first infusion is well tolerated, all subsequent infusions will be delivered over 30 ( ± 10) minutes until a loss of clinical benefit.  Study drug 
administration may be ± 3 days from the scheduled Day 1 of each cycle.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
142/Protocol CO39721, Version 5  Appendix  2  
Schedule of Pharmacokinetic, Immunogenicity, and 
Biomarker  Samples  
Cohort A  
Visit Timepoint  Sample Type(s)  
Cycle 1, Day [ADDRESS_437520] infusion  Atezolizumab PK and ADA 
(serum)  
30 (± 10) minutes following the 
end of atezolizumab infusion Atezolizumab PK (serum)  
2−4 hours after the cobimetinib 
dose  Cobimetinib PK (plasma)  
Cycle 1, Day 15  Prior to cobimetinib dose  
2−[ADDRESS_437521] cobimetinib 
dose  Cobimetinib PK (plasma)  
Cycles 2, 3, 4, 8, 12, and [ADDRESS_437522] infusion  Atezolizumab PK and ADA (serum)  
Cycles 1 and 2, Day 1  
At time of tumor assessments (preferably within 3 days)  
At disease progression  Predose  Biomarker (plasma, PBMC)  
Treatment discontinuation visit
 a At visit  Atezolizumab PK and ADA (serum)  
 Biomarker (plasma, PBMC) b 
120 days ± [ADDRESS_437523] 
atezolizumab infusion  At visit  Atezolizumab PK and ADA 
(serum)  
ADA  = anti-drug antibody; PBMC  = peripheral blood mononuclear cell; PK  = pharmacokinetic . 
Note:  Except for Day 1 of Cycle 1, all other study visits and assessments during the treatment 
period should be performed within ±  3 days of the scheduled date.  Study assessments may be 
delayed or moved ahead of the window to accommodate holidays, vacations, and unforeseen 
delays.  
a Patients who discontinue study drug will return to the clinic for a treatment discontinuation visit 30 (±
 3) days  after the last dose of study drug.  The visit at which response assessment 
shows progressive disease may be used as the treatment discontinuation visit.  
b At confirmed disease progression, lack of clinical benefit, or at treatment discontinuation.   
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
143/Protocol CO39721, Version 5  Appendix  2  
Schedule of Pharmacokinetic, Immunogenicity, and 
Biomarker  Samples (cont.)  
Cohort B  
Visit Timepoint  Sample Type(s)  
Cycle 1, Day [ADDRESS_437524] infusion  Atezolizumab PK and ADA 
(serum)  
 30 (± 10) minutes following the 
end of atezolizumab infusion Atezolizumab PK (serum)  
 Prior to cobimetinib dose  
2−[ADDRESS_437525] cobimetinib dose  Cobimetinib PK (plasma)  
Cycles 2, 3, 4, 8, 12, and [ADDRESS_437526] infusion  Atezolizumab PK and ADA (serum)  
Cycles 1 and 2, Day 1  
At time of tumor assessments (preferably within 3 days)  
At disease progression  Predose  Biomarker (plasma, PBMC)  
Treatment discontinuation visit
 a At visit  Atezolizumab PK and ADA 
(serum)  
 Biomarker (plasma, PBMC) b 
120 days ± [ADDRESS_437527] atezolizumab infusion  At visit  Atezolizumab PK and ADA (serum)  
ADA  = anti-drug antibody; PBMC  = peripheral blood mononuclear cell; PK  = pharmacokinetic ; 
RECIST  = Response Evaluation Criteria in Solid Tumors . 
Note:  Except for Day 15 of Cycle 1, all other study visits and assessments during the treatment period should be performed within ±
 3 days of the scheduled date.  Study assessments may be 
delayed or moved ahead of the window to accommodate holidays, vacations, and unforeseen delays.  
a Patients who discontinue study drug will return to the clinic for a treatment discontinuation 
visit 30 (± 3) days  after the last dose of study drug.  The visit at which response assessment 
shows progressive disease may be used as the treatment discontinuation visit.  
b At confirmed disease progression, lack of clinical benefit, or at treatment discontinuation.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
144/Protocol CO39721, Version 5  Appendix  2  
Schedule of Pharmacokinetic, Immunogenicity, and 
Biomarker  Samples (cont.)  
Cohort C  
Visit Timepoint  Sample Type(s)  
Cycle 1, Day [ADDRESS_437528] infusion  Atezolizumab PK and ADA 
(serum)  
30 (± 10) minutes following the 
end of atezolizumab infusion Atezolizumab PK (serum)  
Cycles 2, 3, 4, 8, 12, and [ADDRESS_437529] infusion  Atezolizumab PK and ADA (serum)  
Cycles 1 and 2, Day 1  
At time of tumor assessments (preferably within 3 days)  
At disease progression  Predose  Biomarker (plasma, PBMC)  
Treatment discontinuation visit
 a At visit  Atezolizumab PK and ADA (serum)  
 Biomarker (plasma, PBMC) b 
120 days ± [ADDRESS_437530] 
atezolizumab infusion  At visit  Atezolizumab PK and ADA (serum)  
ADA  = anti-drug antibody; PBMC  = peripheral blood mononuclear cell; PK  = pharmacokinetic.  
Note:  Except for Day 1 of Cycle 1, all other study visits and assessments during the treatment period should be performed within ±
 3 days of the scheduled date.  Study assessments may be 
delayed or moved ahead of the window to accommodate holidays, vacations, and unforeseen delays.  
a Patients who discontinue study drug will return to the clinic for a treatment discontinuation 
visit 30 (± 3) days  after the last dose of study drug.  The visit at which response assessment 
shows progressive disease may be used as the treatment discontinuation visit.  
b At confirmed disease progression, lack of clinical benefit, or at treatment discontinuation.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
145/Protocol CO39721, Version 5  Appendix  3  
Response Evaluation Criteria in Solid Tumors:  Modified Excerpt 
from Original Publication 
Selected sections from the Response Evaluation Criteria in Solid Tumors (RECIST), 
Version 1.1 1 are presented below, with slight modifications and the addition of 
explanatory text as needed for clarity.2 
MEASURABILITY OF TUM OR AT BASELINE  
DEFINITIONS  
At baseline, tumor lesions/lymph nodes will be categorized measurable or non-measurable as follows:  
Measurable Tumor Lesions  
Tumor Lesions.   Tumor lesions must be accurately measured in at least one dimension 
(longest diameter in the plane of measurement is to be recorded) with a minimum size of:  
• 10 mm by [CONTACT_20420] (CT) or magnetic resonance imaging (MRI) scan 
(CT/MRI scan slice thickness/interval no greater than 5 mm) 
• 10-mm caliper measurement by [CONTACT_12148] (lesions that cannot be 
accurately measured with calipers should be recorded as non- measurable)  
• [ADDRESS_437531] be ≥ [ADDRESS_437532] scan (CT sc an 
slice thickness recommended to be no greater than 5 mm).  At baseline and in follow -up, 
only the short axis will be measured and followed.  See also notes below on “Baseline 
Documentation of Target and Non- target Lesions” for information on lymph node 
measurement.  
Non-Measurable Tumor Lesions  
Non-measurable tumor lesions encompass small lesions (longest diameter < 10 mm 
or pathological lymph nodes with ≥  10 to <  15 mm short axis), as well as truly 
non-measurable lesions.  Lesions considered truly non- measurable include 
leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast 
disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal masses/abdominal organomegaly identified by [CONTACT_150063].  
                                            
 
1 Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: 
Revised RECIST guideline (Version 1.1). Eur J Cancer 2009;45:228– 47. 
[ADDRESS_437533] been made.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
146/Protocol CO39721, Version 5  Appendix  3 
Response Evaluation Criteria in Solid Tumors:  Modified Excerpt 
from Original Publication (cont.)   
Special Considerations Regarding Lesion Measurability  
Bone lesions, cystic lesions, and lesions previously treated with local therapy require 
particular comment, as outlined below.  
Bone lesions:  
• Bone scan, positron emission tomography (PET) scan, or plain films are not 
considered adequate imaging techniques to measure bone lesions.  However, these 
techniques can be used to confirm the presence or disappearance of bone lesions.  
• Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft tissue 
components , that can be evaluated by [CONTACT_12783] -sectional imaging techniques such as 
CT or MR I can be considered measurable lesions if the soft tissue component meets  
the definition of measurability described above.  
• Blastic bone lesions are non- measurable.  
 
Cystic lesions:  
• Lesions that meet the criteria for radiographically defined simple cysts should not  be 
considered malignant lesions (neither measurable nor non- measurable) since they 
are, by [CONTACT_108], simple cysts.  
• Cystic lesions thought to represent cystic metastases can be considered measurable 
lesions if they meet the definition of measurability described above.  However, if noncystic lesions are present in the same patient, these are preferred for selection 
as target lesions.  
 
Lesions with prior local treatment: 
• Tumor lesions situated in a previously irradiated area, or in an area subjected to 
other loco- regional therapy, are usually not considered measurable unless there has 
been demonstrated progression in the lesion.  Study protocols should detail the 
conditions under which such lesions would be considered measurable.  
 
TARGET LESIONS:  SPECIFICATIONS BY [CONTACT_351880], using calipers if clinically 
assessed.  All baseline evaluations should be performed as close as possible to the treatment start and never more than 4 weeks before the beginning of the treatment.  
Method of Assessment  
The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during study.  Imaging -based evaluation should always be the preferred option.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
147/Protocol CO39721, Version 5  Appendix  3 
Response Evaluation Criteria in Solid Tumors:  Modified Excerpt 
from Original Publication (cont.)   
Clinical Lesions.   Clinical lesions will only be considered measurable when they are 
superficial and ≥ 10 mm in diameter as assessed using calipers (e.g., skin nodules).  
For the case of skin lesions, documentation by [CONTACT_6775], including a ruler to 
estimate the size of the lesion, is suggested.  
Chest X -Ray.   Chest CT is preferred over chest X -ray, particularly when progression is 
an important endpoint, since CT is more sensitive than X -ray, particularly in identifying 
new lesions.  However, lesions on chest X -ray may be considered measurable if they 
are clearly defined and surrounded by [CONTACT_6776].  
CT, MRI.   CT is the best currently available and reproducible method to measure lesions 
selected for response assessment.  This guideline has defined measurability of lesions 
on CT scan based on the assumption that CT slice thickness is [ADDRESS_437534] scans with intravenous (IV)  contrast due to allergy or renal insufficiency, the decision as to 
whether a non- contrast CT or MRI (without IV contrast) will be used to evaluate the 
patient at baseline and during the study should be guided by [CONTACT_234632].  For patients who develop contraindications to contrast after baseline contrast CT is done, the decision as to whether non- contrast CT or MRI (enhanced or nonenhanced) will be performed should 
also be based on the tumor type and the anatomic location of the disease and should be optimized to allow for comparison with the prior studies if possible.  Each case should be discussed with the radiologist to determine if substitution of these other approaches is possible and, if not, the pat ient should be considered not evaluable from that point 
forward.   Care must be taken in measurement of target lesions on a different modality 
and interpretation of non -target disease or new  lesions since the same lesion may 
appear to have a different size using a new  modality.  
Ultrasound.   Ultrasound is not useful in the assessment of lesion size and should not be 
used as a method of measurement.  
Endoscopy, Laparoscopy, Tumor Markers, Cytology, Histology.   The utilization of 
these techniques for objective t umor evaluation cannot generally be advised.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
148/Protocol CO39721, Version 5  Appendix  3 
Response Evaluation Criteria in Solid Tumors:  Modified Excerpt 
from Original Publication (cont.)   
TUMOR RESPONSE EVALU ATION  
ASSESSMENT OF OVERAL L TUMOR BURDEN AND M EASURABLE 
DISEASE  
To assess objective response or future progression, it is necessary to estimate the 
overall tumor burden at baseline and to use this as a comparator for subsequent measurements.  Measurable disease is defined by [CONTACT_12155], as detailed above.  
BASELINE DOCUMENTATION OF TARGET AND NON- TARGET LESIONS  
When more than one measurable lesion is present at baseline, all lesions up to a maximum of five lesions total (and a maximum of two lesions per organ) representative of all involved organs should be identified as target lesions and will be recorded and measured at baseline.  This means in instances where patients have only one or two organ sites involved, a maximum of two lesions (one site) and four lesions (two sites), respectively, will be recorded.  Other lesions (albeit measurable) in those organs will be 
recorded as non -measurable lesions (even if the size is >
 [ADDRESS_437535]  scan).   
Target lesions should be selected on the basis of their size (lesions with the longest diameter) and be representative of all involved organs, but additionally, should lend themselves to reproducible repeated measurements.  It may be the case that, 
on occasion, the largest lesion does not lend itself to reproducible measurement, 
in which circumstance the nex t largest lesion that can be measured reproducibly should 
be selected.  
Lymph nodes merit special mention since they are normal anatomical structures that may be visible by [CONTACT_33490].  As noted above, pathological nodes that are defined as measurable and may be identified as target lesions must meet the criterion of a short axis of ≥
 [ADDRESS_437536] in which the image is obtained (for CT scan, this 
is almost always the axial plane; for MRI the plane of acquisition may be axial , sagittal, 
or coronal).  The smaller of these measures is the short axis.  For example, an abdominal node that is reported as being 20 mm
 × 30 mm has a short axis of 20 mm and 
qualifies as a malignant, measurable node.  In this example, 20  mm should be recorded 
as the node measurement.  All other pathological nodes (those with short axis ≥  10 mm 
but < 15 mm) should be considered non- target lesions.  Nodes that have a short axis 
< 10 mm are considered non- pathological and should not be recorded or followed.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
149/Protocol CO39721, Version 5  Appendix  3 
Response Evaluation Criteria in Solid Tumors:  Modified Excerpt 
from Original Publication (cont.)   
A sum of the diameters (longest for non- nodal lesions, short axis for nodal lesions) for  all 
target lesions will be calculated and reported as th e baseline sum of diameters .  If lymph 
nodes are to be included in the sum, then, as noted above, only the short axis is added 
into the sum.  The baseline sum of diameters will be used as a reference to further characterize any objective tumor regression i n the  measurable dimension of the disease.  
All other lesions (or sites of disease), including pathological lymph nodes, should be 
identified as non -target lesions and should also be recorded at baseline.  Measurements 
are not required and these lesions should be followed as “present,” “absent,” or in rare 
cases “unequivocal progression.” 
In addition, it is possible to record multiple non- target lesions involving the same organ 
as a single item on the Case Report Form (CRF) (e.g., “multiple enlarged pelvic lymph nodes” or “multiple liver metastases”). 
RESPONSE CRITERIA  
Evaluation of Target Lesions  
This section provides the definitions of the criteria used to determine objective tumor 
response for target lesions.  
• Complete response (CR) :  disappearance of al l target lesions  
Any pathological lymph nodes (whether target or non- target) must have 
reduction in short axis to < 10 mm.  
• Partial response (PR) :  at least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum of di ameters  
• Progressive disease (PD) :  at least a 20% increase in the sum of diameters 
of target lesions, taking as reference the smallest sum on study (nadir), 
including  baseline 
In addition to the relative increase of 20%, the sum must also demonstrate 
an absolute increase of at least 5 mm.  
The appearance of one or more new lesions is also considered progression.  
• Stable disease (SD) :  neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum  on study  
 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
150/Protocol CO39721, Version 5  Appendix  3 
Response Evaluation Criteria in Solid Tumors:  Modified Excerpt 
from Original Publication (cont.)   
Special Notes on the Assessment of Target Lesions  
Lymph Nodes.   Lymph nodes identified as target lesions should always have the actual 
short axis measurement recorded (measured in the same anatomical plane as the 
baseline examination), even if the nodes regress to < 10 mm on study.  This  means that 
when lymph nodes are included as target lesions, the sum of lesions may not be zero 
even if CR criteria are met since a normal lymph node is defined as having a short axis 
< 10 mm.  
Target Lesions That Become Too Small to Measure.   While in the study, all lesions 
(nodal and non- nodal) that are recorded at baseline should be recorded as actual 
measurements at each subsequent evaluation, even when very small (e.g., 2 mm).  
However, sometimes lesions or lymph nodes that are recorded as target lesions at baseline become so faint on the CT scan that the radiologist may not feel comfortable 
assigning an exact measure and may report them as being too small to measure.  When 
this occurs, it is important that a value be recorded on the CRF as follows:  
• If it is the opi[INVESTIGATOR_26191], 
the measurement should be recorded as 0 mm.  
• If the lesion is believed to be present and is faintly seen but too small to measure, a 
default value of 5 mm should be assigned and below  measurable limit (BML) should 
be ticked.  (Note:  It is less likely that this  rule will be used for lymph nodes since they 
usually have a definable size when normal and  are frequently surrounded by [CONTACT_40911]; however, if  a lymph node is believed to be present and 
is faintly seen but too small to measure, a default value of 5 mm should be  assigned 
in this circumstance as well and BML should also be ticked.)  
 
To reiterate, however, if the radiologist is able to provide an actual measure, that should 
be recorded,  even if it is below [ADDRESS_437537] diameter for the coalesced lesion.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
151/Protocol CO39721, Version 5  Appendix  3 
Response Evaluation Criteria in Solid Tumors:  Modified Excerpt 
from Original Publication (cont.)   
Evaluation of Non- target Lesions  
This section provides the definitions of the criteria used to determine the tumor response 
for the group of non- target lesions.  While some non- target lesions may actually be 
measurable, they need not be measured and, instead, should be assessed only 
qualitatively at the timepoints specified in the protocol.  
• CR:  disappearance of all non- target lesions and (if  applicable) normalization of 
tumor marker level)  
All lymph nodes must be non- pathological in size ( < 10 mm short axis).  
• Non-CR/Non -PD:  persistence of one or more  non-target lesion(s) and/or (if 
applicable) maintenance of tumor marker level above the normal limits  
• PD:  unequivocal progression of existing non -target lesions  
The appearance of one or more new lesions is also considered progression.  
 
Special Notes on A ssessment of Progression of Non- target Disease  
When the Patient Also Has Measurable Disease.   In this setting, to achieve 
unequivocal progression on the basis of the non -target disease, there must be an overall 
level of substantial worsening in non -target disease in a magnitude that, even in the 
presence of SD or PR in target disease, the overall tumor burden has increased 
sufficiently to merit discontinuation of therapy.  A modest increase in the size of one or more non- target lesions is usually not sufficient to qualify for unequivocal progression 
status.  The designation of overall progression solely on the basis of change in non-
target disease in the face of SD or PR of target disease will therefore be extremely rare.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
152/Protocol CO39721, Version 5  Appendix  3 
Response Evaluation Criteria in Solid Tumors:  Modified Excerpt 
from Original Publication (cont.)   
When the Patient Has Only Non- Measurable Disease.   This circumstance arises in 
some Phase III studies when it is not a criterion of study entry to have measurable 
disease.  The same general concepts apply here as noted above; however, in this instance, there is no measurable disease assessment to factor into the interpretation of an increase in non- measurable disease burden.  Because worsening in non- target 
disease cannot be easily quantified (by [CONTACT_108]:  if all lesions are truly non- measurable), 
a useful test that can be applied when assessing patients for unequivocal progression is to consider if the  increase in overall disease burden based on the change in non-
measurable disease is comparable in magnitude to the increase that would be required 
to declare PD for measurable disease, that is, an increase in tumor burden representing an additional 73%  increase in volume (which is equivalent to a 20%  increase in diameter 
in a measurable lesion).  Examples include an increase in a pleural effusion from “trace” to “large” or an increase in lymphangitic disease from localized to widespread or may 
be described in protocols as “sufficient to require a change in therapy.”  If unequivocal 
progression is seen, the patient should be considered to have had overall PD at that 
point.  While it would be ideal to have objective criteria to apply to non- measurable 
disease, the very nature of that disease makes it impossible to  do so; therefore, the 
increase must be substantial.  
New Lesions  
The appearance of new malignant lesions denotes disease progression; therefore, some  
comments on detection of new lesions are important.  There are no specific criteria for the identification of new radiographic lesions; however, the finding of a new lesion 
should be unequivocal, that is, not attributable to differences in scanning technique, 
change in imaging  modality, or findings thought to represent something other than tumor 
(for example, some  “new” bone lesions may be simply healing or  flare of preexisting 
lesions).  This is  particularly important when the patient ’s baseline lesions show partial or 
complete  response.  For example, necrosis of a liver lesion may be reported on a CT 
scan report as a “ new” cystic lesion, which it is not.  
A lesion identified during the study in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression.  
If a new lesion is equivocal, for example because of its small size, continued therapy and follow -up evaluation will clarify if it represents truly new disease.  If repeat scans confirm 
there is definitely a new lesion, then progression should be declared using the date of the initial scan.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
153/Protocol CO39721, Version 5  Appendix  3 
Response Evaluation Criteria in Solid Tumors:  Modified Excerpt 
from Original Publication (cont.)   
EVALUATION OF RESPON SE 
Timepoint Response (Overall Response)  
It is assumed that at each protocol- specified timepoint, a response assessment occurs.   
Table [ADDRESS_437538] non- measurable (ther efore non -target) disease only, Table 2  is to 
be used.  
Table  1 Timepoint Response:  Patients with Target Lesions  
(with or without Non- target Lesions)  
Target Lesions  Non- target Lesions  New Lesions  Over all Response  
CR CR No CR 
CR Non- CR/non- PD No PR 
CR Not evaluated  No PR 
PR Non- PD or not all 
evaluated  No PR 
SD Non- PD or not 
all evaluated  No SD 
Not all evaluated  Non- PD No NE 
PD Any Yes or no  PD 
Any PD Yes or no  PD 
Any Any Yes PD 
CR  = complete response; NE  = not evaluable; PD  = progressive disease; 
PR  = partial  response; SD  = stable disease.   
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
154/Protocol CO39721, Version 5  Appendix  3 
Response Evaluation Criteria in Solid Tumors:  Modified Excerpt 
from Original Publication (cont.)   
Table  2 Timepoint Response:  Patients with Non- target Lesions Only  
Non- target Lesions  New Lesions  Overall Response  
CR No CR 
Non- CR/non- PD No Non- CR/non- PD a 
Not all evaluated  No NE 
Unequivocal PD  Yes or no  PD 
Any Yes PD 
CR  = complete response; NE  = not evaluable; PD  = progressive disease.  
a “Non- CR/non -PD” is preferred over “stable disease” for non- target 
disease since stable disease is increasingly used as an endpoint for 
assessment of efficacy in some studies; thus, assigning “stable disease” 
when no lesions can be m easured is not advised.   
Missing Assessments and Not -Evaluable Designation  
When no imaging/measurement is done at all at a particular timepoint, the patient is not 
evaluable at that timepoint.  If only a subset of lesion measurements are made at an assessment, usually the case is also considered not evaluable at that timepoint, unless a convincing argument can be made that the contribution of the individual missing lesion(s) would not change the assigned timepoint response.  This would be most likely to happen in the case of PD.  For example, if a patient had  a baseline sum of [ADDRESS_437539] achieved PD  status, regardless of the con tribution 
of the missing lesion.  
If one or more target lesions were not assessed either because the scan was not done 
or the scan could not be assessed because of poor image quality or obstructed view, the response for target lesions should be “unable to assess” since the patient is not evaluable.  Similarly, if one or more non -target lesions are not assessed, the response 
for non- target lesions should be “unable to assess” except where there is clear 
progression.  Overall response would be “unable to assess” if either the target response or the non -target response is “unable to assess,” except where this  is clear evidence of 
progression as this equates with the case being not evaluable at that timepoint.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
155/Protocol CO39721, Version 5  Appendix  3 
Response Evaluation Criteria in Solid Tumors:  Modified Excerpt 
from Original Publication (cont.)   
Table  [ADDRESS_437540] Overall Response  
CR CR CR 
CR PR SD, PD, or PR a 
CR SD SD, provided minimum duration 
for SD was met; otherwise, PD  
CR PD SD, provided minimum duration 
for SD was met; otherwise, PD  
CR NE SD, provided minimum duration 
for SD was met; otherwise, NE  
PR CR PR 
PR PR PR 
PR SD SD 
PR PD SD, provided minimum duration for SD was met; otherwise, PD  
PR NE SD, provided minimum duration 
for SD was met; otherwise, NE  
NE NE NE 
CR  = complete response; NE  = not evaluable; PD  = progressive disease; PR  = partial response; 
SD  = stable disease.  
a If a CR is truly met at the first timepoint, any disease seen at a subsequent timepoint, even  disease meeting PR criteria relative to baseline, qualifies as PD at that point 
(since  disease must have reappeared after CR).  Best response would depend on whet her 
the minimum duration for SD was met.  However, sometimes CR may be claimed when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR, at the first timepoint.  Under these circumstances, the original CR  should be 
changed to PR  and the best response is PR.  
 
Special Notes on Response Assessment  
When nodal disease is included in the sum of target lesions and the nodes decrease to 
“normal” size ( < 10 mm), they may still have a measurement reported on scans.   This 
measurement should be recorded even though the nodes are normal in order not to overstate progression should it be based on increase in size of the nodes.  As noted earlier, this means that patients with CR may not have a total sum of “zero” on the CRF.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
156/Protocol CO39721, Version 5  Appendix  3 
Response Evaluation Criteria in Solid Tumors:  Modified Excerpt 
from Original Publication (cont.)   
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be  reported as 
“symptomatic deterioration.”  Every effort should be made to document objective progression even after discontinuation of treatment.  Symptomatic deterioration is not a descriptor of an objective response; it is a reason for stoppi[INVESTIGATOR_12003].  The objective response status of such patients is to be determined by [CONTACT_12157]- target disease as shown in Table  1 , Table 2 , and Table 3 . 
For equivocal findings of progression (e.g., very small and uncertain new lesions; cystic changes or necrosis in existing lesions), treatment may continue until the next scheduled assessment.  If at the next scheduled assessment progression is confirmed, the date of progression should be the earlier date when progression was suspected.  
In studies for which patients with advanced disease are eligible (i.e., primary disease still or partially present), the primary tumor should also be captured as a target or non- target 
lesion, as  appropriate.  This is to avoid an incorrect assessment of complete response if 
the primary tumor is still present but not evaluated as a target or non- target lesion.  
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
157/Protocol CO39721, Version 5  Appendix  4  
Response Evaluation Criteria in Solid Tumors:  
Modified -Immune Criteria (Excerpt from Original Publication)  
Conventional response criteria may not be adequate to characterize the anti -tumor 
activity of immunotherapeutic agents like atezolizumab, which can produce delayed 
responses that may be preceded by  [CONTACT_246789], including 
the appearance of new lesions.  Therefore, immune- modified response criteria have 
been developed to incorporate new lesions into the assessment of total tumor burden and allow radiographic progression to be confirmed at a subsequent assessment.  Immune- modified Response Evaluation Criteria in Solid Tumors (RECIST), as described 
within this appendix, were adapted from RECIST, Version 1.1 (v1.1) (Eisenhauer et al. 
2009) , in the same manner that immune- related response criteria were adapted from 
WHO criteria (Wolchok et al. 2009)  and RECIST v1.0 (Nishino et al. 2014 )
.  When not 
otherwise specified, RECIST v1.[ADDRESS_437541]  
Measurable new lesions  Always represent progression  Incorporated into the total tumor 
burden a and followed  
Non- measurable new 
lesions  Always represent progression  Do not represent progression, but preclude CR  
Non- target lesions  Contribute to defining CR, PR, SD, and PD  Contribute to defining CR only 
CR Disappearance of all lesions  Disappearance of all lesions  
PR ≥ 30% decrease in sum of 
diameters of target lesions, in the absence of CR, new lesions, and unequivocal progression in non- target 
lesions  ≥
 30% decrease in tumor burden, a 
in the absence of CR  
PD ≥ 20% increase in sum of 
diameters of target lesions, unequivocal progression in non-target lesions, and/or 
appearance of new lesions  ≥
 20% increase in tumor burden a 
SD Neither sufficient shrinkage to 
qualify for CR or PR nor 
sufficient increase to qualify for 
PD Neither sufficient shrinkage to 
qualify for CR or PR nor sufficient 
increase to qualify for PD  
CR  = complete response; PD  = progressive disease; PR  = partial response; RECIST  = Response 
Evaluation Criteria in Solid Tumors; SD  = stable disease.  
a Tumor burden is the sum of diameters of target lesions and measurable new lesions.   
 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors:   
Modified-Immune Criteria (Excerpt from Original Publication) 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
158/Protocol CO39721, Version 5  TUMOR MEASURABILITY  
At baseline, tumor lesions/lymph nodes will be categorized as measurable or 
non-measurable as described below.  All measurable and non- measurable lesions 
should be assessed at screening and at subsequent protocol -specified tumor 
assessment timepoints.  Additional assessments may be performed as clinically indicated for suspi[INVESTIGATOR_55519].   
DEFINITION OF MEASUR ABLE LESIONS  
Tumor Lesions  
Tumor lesions must be accurately measured in at least one dimension (longest diameter 
in the plane of measurement is to be recorded) with a minimum size as follows :  
• 10 mm by [CONTACT_20420] (CT) or magnetic resonance imaging (MRI) scan 
(CT/MRI scan slice thickness/interval ≤  5 mm) 
• 10-mm caliper measurement by [CONTACT_12148] (lesions that cannot be 
accurately measured with calipers should be recorded as non- measurable)  
• [ADDRESS_437542] be 
≥ [ADDRESS_437543]  scan (CT scan slice thickness 
recommended to be ≤ 5 mm).  At baseline and follow- up, only the short axis will be 
measured and followed.  Additional information on lymph node measurement is provided below (see "Identification of Target and Non-Target Lesions," "New Lesions," and "Calculation of Sum of Diameters").  
DEFINITION OF NON- MEASURABLE LESIONS 
Non-measurable tumor lesions encompass small lesions (longest diameter < 10 mm or 
pathological lymph nodes with short axis ≥  10 mm but < 15 mm) as well as truly 
non-measurable lesions.  Lesions considered truly non- measurable include 
leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal mass/abdominal organomegaly identified by [CONTACT_351881].  
SPECIAL CONSIDERATIO NS REGARDING LESION MEASURABILITY  
Bone lesions, cystic lesions, and lesions previously treated with local therapy require particular comment, as outlined below.  
 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors:   
Modified-Immune Criteria (Excerpt from Original Publication) 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
159/Protocol CO39721, Version 5  Bone Lesions:  
• Technetium -99m bone scans, sodium fluoride positron emission tomography scans, 
and plain films are not considered adequate imaging techniques for measuring bone 
lesions.  However, these techniques can be used to confirm the presence or disappearance of bone lesions.  
• Lytic bone lesions or mixed lytic -blastic lesions with identifiable soft tissue 
components  that can be evaluated by [CONTACT_12783] -sectional imaging techniques such as 
CT or MRI can be considered measurable lesions if the soft tissue component 
meets  the definition of measurability described above.  
• Blastic bone lesions are non- measurable.  
 
Cystic Lesions:  
• Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered malignant lesions (neither measurable nor non- measurable) since they 
are, by [CONTACT_351882], simple cysts.  
• Cystic lesions thought to represent cystic metastases can be considered measurable lesions if they meet the definition of measurability described above.  
However, if non -cystic lesions are present in the same patient, these are pref erred 
for selection as target lesions.  
 
Lesions with Prior Local Treatment: 
• Tumor lesions situated in a previously irradiated area or in an area subjected to 
other loco- regional therapy are usually not considered measurable unless there has 
been demonstrated progression in the lesion.  
 
METHODS FOR ASSESSIN G LESIONS  
All measurements should be recorded in metric notation, using calipers if clinically 
assessed.  All baseline evaluations should be performed as close as possible to the treatment start and never more than 4 weeks before the beginning of the treatment.  
The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during the study.  Imaging -based evaluation should always be the preferred option.  
 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors:   
Modified-Immune Criteria (Excerpt from Original Publication) 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
160/Protocol CO39721, Version 5  CLINICAL LESIONS  
Clinical lesions will only be considered measurable when they are superficial and 
≥ 10 mm in diameter as assessed using calipers (e.g., skin nodules).  For the case of 
skin lesions, documentation by [CONTACT_6775], including a ruler to estimate the size of the lesion, is suggested.  
CHEST X -RAY  
Chest CT is preferred over chest X- ray, particularly when progression is an important 
endpoint, since CT is more sensitive than X -ray, particularly in identifying new lesions.  
However, lesions on chest X- ray may be considered measurable if they are clearly 
defined and surrounded by [CONTACT_6776].  
CT AND MRI SCANS  
CT is the best currently available and reproducible method to measure lesions selected for response assessment.  In this guideline, the definition of measurability of lesions on CT scan is based on the assumption that CT slice thickness is ≤
 [ADDRESS_437544] slice thickness of > [ADDRESS_437545] scans with intravenous (IV) contrast because of allergy or renal insufficiency, the decision as to whether a non- contrast CT or MRI (without IV contrast) will be used to evaluate the 
patient at baseline and during the study should be guided by [CONTACT_234632].  For patients who develop contraindications to contrast after baseline contrast CT is done,  the decision as to 
whether non- contrast CT or MRI (enhanced or non- enhanced) will be performed should 
also be based on the tumor type and the anatomic location of the disease, and should be optimized to allow for comparison with the prior studies if possi ble.  Each case should 
be discussed with the radiologist to determine if substitution of these other approaches is possible and, if not, the patient should be considered not evaluable from that point 
forward.  Care must be taken in measurement of target lesions and interpretation of 
non-target disease or new lesions on a different modality, since the same lesion may 
appear to have a different size using a new modality.  
ENDOSCOPY, LAPAROSCOPY, ULTRASOUND, TUMOR MARKERS, 
CYTOLOGY, HISTOLOGY  
Endoscopy, laparoscopy, ultrasound, tumor markers, cytology, and histology cannot be 
utilized for objective tumor evaluation.  
 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors:   
Modified-Immune Criteria (Excerpt from Original Publication) 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
161/Protocol CO39721, Version 5  ASSESSMENT OF TUMOR BURDEN  
To assess objective response or future progression, it is necessary to estimate the 
overall tumor burden at baseline and use this as a comparator for subsequent measurements.  
IDENTIFICATION OF TA RGET AND NON- TARGET LESIONS  
When more than one measurable lesion is present at baseline, all lesions up to a maximum of five lesions total (and a maximum of two lesions per organ) re presentative 
of all involved organs should be identified as target lesions and will be recorded and measured at baseline.  This means that, for instances in which patients have only one or two organ sites involved, a maximum of two lesions (one site) and four lesions (two sites), respectively, will be recorded.  Other lesions (albeit measurable) in those organs will be considered non- target lesions.   
Target lesions should be selected on the basis of their size (lesions with the longest diameter) and be representative of all involved organs, but in addition should lend themselves to reproducible repeated measurements.  It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement, in which circumstance the next largest lesion that can be measured reproducibly should be selected.  
Lymph nodes merit special mention since they are normal anatomical structures that may be visible by [CONTACT_33490].  As noted above, pathological nodes that are defined as measurable and may be identified as target lesions must meet the criterion of a short axis of ≥
 [ADDRESS_437546] in which the image is obtained (for CT, this is almost always the axial plane; for MRI, the plane of acquisition may be axial, sagittal, or coronal).  The smaller of these measures is the short axis.  For example, an 
abdominal node that is reported as being 20 mm
 × 30 mm has a short axis of 20 mm and 
qualifies as a malignant, measurable node.  In this example, 20 mm should be recorded as the node measurement.  All other pathological nodes (those with short axis ≥
 10 mm 
but < 15 mm) should be considered non- target lesions.  Nodes that have a short axis of 
< 10 mm are considered non- pathological and should not be recorded or followed.  
All lesions (or sites of disease) not selected as target lesions (measurable or non-measurable), including pathological lymph nodes, should be identified as non- target 
 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors:   
Modified-Immune Criteria (Excerpt from Original Publication) 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
162/Protocol CO39721, Version [ADDRESS_437547] multiple non- target lesions involving the same organ as a single item 
on the Case Report Form (CRF) (e.g., "multiple enlarged pelvic lymph nodes" or "multiple liver metastases").  
NEW LESIONS  
New lesions identified after baseline will be evaluated for measurability with use of the same criteria applied to prospective target lesions at baseline per RECIST (e.g.,  non− lymph  node lesions must be ≥
 [ADDRESS_437548] diameter; new lymph 
nodes must be ≥ 15 mm on the short axis [see note below]).  All new lesions 
(measurable or non -measurable) must be assessed and recorded at the time of 
identification and at all subsequent tumor assessment timepoints.  
Up to a maximum of five measurable new lesions total (and a maximum of two lesions per organ) can be included in the calculation of tumor burden that is performed as part of the tumor response evaluation.  New lesion types that would not qualify as target lesions per RECIST cannot be included in the calculation of tumor burden and thus will not affect overall tumor response evaluation.  New lesions that are not measurable at first appearance but meet measurability criteria at a subsequent timepoint can be included in the tumor response evaluation from that point on, if the maximum number of measurable new lesions has not been reached.  
Note regarding new lymph node lesions:  If at first appearance the short axis of a lymph 
node lesion is ≥ [ADDRESS_437549] 
appearance the short axis of a lymph node lesion is ≥  10 mm and < [ADDRESS_437550] appearance the short 
axis o f a lymph node is  <
 10 mm, the lymph node should not be considered pathological 
and should not be considered a new lesion.  A lymph node can subsequently become measurable, when the short axis is ≥
 15 mm.  
CALCULATION OF SUM OF DIAMETERS  
A sum of the diamet ers (longest diameter for non− lymph node lesions, short axis for 
lymph node lesions) will be calculated for all target lesions at baseline as a measure of tumor burden.  At each subsequent tumor assessment, a sum of the diameters  (longest 
diameter for non -lymph node lesions, short axis for lymph node lesions) will be 
calculated for all target lesions plus measurable new lesions (up to five new lesions, with a maximum of two new lesions per organ) that have emerged after baseline.  Hence, 
 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors:   
Modified-Immune Criteria (Excerpt from Original Publication) 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
163/Protocol CO39721, Version [ADDRESS_437551] appearance the short axis of a new lymph node lesion is ≥ 15 mm, it will be 
considered a measurable new lesion and may be included in the sum of the diameters.  
If the new lymph node lesion is included in the sum of diameters, it will continue to be measured and included in the sum of diameters at subsequent timepoints, even if the short axis decreases to <
 15 mm (or even < 10 mm).  However, if it subsequently 
decreases to <  [ADDRESS_437552] also 
decreased to a short axis of <  10 mm (if lymph nodes), a response assessment of 
complete response may be assigned.  
Lymph nodes should always have the actual short axis measurement recorded (measured in the same anatomical plane as the baseline examination), even if the node regresses to <
 10 mm during the study.  Thus, when lymph nodes are included in the 
sum of diameters, the sum may not be zero even if complete response criteria are met, since a normal lymph node is defined as having a short axis of <
 10 mm. 
Measuring Lesions That Become Too Small to Measure  
During the study, all target lesions and up to five measurable new lesions (lymph node and non− lymph node) should have their actual measurements recorded at each 
subsequent evaluation, even when very small (e.g., 2 mm).  However, somet imes 
lesions or lymph nodes become so faint on CT scan that the radiologist may not feel comfortable assigning an exact measurement and may report them as being too small to measure.  When this occurs, it is important that a value be recorded on the CRF, as 
follows:  
• If it is the opi[INVESTIGATOR_26191], the 
measurement should be recorded as 0 mm.  
• If the lesion is believed to be present and is faintly seen but too small to measure, a default value of 5 mm should be assigned and "too small to measure" should be 
ticked.  (Note:  It is less likely that this rule will be used for lymph nodes since they 
usually have a definable size when normal and are frequently surrounded by [CONTACT_169902]; however, if a lymph node is believed to be present 
and is faintly seen but too small to measure, a default value of 5 mm should be assigned in this circumstance as well and "too small to measure" should also be 
ticked).  
 
 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors:   
Modified-Immune Criteria (Excerpt from Original Publication) 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
164/Protocol CO39721, Version [ADDRESS_437553] is able to provide an actual measurement, that 
should be recorded, even if it is < 5 mm, and in that case "too small to measure" should 
not be ticked.  
Measuring Lesions That Split or Coalesce on Treatment  
When non −lymph node lesions fragment, the longest diameters of the fragmented 
portions should be added together to calculate the sum of diameters.  Similarly, as 
lesions coalesce, a plane between them may be maintained that would aid in obtaining maximal diameter m easurements of each individual lesion.  If the lesions have truly 
coalesced such that they are no longer separable, the vector of the longest diameter in this instance should be the maximum longest diameter for the coalesced lesion.  
EVALUATION OF NON -TARGE T LESIONS AND NON- MEASURABLE 
NEW  LESIONS  
Measurements are not required for non -target lesions or non- measurable new lesions.  
Non-target lesions should be noted at baseline, and non-measurable new lesions should 
be noted at the time of identification.  At subsequent evaluations, non -target lesions and 
non-measurable new lesions will be categorized as "present" or "absent."  
After baseline, changes in non- target lesions or non- measurable new lesions (or 
measurable new lesions in excess of five total or two per organ) will contribute only in the assessment of  complete response (i.e., a complete response is attained only with 
the complete disappearance of all tumor lesions, including non -target lesions and 
non-measurable new lesions) and will not be used to  asse ss progressive disease.  
RESPONSE CRITERIA  
Definitions of the criteria used to determine objective tumor response are provided below:  
• Complete response (CR):  Disappearance of all lesions  
Any pathological lymph nodes must have reduction in short axis to < 10 mm.  
• Partial response (PR):  At least a 30% decrease in the sum of diameters of all target 
lesions plus measurable new lesions (up to a maximum of five total or two per 
organ), taking as reference the baseline sum of diameters, in the absence of CR  
 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors:   
Modified-Immune Criteria (Excerpt from Original Publication) 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
165/Protocol CO39721, Version 5  • Progressive disease (PD):  At least a 20% increase in the sum of diameters of all 
target lesions plus measurable new lesions (up to a maximum of five total or two per 
organ), taking as reference the smallest sum of diameters on study (including 
baseline)  
In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of ≥
 [ADDRESS_437554] tumor 
response.  
• Stable disease (SD):  Neither sufficient shrinkage to qualify for CR or PR nor 
sufficient increase to qualify for PD  
 
CRITERIA FOR OVERALL  RESPONSE AT A SINGLE TIMEPOINT  
Table [ADDRESS_437555] measurable disease at baseline.  
Table  2 Criteria for Overall Response at a Single Timepoint :  Patients 
with Target Lesions (with or without Non- Target Lesions)  
Target Lesions and 
Measurable New Lesions a Non- Target Lesions and 
Non- Measurable New Lesions b Overall Response  
CR Absent  CR 
CR Present or not all evaluated  PR 
PR Any PR 
SD Any SD 
Not all evaluated  Any NE 
PD Any PD 
CR  = complete response; NE  = not evaluable; PD  = progressive disease; PR  = partial 
response; SD  = stable disease.  
a Up to a maximum of five measurable new lesions total (and a maximum of two lesions 
per organ) can be included in the calculation of tumor burden, in addition to the target lesions identified at baseline.  
b Also includes measurable new lesions in excess of five total or two per organ.  
 
 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors:   
Modified-Immune Criteria (Excerpt from Original Publication) 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
166/Protocol CO39721, Version 5  MISSING ASSESSMENTS AND NOT -EVALUABLE DESIGNATIO N 
When no imaging/measurement is done at all at a particular timepoint, the patient is not 
evaluable at that timepoint.  If measurements are made on only a subset of target or measurable new lesions at a timepoint, usually the case is also considered not evaluable at that timepoint, unless a convincing argument can be made that the contribution of the individual missing lesions would not change the assigned timepoint response.  This would be most likely to happen in the case of PD.  For example, if a patient had a baseline sum of [ADDRESS_437556] achieved PD status, regardless of the contribution of the missing lesion.  
SPECIAL NOTES ON RESPONSE ASSESSMENT  
Patients with a global deterioration in health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as "symptomatic deterioration."  Every effort should be made to  document objective 
progression even after discontinuation of treatment.  Symptomatic deterioration is not a descriptor of an objective response; it is a reason for stoppi[INVESTIGATOR_12003].  The objective response status of such patients is to be determined by [CONTACT_70186]- target lesions, as well as new lesions, as shown in Table 1 . 
REFERENCES  
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228 −47.   
Nishino M, Gargano M, Suda M, et al. Optimizing immune -related tumor response 
assessment: does reducing the number of lesions impact response assessment in 
melanoma patients treated with ipi[INVESTIGATOR_125]? J Immunother Can 2014;2:17.  
Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy 
activity in solid tumors: immune -related response criteria. Clin Can Res 
2009;15:7412 −20. 
 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
167/Protocol CO39721, Version 5  Appendix  5  
Eastern Cooperative Oncology Group Performance Status Scale  
Grade  Description  
0 Fully active, able to carry on all predisease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry 
out work  of a light or sedentary nature  (e.g., light housework or office work ) 
2 Ambulatory and capable of all self -care but unable to carry out any work 
activities; up and about >  50% of waking hours  
3 Capable of only limited self -care, confined to a bed or chair >  50% of 
waking hours  
4 Completely disabled; cannot carry on any self -care; totally confined to 
bed or chair  
5 Dead  
 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
168/Protocol CO39721, Version 5  Appendix  6  
Preexisting Autoimmune Diseases and Immune Deficiencies  
Patients should be carefully questioned regarding their history of acquired or congenital 
immune deficiencies or autoimmune disease.  Patients with any history of immune deficiencies or autoimmune disease listed in the table below are excluded from participating in the study.  Possible exceptions to this exclusion could be patients with a medical history of such entities as atopic disease or childhood arthralgias for whom the clinical suspi[INVESTIGATOR_33415].  Patients with a history of autoimmune- related hypothyroidism on a stable dose of thyroid- replacement hormone 
may be eligible for this study.  In addition, transient autoimmune manifestations of an acute infectious disease that resolved upon treatment of the infectious agent are not excluded (e.g.,  acute Lyme arthritis).  Contact [CONTACT_351883].  
Autoimmune Diseases and Immune Deficiencies  
• Acute disseminated 
encephalomyelitis  
• Addison disease  
• Ankylosing spondylitis  
• Antiphospholipid antibody 
syndrome 
• Aplastic anemia 
• Autoimmune hemolytic anemia 
• Autoimmune hepatitis  
• Autoimmune hypoparathyroidism  
• Autoimmune hypophysitis  
• Autoimmune myocarditis  
• Autoimmune oophoritis  
• Autoimmune orchitis  
• Autoimmune thrombocytopenic purpura  
• Behçet disease  
• Bullous pemphigoid  
• Chronic fatigue syndrome 
• Chronic inflammatory 
demyelinating 
polyneuropathy  
• Churg -Strauss syndrome  
• Crohn disease  • Dermatomyositis  
• Diabetes mellitus type 1  
• Dysautonomia  
• Epi[INVESTIGATOR_163515]  
• Gestational pemphigoid  
• Giant cell arteritis  
• Goodpasture syndrome 
• Graves disease  
• Guillain -Barré syndrome 
• Hashimoto disease  
• IgA nephropathy  
• Inflammatory bowel disease 
• Interstitial cystitis  
• Kawasaki disease  
• Lambert -Eaton myasthenia 
syndrome 
• Lupus erythematosus  
• Lyme disease, chronic  
• Meniere syndrome 
• Mooren ulcer  
• Morphea  
• Multiple sclerosis  
• Myasthenia gravis  • Neuromyotonia  
• Opsoclonus my oclonus 
syndrome 
• Optic neuritis  
• Ord thyroiditis  
• Pemphigus  
• Pernicious anemia  
• Polyarteritis nodosa  
• Polyarthritis  
• Polyglandular autoimmune syndrome 
• Primary biliary cirrhosis  
• Psoriasis  
• Reiter syndrome  
• Rheumatoid arthritis  
• S
arcoidosis  
• Scleroderma  
• Sjögren syndrome  
• Stiff-Person syndrome  
• Takayasu arteritis  
• Ulcerative colitis  
• Vitiligo  
• Vogt-Koyanagi -Harada 
disease  
• Wegener granulomatosis  
 
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
169/Protocol CO39721, Version 5  Appendix  7  
Anaphylaxis Precautions  
PRECAUTIONS  
Equipment needed:  
• Tourniquet  
• Oxygen  
• Epi[INVESTIGATOR_33414], intravenous (IV), and/or endotracheal use in 
accordance with standard practice  
• Antihistamines  
• Corticosteroids  
• IV infusion solutions, tubing, catheters, tape  
 
PROCEDURES  
In the event of a suspected anaphylactic reaction during study drug infus ion, the 
following procedures should be performed:  
1. Stop the drug infusion.  
2. Apply a tourniquet proximal to the injection site to slow systemic absorption of study 
drug.  Do not obstruct arterial flow in the limb. 
3. Maintain adequate airway.  
4. Administer antihis tamines, epi[INVESTIGATOR_238], or other medications as required by [CONTACT_351884].  
5. Continue to observe the patient  and document observations
 
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
170/Protocol CO39721, Version [ADDRESS_437557], and in severe cases, immune- related toxi cities 
may require acute management with topi[INVESTIGATOR_11930], systemic corticosteroids, or other immunosuppressive agents.  
The investigator should consider the benefit −risk balance a given patient may be 
experiencing prior to  further administration of  atezolizumab.  In  patients who have met 
the criteria for permanent discontinuation, resumption of atezolizumab may be considered if the patient is deriving benefit and has fully recovered from the immune- related event.  Patients can  be re- challenged with atezolizumab only after 
approval has been documented by [CONTACT_33494] (or an appropriate delegate) and the Medical Monitor.  
PULMONARY EVENTS 
Dyspnea, cough, fatigue, hypoxia, pneumonitis, and pulmonary infiltrates have been associated with the administration of atezolizumab.  Patients will be assessed for pulmonary signs and symptoms throughout the study and will also have computed tomography (CT) scans of the chest performed at every tumor assessment.   
All pulmonary events should be thoroughly evaluated for other commonly reported etiologies such as pneumonia or other infection,  lymphangitic carcinomatosis, pulmonary 
embolism, heart failure, chronic obstructive pulmonary disease, or pulmonary hypertension.   Management guidelines for pulmonary events are provided in Table 1 . 
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
171/Protocol CO39721, Version 5  Table  1 Management Guidelines for Pulmonary Events, Including 
Pneumonitis  
Event  Management  
Pulmonary 
event, Grade 1  • Continue atezolizumab and  monitor closely.  
• Re-evaluate on serial imaging.  
• Consider patient referral to pulmonary specialist.  
Pulmonary event, Grade 2  • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Refer patient to pulmonary and infectious disease specialists and 
consider bronchoscop y or BAL.  
• Initiate treatment with 1− 2 mg/kg/day oral prednisone or equivalent.  
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade [ADDRESS_437558] 
Medical Monitor. c 
• For recurrent events, treat as a Grade 3 or 4 event.  
Pulmonary 
event, Grade 3 
or 4 • Permanently discontinue atezolizumab and contact [CONTACT_25290]. c 
• Bronchoscopy or BAL is recommended.  
• Initiate treatment with 1− 2 mg/kg/day oral prednisone or equivalent.  
• If event does not improve within 48 hours after initiating corticosteroids, consider adding an immunosuppressive agent.  
• If event resolves to Grade 1 or better, taper corticosteroids over ≥
 1 month.  
BAL  = bronchoscopic alveolar lavage.  
a Atezolizumab may be withheld for a longer period of time (i.e., >  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral 
prednisone or equivalent.  The acceptable length of  the extended period of time must be 
agreed upon by [CONTACT_33495].  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune- related event.  Patients can be re- challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor.  
 
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
172/Protocol CO39721, Version [ADDRESS_437559] adequate liver function, as manifested by [CONTACT_33496], and liver function will be monitored throughout study treatment.  Management guidelines for hepatic events are provided in Table 2 . 
Patients with right upper -quadrant abdominal pain and/or unexplained nausea or 
vomiting should have liver function tests (LFTs) performed immediately and reviewed 
before administration of the next dose of study drug.  
For patients with elevated LFTs, concurrent medication, viral hepatitis, and toxic or neoplastic etiologies should be considered and addressed, as  appropriate.  
Table  2 Management Guidelines for Hepatic Events 
Event  Management  
Hepatic event, 
Grade 1  • Continue atezolizumab.  
• Monitor LFTs until values resolve to within normal limits.  
Hepatic event, Grade 2  All events:  
• Monitor LFTs more frequently until return to baseline values.  
Events of >  5 days’ duration : 
• Withhold atezolizumab for up to 12 weeks after event onset. a 
• Initiate treatment with 1− 2 mg/kg/day oral prednisone or 
equivalent.  
• If event resolves to Grade 1 or  better, resume atezolizumab. b 
• If event does not resolve to Grade [ADDRESS_437560] Medical Monitor.
 c 
LFT  = liver function tests.  
a Atezolizumab may be withheld for a longer period of time (i.e., >  12 weeks after 
event onset) to allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day 
oral prednisone or equivalent.  The acceptable length of the extended period of time 
must  be agreed upon by [CONTACT_33495].  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to 
≤ 10 mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully recovered from the immune- related event.  Patients can be 
re-challenged with atezolizumab only after approval has been documented by [CONTACT_33497] (or an appropriate delegate) and the M edical Monitor.  
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
173/Protocol CO39721, Version 5  Table  2 Management Guidelines for Hepatic Events (cont.)   
Event  Management  
Hepatic event, 
Grade 3 or 4  • Permanently discontinue atezolizumab and contact [CONTACT_25290].  
c 
• Consider patient referral to gastrointestinal specialist for evaluation and liver biopsy to establish etiology of hepatic 
injury.  
• Initiate treatment with 1− 2 mg/kg/day oral prednisone or 
equivalent.  
• If event does not improve within 48 hours after initiati ng 
corticosteroids, consider adding an immunosuppressive agent.  
• If event resolves to Grade 1 or better, taper corticosteroids over ≥
 1 month.  
LFT  =liver function tests.  
a Atezolizumab may be withheld for a longer period of time (i.e., >  12 weeks after 
event onset) to allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day 
oral prednisone or equivalent.  The acceptable length of the extended period of time 
must be agreed upon by [CONTACT_33495].  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to 
≤ 10 mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully recovered from the immune- related event.  Patients can be 
re-challenged with atezolizumab only after approval has been documented by [CONTACT_33497] (or an appropriate delegate) and the Medical Monitor.  
 
GASTROINTESTINAL EVENTS  
Immune- related colitis has been associated with the administration of atezolizumab.  
Management guidelines for diarrhea or colitis are provided in Table 3 . 
All events of diarrhea or colitis should be thoroughly evaluated for other more common 
etiologies.  For events of significant duration or magnitude or associated with signs of systemic inflammation or acute -phase reactants (e.g.,  increa sed C -reactive protein, 
platelet count, or bandemia):  Perform sigmoidoscopy (or colonoscopy, if appropriate) with colonic biopsy, with three to five specimens for standard paraffin block to check for inflammation and lymphocytic infiltrates to confirm col itis diagnosis.  
 
 
A p p e n di x 8  
Ri s k s A s s o ci at e d wit h At e z oli z u m a b a n d G ui d eli n e s f or 
M a n a g e m e nt of A d v er s e E v e nt s A s s o ci at e d wit h At e z oli z u m a b 
( c o nt.)   
C o bi m eti ni b a n d At e z oli z u m a b —F.  H off m a n n -L a R o c h e Lt d  
1 7 4 /Pr ot o c ol C O 3 9 7 2 1, V er si o n 5  T a bl e  3 M a n a g e m e nt G ui d eli n e s f or G a str oi nt e sti n al E v e nt s ( Di arr h e a or 
C oliti s)  
E v e nt  M a n a g e m e nt  
Di arr h e a or 
c oliti s, Gr a d e 1  • C o nti n u e at e z oli z u m a b.  
• I niti at e s y m pt o m ati c tr e at m e nt.  
• E n d o s c o p y i s r e c o m m e n d e d if s y m pt o m s p er si st f or > 7 d a y s.  
• M o nit or cl o s el y.  
Di arr h e a or 
c oliti s, Gr a d e 2  • Wit h h ol d at e z oli z u m a b f or u p t o 1 2 w e e k s aft er e v e nt o n s et.  a 
• I niti at e s y m pt o m ati c tr e at m e nt.  
• P ati e nt r ef err al t o GI s p e ci ali st i s r e c o m m e n d e d.  
• For r e c urr e nt e v e nt s or e v e nt s t h at p er si st  5 d a y s, i niti at e tr e at m e nt 
wit h 1 −2 m g/ k g/ d a y or al pr e d ni s o n e or e q ui v al e nt.  
• If e v e nt r e s ol v e s t o Gr a d e 1 or b ett er, r e s u m e at e z oli z u m a b.  b  
• If e v e nt d o e s n ot r e s ol v e t o Gr a d e [ADDRESS_437561] 
M e di c al M o nit or.  c  
Di arr h e a or 
c oliti s, Gr a d e 3  • Wit h h ol d at e z oli z u m a b  f or u p t o 1 2 w e e k s aft er e v e nt o n s et.  a  
• R ef er p ati e nt t o GI s p e ci ali st f or e v al u ati o n a n d c o nfir m at or y bi o p s y.  
• I niti at e tr e at m e nt wit h 1 −2 m g/ k g/ d a y I V m et h yl pr e d ni s ol o n e or 
e q ui v al e nt a n d c o n v ert t o 1−2 m g/ k g/ d a y or al pr e d ni s o n e or e q ui v al e nt  
u p o n i m pr o v e m e nt.  
• If e v e nt r e s ol v e s t o Gr a d e 1 or b ett er, r e s u m e at e z oli z u m a b.  b  
• If e v e nt d o e s n ot r e s ol v e t o Gr a d e [ADDRESS_437562] 
M e di c al M o nit or.  c  
GI  = g a str oi nt e sti n al.  
a At e z oli z u m a b m a y b e wit h h el d f or a l o n g er p eri o d of ti m e (i. e., > 1 2 w e e k s aft er e v e nt 
o n s et) t o all o w f or c orti c o st er oi d s (if i niti at e d) t o b e r e d u c e d t o ≤ 1 0 m g/ d a y or al 
pr e d ni s o n e or e q ui v al e nt.  T h e a c c e pt a bl e l e n gt h of t h e e xt e n d e d p eri o d of ti m e m u st b e 
a gr e e d u p o n b y t h e i n v e sti g at or a n d t h e M e di c al M o nit or.  
b If c orti c o st er oi d s h a v e b e e n i niti at e d, t h e y m u st b e t a p er e d o v er ≥ 1 m o nt h t o ≤ 1 0 m g/ d a y 
or al pr e d ni s o n e or e q ui v al e nt b ef or e at e z oli z u m a b c a n b e r e s u m e d.  
c R e s u m pti o n of at e z oli z u m a b m a y b e c o n si d er e d i n p ati e nt s w h o ar e d eri vi n g b e n efit a n d 
h a v e f ull y r e c o v er e d fr o m t h e i m m u n e -r el at e d e v e nt.  P ati e nt s c a n b e r e -c h all e n g e d wit h 
at e z oli z u m a b o nl y aft er a p pr o v al h a s b e e n d o c u m e nt e d b y b ot h t h e i n v e sti g at or ( or a n 
a p pr o pri at e d el e g at e) a n d t h e M e di c al M o nit or.  
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
175/Protocol CO39721, Version 5  Table  3 Management Guidelines for Gastrointestinal Events (Diarrhea or 
Colitis) (cont.)  
Event  Management  
Diarrhea or 
colitis, Grade 4  • Permanently discontinue atezolizumab and contact [CONTACT_25290]. c 
• Refer patient to GI specialist for evaluation and confirmation biopsy.  
• Initiate treatment with 1−2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 1 −2 mg/kg/day oral prednisone or 
equivalent  upon improvement.  
• If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
• If event resolves to Grade 1 or better, taper corticosteroids over 
≥ 1 month.  
GI  = gastrointestinal.  
a Atezolizumab may be withheld for a longer period of time (i.e., >  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be 
agreed upon by [CONTACT_33495].  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune- related event.  Patients can be re- challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor.  
 
ENDOCRINE EVENTS  
Thyroid disorders, adrenal insufficiency, diabetes mellitus, and pi[INVESTIGATOR_33417].  Management guidelines for endocrine events are provided in Table [ADDRESS_437563] if an endocrinopathy is suspected.  Thyroid- stimulating hormone (TSH) 
and free triiodothyronine and thyroxine levels should be measured to determine whether thyroid abnormalities are present.  Pi[INVESTIGATOR_33418] (e.g., TSH, growth hormone, luteinizing hormone, follicle- stimulating hormone, testosterone, 
prolactin, adrenocorticotropic hormone [ACTH] levels, and ACTH stimulation test) and magnetic resonance imaging (MRI) of the brain (with detailed pi[INVESTIGATOR_33419]) may help to differentiate primary pi[INVESTIGATOR_33420].  
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
176/Protocol CO39721, Version 5  Table  4 Management Guidelines for Endocrine Events  
Event  Management  
Asymptomatic 
hypothyroidism • Continue atezolizumab.  
• Initiate treatment with thyroid replacement hormone.  
• Monitor TSH weekly.  
Symptomatic 
hypothyroidism • Withhold atezolizumab.  
• Initiate treatment with thyroid replacement hormone.  
• Monitor TSH weekly.  
• Consider patient referral to endocrinologist.  
• Resume atezolizumab when symptoms are controlled and thyroid function is improving.  
Asymptomatic hyperthyroidism  TSH ≥ 0.1 mU/L and < 0.5 mU/L:  
• Continue atezolizumab.  
• Monitor TSH every 4 weeks.  
TSH < 0.1 mU/L:  
• Follow guidelines for symptomatic hyperthyroidism.  
Symptomatic hyperthyroidism  • Withhold atezolizumab.  
• Initiate treatment with anti -thyroid drug such as methimazole 
or carbimazole as needed.  
• Consider patient referral to endocrinologist.  
• Resume atezolizumab when symptoms are controlled and thyroid function is improving.  
• Permanently discontinue atezolizumab and contact [CONTACT_246795]- threatening immune- related hyperthyroidism.
 c 
MRI  = magnetic resonance imaging; TSH  = thyroid -stimulating hormone.  
a Atezolizumab may be withheld for a longer period of time (i.e., >  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be 
agreed upon by [CONTACT_33495].  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune- related event.  Patients can be re- challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor.  
  
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
177/Protocol CO39721, Version 5  Table  4 Management Guidelines for Endocrine Ev ents (cont.)  
Event  Management  
Symptomatic adrenal 
insufficiency, 
Grade 2−4  • Withhold atezolizumab for up to 12 weeks after event onset . a 
• Refer patient to endocrinologist.  
• Perform appropriate imaging.  
• Initiate treatment with 1−2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 1−2 mg/kg/day oral prednisone or 
equivalent  upon improvement . 
• If event resolves to Grade 1 or better and patient is stable on replacement therapy, resume atezolizumab.
 b 
• If event does not resolve to Grade [ADDRESS_437564] Medical 
Monitor.
 c 
Hyperglycemia, 
Grade 1 or 2  • Continue atezolizumab.  
• Initiate treatment with insulin if needed.  
• Monitor for glucose control.  
Hyperglycemia, Grade 3 or 4  • Withhold atezolizumab.  
• Initiate treatment with insulin.  
• Monitor for glucose control.  
• Resume atezolizumab when symptoms resolve and glucose 
levels are stable.  
MRI  = magnetic resonance imaging; TSH  = thyroid -stimulating hormone.  
a Atezolizumab may be withheld for a longer period of time (i.e., >  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be 
agreed upon by [CONTACT_33495].  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune- related event.  Patients can be re- challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor.  
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
178/Protocol CO39721, Version 5  Table  4 Management Guidelines for Endocrine Events (cont.)   
Event  Management  
Hypophysitis 
(pan- hypopi[INVESTIGATOR_297]), 
Grade 2 or 3  • Withhold atezolizumab for up to 12 weeks after event onset . a 
• Refer patient to endocrinologist.  
• Perform brain MRI (pi[INVESTIGATOR_33421]).  
• Initiate treatment with 1−2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 1−2 mg/kg/day oral prednisone or 
equivalent  upon improvement.  
• Initiate hormone replacement if clinically indicated.  
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade [ADDRESS_437565] M edical Monitor. c 
• For recurrent hypophysitis, treat as a Grade 4 event.  
Hypophysitis 
(pan- hypopi[INVESTIGATOR_297]), 
Grade 4  • Permanently discontinue atezolizumab and contact [CONTACT_31807]. c 
• Refer patient to endocrinologist.  
• Perform brain MRI (pi[INVESTIGATOR_33421]).  
• Initiate treatment with 1−2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 1−2 mg/kg/day oral prednisone or 
equivalent  upon improvement.  
• Initiate hormone replacement if clinically indicated.  
MRI  = magnetic resonance imaging; TSH  = thyroid -stimulating hormone.  
a Atezolizumab may be withheld for a longer period of time (i.e., >  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be 
agreed upon by [CONTACT_33495].  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully recovered from the immune- related event.  Patients can be re- challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor.  
 
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
179/Protocol CO39721, Version [ADDRESS_437566] should evaluate visual complaints (e.g., uveitis, retinal events).  
Management guidelines for ocular events are provided in Table 5 . 
Table  5 Management Guidelines for Ocular Events 
Event  Management  
Ocular event, 
Grade 1  • Continue atezolizumab.  
• Patient referral to ophthalmologist is strongly recommended.  
• Initiate treatment with topi[INVESTIGATOR_33422].  
• If symptoms persist, treat as a Grade 2 event.  
Ocular event, 
Grade 2  • Withhold atezolizumab for up to 12 weeks after event onset . a 
• Patient referral to ophthalmologist is strongly recommended.  
• Initiate treatment with topi[INVESTIGATOR_33422].  
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade [ADDRESS_437567] 
Medical Monitor. c 
Ocular event, Grade 3 or 4  • Permanently discontinue atezolizumab and contact [CONTACT_25290].
 c 
• Refer patient to ophthalmologist.  
• Initiate treatment with 1− 2 mg/kg/day oral prednisone or equivalent.   
• If event resolves to Grade 1 or better, taper corticosteroids over ≥
 1 month.  
a Atezolizumab may be withheld for a longer period of time (i.e., >  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must  be 
agreed upon by [CONTACT_33495].  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to 
≤ 10 mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune- related event.  Patients can be re- challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the M edical Monitor.  
 
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
180/Protocol CO39721, Version [ADDRESS_437568] pain, palpi[INVESTIGATOR_814], fatigue, decreased exercise tolerance, or syncope.  Immune- related myocarditis needs to be distinguished from myocarditis resulting from 
infection (commonly viral, e.g., in a patient who reports a recent history of gastrointestinal illness), ischemic events, underlying arrhythmias, exacerbation of preexisting cardiac conditions, or progression of malignancy.   
All patients with possible myocarditis should be urgently evaluated by [CONTACT_246797], an ECG, a chest X -ray, an echocardiogram, and a cardiac MRI as 
appropriate per institutional guidelines.  A cardiologist should be consulted.  An endomyocardial biopsy may be considered to enable a definitive diagnosis and appropriate treatment, if clinically indicated.  
Patients with signs and symptoms of myocarditis, in the absence of an identified 
alternate etiology, should be treated according to the guidelines in Table 6 . 
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
181/Protocol CO39721, Version 5  Table  6 Management Guidelines for Immune -Related Myocarditis  
Event  Management  
Immune- related 
myocarditis, Grade 1  • Refer patient to cardiologist.  
• Initiate treatment as per institutional guidelines.  
Immune- related 
myocarditis, Grade 2  • Withhold atezolizumab for up to [ADDRESS_437569] Medical Monitor.  
• Refer patient to cardiologist.  
• Initiate treatment as per institutional guidelines and consider 
antiarrhythmic drugs, temporary pacemaker, ECMO, or VAD as 
appropriate.  
• Consider treatment with 1− 2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 1 −2 mg/kg/day oral prednisone or 
equivalent upon improvement.  
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade [ADDRESS_437570] 
Medical Monitor. c 
Immune- related 
myocarditis, Grade 3-4  • Permanently discontinue atezolizumab and contact [CONTACT_25290].
 c 
• Refer patient to cardiologist.  
• Initiate treatment as per institutional guidelines and consider 
antiarrhythmic drugs, temporary pacemaker, ECMO, or VAD as 
appropriate.  
• Initiate treatment with 1− 2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 1 −2 mg/kg/day oral prednisone or 
equivalent upon improvement.  
• If event does not improve within 48 hours after initiating corticosteroids, consider adding an immunosuppressive agent.  
• If event resolves to Grade 1 or better, taper corticosteroids over
 ≥ 1 month.  
ECMO  = extracorporeal membrane oxygenation; VAD  = ventricular assist device . 
a Atezolizumab may be withheld for a longer period of time (i.e., >  12 weeks after event onset) to 
allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral prednisone or equivalent.  
The acceptable length of the extended period of time must be agreed upon by [CONTACT_33501].  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day oral 
prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully recovered from the immune- related event.  Patients can be re- challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor.  
 
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
182/Protocol CO39721, Version 5  INFUSION -RELATED REACTIONS  
No premedication is indicated for the administration of Cycle 1 of atezolizumab.  
However, patients who experience an infusion- related reaction (IRR) with Cycle 1 of 
atezolizumab may receive premedication with antihistamines or antipyretics/analgesics (e.g., acetaminophen) for subsequent infusions.  Metamizole (dipyrone) is prohibited in treating atezolizumab- associated IRRs because of  its potential for causing 
agranulocytosis.  
Guidelines for medical management of IRRs during Cycle 1 are provided in Table 7 .  For 
subsequent cycles, IRRs should be managed according to institutional guidelines.  
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
183/Protocol CO39721, Version 5  Table  7 Management Guidelines for Infusion- Related Reactions  
Event  Management  
IRR, Grade 1  • Reduce infusion rate to half the rate being given at the time of 
event onset.  
• After the event has resolved, the investigator should wait for 30 
minutes while delivering the infusion at the reduced rate.  
• If the infusion is tolerated at the reduced rate for [ADDRESS_437571] resolved, the infusion rate may  be increased to 
the original rate.  
IRR, Grade 2  • Interrupt atezolizumab infusion.  
• Administer aggressive symptomatic treatment (e.g., oral or IV antihistamine, anti -pyretic medication, glucocorticoids, 
epi[INVESTIGATOR_238], bronchodilators, oxygen).  
• After symptoms have resolved to baseline, resume infusion at half 
the rate being given at the time of event onset.  
• For subsequent infusions, consider administration of oral 
premedication with antihistamines, anti -pyretics, and/or analgesics 
and monitor closely for IRRs.  
IRR, Grade 3 or 4  • Stop infusion.  
• Administer aggressive symptomatic treatment (e.g., oral or IV antihistamine, anti -pyretic, glucocorticoids, epi[INVESTIGATOR_238], 
bronchodilators, oxygen).  
• Permanently discontinue atezolizumab and contact [CONTACT_31807].
 a 
IRR  = infusion- related reaction.  
a Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune- related event.  Patients can be 
re-challenged with atezolizumab only after approval has been documented by [CONTACT_33502] (or an appropriate delegate) and the Medical Monitor.  
 
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
184/Protocol CO39721, Version [ADDRESS_437572] been associated with the administration of atezolizumab.  The differential diagnosis of acute abdominal pain should include pancreatitis.  Appropr iate work -up should include an evaluation for ductal obstruction, as well as 
serum amylase and lipase tests.  Management guidelines for pancreatic events, including pancreatitis, are provided in Table 8 . 
Table  8 Management Guidelines for Pancreatic Events, Including 
Pancreatitis  
Event  Management  
Amylase and/or lipase 
elevation, Grade 2  • Continue atezolizumab.  
• Monitor amylase and lipase weekly.  
• For prolonged elevation (e.g., >  3 weeks), consider treatment 
with 10 mg/day oral prednisone or equivalent.  
Amylase and/or lipase elevation, Grade 3 or 4  • Withhold atezolizumab for up to 12 weeks after event onset .
 a 
• Refer patient to GI specialist.  
• Monitor amylase and lipase every other day.  
• If no improvement, consider treatment with 1− 2 mg/kg/day 
oral prednisone or equivalent.  
• If event resolves to Grade 1 or better, resume 
atezolizumab. b 
• If event does not resolve to Grade [ADDRESS_437573] Medical Monitor. c 
• For recurrent events, permanently discontinue atezolizumab and contact [CONTACT_25290].
 c 
GI  = gastrointestinal.  
a Atezolizumab may be withheld for a longer period of time (i.e., >  12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral prednisone or 
equivalent.  The acceptable length of the extended period of time must  be agreed upon by 
[CONTACT_33495].  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune- related event.  Patients can be re- challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the M edical Monitor.  
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
185/Protocol CO39721, Version 5  Table  8 Management Guidelines for Pancreatic Events, Including 
Pancreatitis (cont.)   
Event  Management  
Immune- related pancreatitis, 
Grade 2 or 3  
 • Withhold atezolizumab for up to 12 weeks after event onset . a 
• Refer patient to GI specialist.  
• Initiate treatment with 1− 2 mg/kg/day IV methylprednisolone 
or equivalent and convert to 1− 2 mg/kg/day oral prednisone 
or equivalent upon improvement.  
• If event resolves to Grade 1 or better, resume 
atezolizumab. b 
• If event does not resolve to Grade [ADDRESS_437574] Medical Monitor. c 
• For recurrent events, permanently discontinue atezolizumab and contact [CONTACT_25290].
 c  
Immune- related pancreatitis, 
Grade 4  • Permanently discontinue atezolizumab and contact [CONTACT_31807]. c 
• Refer patient to GI specialist.  
• Initiate treatment with 1− 2 mg/kg/day IV methylprednisolone 
or equivalent and convert to 1− 2 mg/kg/day oral prednisone 
or equivalent upon improvement.  
• If eve nt does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.  
• If event resolves to Grade 1 or better, taper corticosteroids over ≥
 1 month.  
GI  = gastrointestinal.  
a Atezolizumab may be withheld for a longer period of time (i.e., >  12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral prednisone or 
equivalent.  The acceptable length of the extended period of time must  be agreed upon by 
[CONTACT_33495].  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day 
oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune- related event.  Patients can be re- challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the M edical Monitor.  
 
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
186/Protocol CO39721, Version [ADDRESS_437575] should evaluate persistent and/or severe rash or pruritus.  A biopsy should be considered unless contraindicated.  Management guidelines for dermatologic events 
are provided in Table 9 . 
Table  9 Management Guidelines for Dermatologic Events  
Event  Management  
Dermatologic 
event, Grade 1  • Continue atezolizumab.  
• Consider treatment with topi[INVESTIGATOR_33423]/or other 
symptomatic therapy (e.g., antihistamines).  
Dermatologic event, Grade 2  • Continue atezolizumab.  
• Consider patient referral to dermatologist.  
• Initiate treatment with topi[INVESTIGATOR_33424].  
• Consider treatment with higher -potency topi[INVESTIGATOR_33425].  
Dermatologic event, Grade 3  • Withhold atezolizumab for up to 12 weeks after event onset . a 
• Refer patient to dermatologist.  
• Initiate treatment with 10 mg/day oral prednisone or equivalent, increasing dose to 1− 2 mg/kg/day if event does not improve 
within 48−72 hours.  
• If event resolves to Grade 1 or better, resume atezolizumab.
 b 
• If event does not resolve to Grade [ADDRESS_437576] Medical Monitor.
 c 
Dermatologic 
event, Grade 4  • Permanently discontinue atezolizumab and contact [CONTACT_25290].
 c 
a Atezolizumab may be withheld for a longer period of time (i.e., >  12 weeks after 
event onset) to allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day 
oral prednisone or equivalent.  The acceptable length of the extended period of time must be agreed upon by [CONTACT_33495].  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to 
≤ 10 mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune- related event.  Patients can be re-
challenged with atezolizumab only after approval has been documented by [CONTACT_33502] (or an app ropriate delegate) and the Medical Monitor.  
 
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
187/Protocol CO39721, Version [ADDRESS_437577] been observed with single- agent 
atezolizumab.  Patients may present with signs and symptoms of sensory and/or motor 
neuropathy.  Diagnost ic work -up is essential for an accurate characterization to 
differentiate between alternative etiologies.  Management guidelines for neurologic disorders are provided in Table 10. 
Table  10 Management Guidelines for Neurologic Disorders  
Event  Management  
Immune- related 
neuropathy, 
Grade 1  • Continue atezolizumab.  
• Investigate etiology.  
Immune- related 
neuropathy, Grade 2  • Withhold atezolizumab for up to 12 weeks after event onset .
 a 
• Investigate etiology.  
• Initiate treatment as per institutional guidelines.  
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade [ADDRESS_437578] 
Medical Monitor. c 
Immune- related 
neuropathy, Grade 3 or 4  • Permanently discontinue atezolizumab and contact [CONTACT_31807].
 c  
• Initiate treatment as per institutional guidelines.  
Myasthenia 
gravis and 
Guillain -Barré 
syndrome (any 
grade)  • Permanently discontinue atezolizumab and contact [CONTACT_31807]. c 
• Refer patient to neurologist.  
• Initiate treatment as per institutional guidelines.  
• Consider initiation of 1− 2 mg/kg/day oral or IV prednisone or 
equivalent.  
a Atezolizumab may be withheld for a longer period of time (i.e., >  12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral 
prednisone or equivalent.  The acceptable length of the extended period of time must be agreed upon by [CONTACT_33495].  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to 
≤ 10 mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune- related event.  Patients can be re-
challenged with atezolizumab only after approval has been documented by [CONTACT_33502] (or an appropriate delegate) and the Medical Monitor.  
 
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
188/Protocol CO39721, Version 5  IMMUNE -RELATED MENINGOENCEP HALITIS  
Immune- related meningoencephalitis is an identified risk associated with the 
administration of atezolizumab.  Immune -related meningoencephalitis should be 
suspected in any patient presenting with signs or symptoms suggestive of meningitis or 
encephalitis, including, but not limited to, headache, neck pain, confusion, seizure, motor 
or sensory dysfunction, and altered or depressed level of consciousness.  Encephalopathy from metabolic or electrolyte imbalances needs to be distinguished from potential meningoencephalitis resulting from infection (bacterial, viral, or fungal) or progression of malignancy, or secondary to a paraneoplastic process.   
All patients being considered for meningoencephalitis should be urgently evaluated with a CT scan and/or MRI scan of the brain to evaluate for metastasis, inflammation, or edema.  If deemed safe by [CONTACT_1963], a lumbar puncture should be performed and a neurologist should be consulted.  
Patients with signs and symptoms of meningoencephalitis, in the absence  of an 
identified alternate etiology, should be treated according to the guidelines in Table 11. 
Table  11 Managem ent Guidelines for Immune -Related 
Meningoencephalitis  
Event  Management  
Immune- related 
meningoencephalitis, 
all grades  • Permanently discontinue atezolizumab and contact [CONTACT_25290]. a 
• Refer patient to neurologist.  
• Initiate treatment with 1− 2 mg/kg/day IV methylprednisolone or 
equivalent and convert to 1 −2 mg/kg/day oral prednisone or 
equivalent upon improvement.  
• If event does not improve within 48 hours after initiating corticosteroids, consider adding an immunosuppressive agent.  
• If event resolves to Grade 1 or better, taper corticosteroids over ≥
 [ADDRESS_437579] 
fully recovered from the immune- related event.  Patients can be re- challenged with 
atezolizumab only after approval has been documented by [CONTACT_33494] (or an 
appropriate delegate) and the Medical Monitor.  
 
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
189/Protocol CO39721, Version [ADDRESS_437580] adequate renal function, and renal function, including 
serum creatinine, should be monitored throughout study treatment.  Patients with abnor mal renal function should be evaluated and treated for other more common 
etiologies (including prerenal and postrenal causes, and concomitant medications such as non -steroidal anti -inflammatory drugs).  Refer the patient to a renal specialist if 
clinically  indicated.  A renal biopsy may be required to enable a definitive diagnosis 
and appropriate treatment.  
Patients with signs and symptoms of nephritis, in the absence of an identified alternate etiology, should be treated according to the guidelines in  Table  12. 
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
190/Protocol CO39721, Version 5  Table  12 Management Guidelines for Renal Events  
Event  Management  
Renal event, 
Grade 1 • Continue atezolizumab.  
• Monitor kidney function, including creatinine, closely until 
values resolve to within normal limits or to baseline values.  
Renal event, 
Grade 2 • Withhold atezolizumab for up to 12 weeks after event onset. a 
• Refer patient to renal specialist.  
• Initiate treatment with corticosteroids equivalent to 
1−2 mg/kg/day oral prednisone.  
• If event resolves to Grade 1 or better, resume atezolizumab. b 
• If event does not resolve to Grade [ADDRESS_437581] Medical Monitor.
 c 
Renal event, 
Grade 3 or 4  • Permanently discontinue atezolizumab and contact [CONTACT_25290].  
• Refer patient to renal specialist and consider renal biopsy.  
• Initiate treatment with corticosteroids equivalent to 
1
−2 mg/kg/day ora l prednisone.  
• If event does not improve within 48 hours after initiating corticosteroids, consider adding an immunosuppressive agent.  
• If event resolves to Grade 1 or better, taper corticosteroids over 
≥ 1 month.  
a Atezolizumab may be withheld for a longer period of time (i.e., > 12 weeks after 
event onset) to allow for corticosteroids (if initiated) to be reduced to the 
equivalent of ≤ 10 mg/day oral prednisone.  The acceptable length of the extended 
period of time must be agreed upon by [CONTACT_33495].  
b If corticosteroids have been initiated, they must be tapered over ≥ 1 month to the 
equivalent of ≤ 10 mg/day oral prednisone before atezolizumab can be resumed.  
c Resumption of atezolizumab  may be considered in patients who are deriving 
benefit and have fully recovered from the immune -related event.  Patients can be 
re-challenged with atezolizumab only after approval has been documented by [CONTACT_33497] (or an appropriate delegate) a nd the Medical Monitor.  
 
SYSTEMIC IMMUNE ACTI VATION  
Systemic immune activation is a rare condition characterized by [CONTACT_33471].  Given the mechanism of action of atezolizumab, systemic immune activation is considered a potential risk when atezolizumab is given in combination with other immunomodulating agents. 
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
191/Protocol CO39721, Version 5  Recommendations regarding early identification and management of systemic immune 
activation are provided below.  In the event of suspected systemic immune activation, atezolizumab should be withheld and clinical specialists (e.g., rheumatology, clinical immunology, or solid organ or hematopoietic stem cell transplant specialists) and the Medical Monitor should be consulted for additional guidance.  
Early disease recognition is critical, and systemic immune activation should be suspected  if, in the absence of an alternative etiology, the patient meets two or more of 
the following criteria:  
• Hypotension that is refractory to aggressive IV fluid challenge  
Vasopressor support may be required.  
• Respi[INVESTIGATOR_351832].  
• Fever >
 38.5°C 
• Acute renal or hepatic failure 
• Bleeding from coagulopathy  
• Any of the following unexplained laboratory abnormalities (change from baseline):  
cytopenias (in two or more lineages), significant transaminitis, or coagulopathy  
 
For patients with suspected systemic immune activation, an initial evaluation should 
include the following: 
• CBC with peripheral smear  
• PT, PTT, fibrinogen, and D -dimer  
• Ferritin  
• Soluble interleukin 2 (IL- 2) receptor (soluble CD25)  
• Triglycerides  
• AST, ALT, and direct bilirubin 
• LDH 
• Complete neurologic and abdominal examination (assess for hepatosplenomegaly)  
 
Laboratory tests with normal results should be repeated frequently in patients for whom 
a high clinical suspi[INVESTIGATOR_40824]. 
If neurologic abnormalities are present, consider cerebrospi[INVESTIGATOR_120342]/or an MRI of the brain.  
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
192/Protocol CO39721, Version 5  If cytopenias are present ( Grade  ≥ 2 in two or more lineages ) or ferritin is ≥ 3000 ng/mL, 
the following evaluations should also be performed:   
• Bone marrow biopsy and aspi[INVESTIGATOR_337] (assess for evidence of hemophagocytosis)  
• Adenovirus, cytomegalovirus, Epstein- Barr virus, herpes -simplex virus, and human 
herpesvirus 6, 7, and 8 evaluation (for reactivated or active disease)  
 
Diagnostic criteria and recommended management for systemic immune activation are 
provided in Table 13.  The diagnostic criteria apply only when alternative etiologies have 
been excluded. 
An adverse event of systemic immune activation should be reported on the Adverse Event eCRF if it meets the criteria for "consistent with systemic immune activation" or  
"probable systemic immune activation" as outlined in Table 13. 
 
 
Appendix 8  
Risks Associated with Atezolizumab and Guidelines for 
Management of Adverse Events Associated with Atezolizum ab 
(cont.)   
Cobimetinib and Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd  
194/Protocol CO39721, Version 5  REFERENCES  
Hejblum G, Lambotte O, Galicier L, et al. A web -based Delphi study for eliciting helpful 
criteria in the positive diagnosis of hemophagocytic syndrome in adult patients. 
PLoS ONE 2014;9(4):e94024. doi: 10.1371/journal.pone.0094024.  
 